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Abstract
Dietary Plant-derived fibre and resistant starch are fermented in the colon by the 
colonic microflora to short chain fatty acids, acetate, propionate and butyrate. Butyrate 
is a major source of energy for colonocytes and plays a critical role in maintaining 
colonic tissue homeostasis by regulating the expression of genes associated with 
proliferation, apoptosis and differentiation of colonic epithelial cells. Some examples of 
these genes include, Cyclin D1, CD1 (a key positive regulator of cell cycle progression, 
downregulated by butyrate) p21 (a cell cycle inhibitor, upregulated by butyrate), 
intestinal alkaline phosphatase, IAP (a marker of differentiation, upregulated by 
butyrate), bak (upregulated by butyrate) and bcl-xL (down-regulated by butyrate), the 
latter functionally opposing butyrate responsive members of bcl2 family important to 
the regulation of cell death by apoptosis.
Previous work in the laboratory had demonstrated that:
• Butyrate is transported across the colonic luminal membrane by the 
monocarboxylate transporter isoform 1 (MCT1).
• Butyrate regulates MCT1 expression at both transcriptional and post- 
transcriptional levels.
• Using the technique of short interfering RNA to knock down the expression of 
MCT1, and hence butyrate transport, in cultured colonic epithelial cell lines i) 
MCT1 is the major route for the entry of butyrate into the cell and ii) the 
inhibition of MCT1, and butyrate transport, abolishes the butyrate dependant 
regulation of CD1, p21 and IAP, indicating that butyrate entry via MCTIis 
required for regulation of these genes. However inhibition of MCT1 had no 
effect on butyrate modulation of bak and bcl-x, implying a potential presence of 
a butyrate sensor on the colonic luminal membrane to initiate signalling 
pathway involved in regulation of bak and bcl-xL.
Work presented in this thesis:
To identify further the mechanism involved, at the membrane level, for butyrate 
regulation of gene expression in the colon, a membrane impermeable butyrate 
analogue was synthesised. The procedure involved coupling poly(ethy!ene glycol) 6oo 
(PEG60o), a membrane impermeable molecule with an approximate molecular weight of 
600 kDa to the C4 position of butyric acid. Disodium PEG600a,©-dibutyrate was fully 
characterised by 1H and 13C NMR, mass spectrometry and IR spectroscopy, to 
assess the structure and purity.
Disodium PEG6o0a ,©-dibutyrate, was used to treat two colonic epithelial cell lines, 
AA/C1 and HT-29. For control, cells were treated with sodium butyrate. Techniques of 
northern blotting, real-time PCR and western blotting were performed to determine the 
mRNA and protein abundance of IAP, p21, MCT1, bak and bcl-xL in cells treated 
either with disodium PEG600a,©-dibutyrate or sodium butyrate. Disodium PEG60oa,©- 
dibutyrate had no effect on the regulation of p21, IAP, MCT1 and bcl-xL. However, 
disodium PEG60ocx,©-dibutyrate treatment resulted in the up-regulation of bak mRNA 
and protein to the same extent as observed with butyrate treatment. This indicates that 
butyrate regulation of bak is not dependent on entry of butyrate into the cell. In 
contrast butyrate regulation of IAP, p21 and MCT1, demands butyrate entry into the 
cell.
Transport studies using radiolabelled [U-14C] butryate into colonic luminal membrane 
vesicles (LMV) were performed i) to characterise butyrate transport, ii) to determine if 
heptafluorobutyrate (HFB, a non-metabolisable analogue of butyrate), is transported by 
MCT1, and iii) to assess potential and type of inhibition of butyrate transport by HFB. 
Treatment of colonic cells with HFB had no effect on the expression of number genes 
that required butyrate entry into the cell, indicating that the metabolism of butyrate may 
be required for the regulation of these genes.
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CHAPTER 1
Introduction
CHAPTER 1: INTRODUCTION
1.1 Anatomy of the large intestine
1.1.1 Gross anatomy of the large intestine
The large intestine consists of approximately 1.5 to 1.8 m section of the 
alimentary tract that extends from the ileum to the anus; with a diameter of 
approximately 6 cm. The large intestine is attached to the posterior abdominal 
wall by the mesocolon, a double layer of peritoneum, and has four main 
sections: cecum, colon, rectum and anal canal.
The cecum is a small pouch about 6 cm long and is divided from the ileum of 
the small intestine by the ileocecal sphincter. Connected to the cecum is the 
colon which is divided into the ascending, transverse, descending and sigmoid 
colon. The ascending colon has an approximate length of 12 to 20 cm and
TRANSVERSE COLON
Right 
(hepatic) 
flexure
ASCENDING
COLON
ANUS
Ileocecal
sphincter
(valve)
CECUM
VERMIFORM APPENDIX RECTUM  
ANAL CANAL
Left colic 
(splenic) 
flexure
DESCENDING
COLON
Teniae coli
Epiploic
appendages
Haustra
SIGMOID
COLON
Figure 1.1 Gross anatomy of the large intestine
Adapted from Tortora & Derrickson, (2006).
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rises from the cecum up the right side of the abdomen to the liver where it 
turns left to form the right colic (hepatic) flexure. The colon proceeds across 
the abdomen above the small intestine as the transverse colon, which has an 
approximate length of 50 cm, curving beneath the spleen at a 90 ° angle as the 
left colic (splenic) flexure. Here the colon continues descending down the left 
side of the abdomen as the descending colon with an approximate length of 25 
cm, passing the left kidney and terminating at the iliac crest. The sigmoid 
colon, so called due to its S-shape begins near to the iliac crest from the 
descending colon, runs medially to the midline of the abdomen where it 
terminates as the rectum. The rectum extends for approximately the last 20 cm 
of the alimentary tract descending anterior to the coccyx. The last 2 -  3 cm of 
the rectum forms the anal canal with the opening of the anal canal to the 
exterior being the anus. The anus terminates with an internal and external anal 
sphincter (Tortora & Grabowski, 2003).
1.1.2 The colonic wall
Although the large intestine is larger in diameter than the small intestine, there 
are no villi present and so the intestinal wall is thinner. The wall of the colon is 
made up from four layers: mucosa, submucosa, muscularis externa and 
serosa. The mucosa is subdivided into: epithelium containing epithelial, goblet, 
stem and endocrine cells; lamina propria which contains connective tissue to 
support the epithelial layer; and muscular mucosae that consists of longitudinal 
and circular layers of smooth muscle.
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-  MUCOSA
SUBMUCOSA
MUSCULARIS
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Openings of 
intestinal glands
Figure 1.2 Illustration of the human colonic wall
Adapted from Tortora & Grabowski, (2003).
The submucosa consists of supportive connective tissue; intertwined within the 
submucosa are lymphatic and blood vessels. The muscularis consists of an 
external layer of longitudinal smooth muscle that surrounds an internal layer of 
circular smooth muscle. Parts of the longitudinal smooth muscle are thickened 
forming three conspicuous longitudinal bands called the taniae coli that run the 
length of the large intestine. The taniae contract to gather the colon into a 
series of pouches called haustra, giving the colon its characteristic 
appearance. The serosa consists of a continuous sheet of squamous epithelial 
cells and forms part of the visceral peritoneum. Small pouches of visceral 
peritoneum filled with fat are attached to the teniae coli and are referred to as 
epiploic appendages (Shamsuddin, 1990).
- 4 -
CHAPTER 1: INTRODUCTION
1.1.3 The colonic epithelium
The colonic epithelium runs the length of the colon and consists of a great 
number of tubular glands called glands of Lieberkuhn or crypts. The crypts are 
very abundant and stretch from the bottom to the top of the mucosa layer, are 
about 0.5 mm deep in most of the colon and are surrounded by lamina propria 
(Singh & Binder, 2001). At the base of the crypt are 1 to 4 stem cells whose 
daughter cells differentiate into goblet, enteroendocrine and epithelial cells. 
The epithelial cells and goblet cells have a half-life of approximately 6 days; 
the enteroendocrine cells have a longer half-life (Christensen, 1991). The cells 
migrate up the crypt axis from the base to the crypt peak, differentiating in the 
upper portion and after 3 to 4 days undergo apoptosis and are shed into the
Intestinal
gland Absorptive cell 
(absorbs water)
Openings of
intestinal
glands
Lamina propria
Muscularis
mucosae
Submucosa
Goblet cell 
(secretes mucus)
Lymphatic
nodule
Microvilli
Figure 1.3 Illustration of a human colonic crypt
Adapted from Tortora & Grabowski, (2003).
- 5 -
CHAPTER 1: INTRODUCTION
lumen (Kim et al., 1994; Hall et al., 1994).
The epithelial cells, or colonocytes, are the principle cells in the colonic 
epithelium. Colonocytes are tall cylindrical cells that contain microvilli on their 
luminal membranes and have basally positioned nuclei and mitochondria. They 
are joined at the lumen poles by junctional complexes to adjacent colonocytes 
forming a barrier between the lumen of the large intestine from the paracellular 
spaces between the colonocytes. The colonocytes are responsible for the 
absorption of water and nutrients across the epithelia from the lumen into the 
blood stream at the basal pole of the colonocyte (Singh & Binder, 2001).
The goblet cells, so called due to their goblet shape, are mucous producing 
cells. They also contain a basally located nucleus and secrete mucous into the 
lumen which helps the passage of faecal material through the colon. The 
enteroendocrine cells are the least abundant and sit deep within the 
epithelium. Enteroendocrine cells often display an apical finger that extends 
towards the lumen. They are responsible for secretions into the lamina propria 
at the base of the crypts (Colony, 1989).
1.2 Functions of the colon
The colon once thought to have little function, actually plays a significant role in 
the digestion and absorption of ingested food. Approximately 600 -  1500 ml of 
matter enters the colon daily compared to only 200 ml of faeces exiting 
(Macfarlane & Cummings, 1991). The majority of fluid is absorbed by the 
proximal portion of the colon while the rectum is essentially non-absorbing, 
being relatively impermeable to sodium and water (Phillips, 1969). The large 
intestines functions to reabsorb water; absorb nutrients and vitamins released 
by the intestinal microflora; absorption and secretion of inorganic ions;
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compact the contents of the intestine into faeces; and the storage and 
defecation of faeces (Marieb, 2003).
1.2.1 Absorption and secretion of electrolytes and water
The colon is responsible for the reabsorption of water, the secretion of 
bicarbonate, chloride, potassium and protons; as well as the absorption and 
secretion of sodium and chloride ions through a multitude of ion channels and 
transporters.
The human colon absorbs 0.5 -  1.5 litres of water daily, which is coupled to 
sodium absorption (Singh & Binder, 2001). The majority of water absorption is 
accounted for by passive diffusion, transported paracellularly in response to 
osmotic gradients (Phillips, 1969); mechanisms are needed to create the 
osmotic gradients as the osmolarity of the faeces is greater then the plasma 
(Sladen, 1971).
The mammalian colon absorbs sodium against a significant electrochemical 
gradient and can scavenge to retain sodium at times of sodium depletion. 
(Singh & Binder, 2001). The capacity of the small intestine to absorb sodium 
and chloride is limited, however the human colon absorbs 90 % of the sodium 
and chloride that enters the cecum, preventing diarrhoea and sodium 
depletion (Devroede & Phillips, 1969). Patients with ileostomies present with 
chronic sodium depletion and dehydration, highlighting the role of the colon in 
sodium and water absorption (Clarke et al., 1967). Sodium is absorbed in the 
colon through two pathways. A sodium conductive pathway that accounts for 
40 % sodium absorption through epithelial sodium channels (Dudeja et al., 
1994b); and an electroneutral Na/H exchange that accounts for 60 % sodium 
absorption (Dudeja et al., 1994a). Once inside the colonocytes, sodium is 
excluded via the Na+,K+-ATPase across the basolateral membrane.
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Chloride absorption in the human colon is linked to bicarbonate secretion 
(Sladen, 1971), while chloride secretion is linked to the basolateral 
electroneutral Na-K-2CI transporter (Singh & Binder, 2001;Sandle, 1998). 
Chloride transport is electroneutral, with CI/HCO3 exchange coupled to Na/H 
exchange (Foster et al., 1986). Bicarbonate is produced by intracellular 
hydration of C02 by carbonic anhydrase producing carbonic acid which rapidly 
degrades to bicarbonate (Cummings, 1984). CI/HCO3 exchange accounts for a 
portion of chloride absorption with sodium stimulated chloride absorption also 
occurring (Davis et al., 1983). A portion of paracellular chloride absorption also 
takes place (Geibel, 2005).
The colon is responsible for maintaining the potassium balance within the 
body, especially when kidney function is impaired (Cummins, 1984). 
Potassium is secreted and absorbed in the distal colon (Devroede & Phillips, 
1969), where potassium ions are brought into the cell from the blood by the 
Na+,K+-ATPase, on the basal side of the cell and secreted into the lumen by 
potassium channels (Cummings, 1984). Potassium ions are absorbed from the 
lumen by the H+,K+-ATPase (Horisberger, 2001).
1.2.2 The colonic microflora
The large intestine, as mentioned above, plays host to a large colony of 
bacteria. The colon is inoculated after birth and the adult human colon can 
contain up to 400 different species of bacteria, covering 50 genera (Macfarlane 
& Cummings, 1991; Topping & Clifton, 2001); a gram of caecal content may 
contain up to 2 billion organisms (Chapman, 2001). Bacteroides, 
Bifidobacterium and Enterococcus (Bugaut & Bentejac, 1993; Pryde et al., 
2002) are present with eubacterium, lactobacillus and Clostridium being 
predominant, while Bacteroides account for 30 % of the total bacterial dry
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mass (Macfarlane & Cummings, 1991; Hill, 1995a). Table 1.1 outlines the 
bacteria genera, and their numbers present per gram faeces.
On average bacteria make up approximately 40 -  55 % of stool matter with 
approximately 15 g of bacteria being expelled per day by defecation for 
individuals consuming Western style diets (Macfarlane & Gibson, 1995; 
Topping & Clifton, 2001). There is an excess of 1011 bacterial cells per dry 
weight of intestinal content (Bugaut & Bentejac, 1993), that averages 1013 - 
1014 organisms per colon with a metabolic activity of that of the liver (Hill, 
1995a). Bacterial proliferation occurs more significantly in the proximal colon 
where there is fresh intake of food from the small intestine; bacterial 
proliferation in the distal colon is not so prominent (Macfarlane & Cummings, 
1991; Topping & Clifton, 2001).
Diet has been found to influence the microflora of rat, mice and ruminants but 
in man it is accepted that diet does not have a significant effect on the 
microflora population. However persons living on vegetarian, Japanese and 
Western-type diets do exhibit changes in key populations like bifidobacteria 
and eubacteria (Macfarlane & Cummings, 1991). The microflora utilise a wide 
range of organic matter for food consisting of exfoliated epithelial cells, 
glycoproteins, pancreatic secretions, lysed bacterial cells and dietary fibre 
(Bach Knudsen etal., 2003; Bugaut & Bentejac, 1993; Hill, 1995a).
1.2.3 Fermentation of indigestible material by the colonic 
microflora
Starch, the common storage of glucose in cereal grains, potatoes and some 
root potatoes is digested by a-amylases present in the small intestine. The 
remaining polysaccharides that are resistant to digestion by a-amylase, are 
termed non-starch polysaccharides (NSP), or more commonly, dietary fibre.
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NSP represents the plant cell wall materials including the polysaccharides 
cellulose, hemicellulose and pectin; storage polysaccharides, inulin and guar; 
and plant gums and exudates (Cummings, 1981; Kritchevsky, 1995). More 
recently the importance of resistant starch has been noted. Resistant starch 
(RS) is the term used to describe starch polysaccharide that due to food 
processing escapes digestion in the small intestine. RS was discovered 
through investigations into the amount of NSP found in cooked foods. The data 
showed increased amounts of NSP after cooking than the raw foods. This 
increase in NSP was found to be a glycan (referred to as RS) that upon 
investigation was measured as glucose and accounted for the increase in NSP 
after cooking (Englyst & Cummings, 1987).
Table 1.1 Bacterial flora of the adult human colon
Genus of bacteria Log10 (number per g faeces)
Non-sporing anaerobic bacteria
Bacteroides spp 10 -11
Bifidobacterium spp 10 -11
Eubacterium spp 9-11
Propionibacterium spp 9-11
Veillonella spp 5 - 8
Sporing anaerobic bacteria
Clostridium spp 5-10
Bacillus spp 3 - 7
Microanaerobic bacteria
Lactobacillus spp 7 -9
Streptococcus spp 7 -9
Enterococcus spp 5 -7
Facultative organisms
Escherichia spp 7 -9
Other enterobacteria 5 -9
Adapted from Hill, (1995b).
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Currently there are four categories of resistant starch:
Physical inaccessibility, foods which are inaccessible to pancreatic enzymes. 
These include whole or partly milled grains and seeds and foods which in its 
physical form presents a barrier i.e. corn, peas, beans and rice.
Ungelatinised starch granules; starch in its natural form has a granule structure 
that depends on the chain length of the starch. During cooking the granules 
are gelatinised, or breakdown, allowing access to a-amylase. Foods eaten 
raw, such as bananas, contain large amounts of ungelatinised starch. Three 
types of granule are known, distinguished by their X-ray diffraction pattern. 
Retrograde starch; heated foods on cooling or drying produce starch granules. 
The granule produced depends on the temperature of cooking and includes 
potatoes, rice and maize.
Chemically modified; Processed foods that are chemically modified (e.g. 
esterified starches) where the modification interferes with the amylolytic activity 
of the digestive enzymes.
(Macfarlane & Cummings, 1991; Perrin et al., 2001; Topping & Clifton, 2001) 
NSP and RS can be divided into soluble and insoluble depending on there 
solubility in aqueous solutions; soluble fibres are widely fermented while 
insoluble fibres are poorly fermented (Wolever, 1994). Typically 50 - 60 g 
carbohydrate are fermented in the human colon per day for individuals on a 
common European diet (Bergman, 1990). This represents an abundant food 
source for the resident microflora.
Figure 1.4 illustrates the major pathways of carbohydrate fermentation and the 
products formed in the human colon. The polysaccharides, oligosaccharides 
and disaccharides contributed by fibre and RS are metabolised by the colonic 
microflora; saccharides are hydrolysed to their constituent sugars by 
extracellular enzymes before being fermented (Wolin, 1994). Undigested
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proteins or endogenous pancreatic secretions are also fermented, as too are 
the sugars lactose, raffinose and starchylose (Cummings et al., 1987; Topping 
& Clifton, 2001)
Mucus secreted from the small intestine contains mucins that are acidic 
glycoproteins containing galactose, hexosamines and fucose. Mucins also 
enter the large intestine where they are fermented (Macfarlane & Cummings, 
1991); 4 to 6 g of pancreatic enzymes and 2 to 3 g small intestinal mucins may 
enter the colon every day (Macfarlane & Gibson, 1995). In man the principle 
end products of fermentation are short-chain fatty acids (SCFA), the gases, 
CH4, C02 and H2, plus some heat (Bugaut & Bentejac, 1993; Hill, 1995b; 
Pouteau et al., 2003).
CELLULOSE STARCH HEMICELLULOSE
\  & PECTIN
I
HEXOSE PENTOSE
Figure 1.4 Major pathways of carbohydrate fermentation in the
human large intestine
Overview of the major pathways of NSP and RS fermentation in the human large 
intestine and the principle products formed.
Adapted from Macfarlane & Gibson, (1995).
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1.3 Dietary fibre, resistant starch and colonic 
health
Fibre and RS have several promoting effects on the health of the colon. 
Primary investigations into the promoting effect of dietary fibre centred on the 
roughage model. The hypothesis presumed that dietary fibre acted as a 
bulking agent in the large intestine, reducing the transit time of faecal matter 
and so to the amount and time that the colonic mucosa is exposed to 
carcinogens (Burkitt, 1971). However, as previously discussed, it is now known 
that the colonic microflora are able to utilise dietary fibre for their energy 
requirements with short-chain fatty acids (SCFAs) being the down-stream 
products of fermentation and are the source of extensive research. SCFAs 
have widened the previous hypothesis surrounding the protective effect of 
dietary fibre and RS on colon carcinogenesis.
Addition of fibre to the diet has been found to increase stool bulk, reducing 
transit time through the colon, diluting and binding of potential carcinogens, 
reduce the production of secondary bile acids and lowing of the colonic pH 
(Kritchevsky, 1995; Peters et at., 2003). However, it is difficult to identify a 
single mechanism by which dietary fibre modifies colon carcinogenesis 
(Bugaut and Bentejac, 1993). The increase in stool bulk is thought to come 
about by increased proliferation of the colonic microflora through increased 
nitrogen metabolism within the colon (Hill, 1995a). The production of SCFAs 
reduces the colonic pH and the production of secondary bile acids (Bingham et 
at., 2003). Secondary bile acids are said to be colon tumour promoters; 
reduction of secondary bile acids results from the reduction in 7-a- 
dehydroxylase activity, the enzyme responsible for the conversion of primary to 
secondary bile acids. (Le Leu et at., 2003). The addition of fibre to the diet of 
rats has been found to stimulate crypt cell proliferation. Furthermore, the
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addition of fibre to germ-free rats showed no stimulatory effect indicating the 
requirement of fermentation by the colonic microflora (McCullogh et al., 1998). 
Impaired fermentation of dietary fibre and butyrate production leading to 
reduced sodium absorption has been implicated in the causes of diarrhoea 
(Livesey & Elia, 1995). Interactions between dietary fibre and other nutrients 
also have an effect on the health of the colon. Whether these are synergistic 
additive effects have yet to be decided (Kritchevsky, 1995).
1.4 Short-chain fatty acids
1.4.1 Production ofSCFAs
SCFAs are small alkyl carboxylic acids ranging in length from 1 to 6 carbons 
and are produced in large quantities, approximately 80 to 130 mmol per kg of 
luminal contents. Greater numbers of SCFA are produced in the cecum and 
proximal colon, owing to a greater carbohydrate source and lower pH, (pH 6.3) 
than the distal colon (pH 6.6) (Macfarlane & Cummings, 1991). The principle 
SCFAs produced by far, are acetate, propionate and butyrate, which account 
for 85 to 95 % of total SCFA production (Bergman, 1990). The branched chain 
fatty acids isobutyrate and isovalerate are found, but in much smaller 
quantities. Production of acetate, propionate and butyrate is not equal with the 
ratio of acetate:propionate:butyrate averaging approximately 57:22:21 (Bugaut 
& Bentejac, 1993; Cummings, 1994); the actual ratio of acetate, propionate 
and butyrate depends on the food source.
Table 1.2 lists several sources of NSP and RS with the ratio of acetate, 
propionate and butyrate produced after fermenting for 24 hours in in vitro 
incubation systems inoculated with fresh human faecal flora. Resistant starch, 
wheat bran and oat bran produced high amounts of butyrate whereas xylan,
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pectin and guar gum produce relatively little amounts of butyrate upon 
fermentation (Bach Knudsen etal., 2003; Kritchevsky, 1995).
Table 1.2 SCFA fermentation ratios obtained from dietary fibres
Substrate % Acetate % Propionate % Butyrate
Resistant starch 41 21 38
Starch 50 22 29
Oat bran 57 21 23
Wheat bran 57 15 19
Cellulose 61 20 19
Guar gum 59 26 11
Ispaghula 56 26 10
Pectin 75 14 9
SCFA ratios obtained from dietary fibres in in vitro incubation systems inoculated with 
fresh human faecal flora.
Adapted from Kritchevsky, (1995).
1.4.2 Metabolism of SCFAs
SCFA are rapidly absorbed from the lumen by the colonic epithelium; with 
approximately 90 % of SCFA absorbed and only 10 % residing in the faeces 
(Hill, 1995a; Macfarlane & Cummings, 1991). SCFA are transported across the 
colonocytes into the blood where they are transported through the circulation 
to be utilised by different tissues depending on the SCFA. The transepithelial 
transport of butyrate is significantly lower than for acetate or propionate with 
the majority of butyrate being utilised by the colonocytes as their preferred food 
source (Demigne & Remesy, 1994). Butyrate metabolism within the colonocyte 
is preferred over propionate and acetate (Cummings et al., 1987) with more 
than 70 % of oxygen consumption by isolated colonocytes due to butyrate 
metabolism in vitro (Roediger, 1980). Moreover butyrate oxidation in
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colonocytes is not suppressed in the presence of other energy-providing 
substrates, while the presence of butyrate will suppress the oxidation of other 
SCFAs including acetate (Fitch & Fleming, 1999). Butyrate is metabolised in 
the mitochondria to acetyl-CoA via the p-oxidation cycle. Mitochondrial acetyl- 
CoA is then used in the TCA cycle for the production of ATP, and the synthesis 
of the ketone bodies 3-hydroxybutyrate and acetoacetate via ketogenesis 
(Livesey & Elia, 1995), However this is a minor route for butyrate metabolism 
(Bugaut, 1987). Acetyl-CoA yielded from butyrate metabolism is also used as a 
precursor for de novo lipid synthesis in the cytosol (Macfarlane & Cummings, 
1991). However, butyrate utilisation in de novo lipogenesis is secondary to 
acetate utilisation in rat colonocytes (Zambell et at., 2003).
The majority of acetate is transported across the colonic epithelium where it 
enters the bloodstream and is metabolised by the peripheral tissues. Acetate is 
metabolised in brain and muscle tissue to C02 (Livesey & Elia, 1995) and is 
metabolised by the liver during ketogenesis. Hepatic vein SFCA concentrations 
are lower than the portal blood indicating take up of SCFA by the liver 
(Cummings et at., 1987; Livesey & Elia, 1995), with propionate and butyrate 
being almost exclusively taken up by the liver (Bergman, 1990; Bach Knudsen 
et al., 2003). Propionate absorbed by the liver is principally metabolised to 
succinyl-CoA; conversion with acetyl-CoA yields oxaloacetate which enters the 
TCA cycle (Stephen, 1994). Butyrate taken up by the liver is metabolised to 
acetyl-CoA via p-oxidation, which is oxidised to C 02 during the TCA cycle 
(Demigne & Remesy, 1994).
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1.4 Transport of SCFAs
SCFAs are weak acids with pKa’s around 4.5. The luminal environment of the 
colon has an approximately neutral pH resulting in significant dissociation of 
the SCFAs; 99 % of SCFAs are in their anionic form. Table 1.3 shows the pKa 
values for SCFAs with carbon numbers of 1 to 6. Transport of SCFA is 
accompanied with increased luminal bicarbonate and is thought to be coupled 
to Na/H exchange, which accounts for the stimulated sodium absorption and 
bicarbonate secretion that accompanies the absorption of SCFAs (Sellin, 1999; 
Cummings, 1981). There are currently two widely accepted models of SCFA 
transport in the colonic mucosa, non-ionic diffusion and carrier-mediated 
transport; both are discussed below.
1.4.1 Non-ionic diffusion
The first investigations into transport of SCFAscentred on the idea of non-ionic 
diffusion of SCFAs across the luminal membrane. Early studies proposed 
SCFA diffusion linked to sodium absorption (Smyth & Taylor, 1958). Ionic 
diffusion of the Na+ or K+ salt of the SCFA has also been proposed that 
accounted for a small portion of SCFA transport (Ruppin et al., 1980). As the 
SCFA are present in the lumen in their anionic form, protonation to the 
corresponding acid must occur prior to non-ionic diffusion.
There are two mechanisms for the production of protons for the protonation of 
SCFAs. 1) HC03‘ and H+ are produced in the lumen by the colonic microflora 
from the hydration of C02; 2) intracellular secretion of H+ into the lumen by the 
Na+/H+ exchanger or H+/K+ exchanger could also supply the necessary protons 
(Ruppin et al., 1980; Bugaut, 1987).
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As the degree of SCFA dissociation is so great, a high degree of protonation 
would be required to account for the rapid transport of SCFAs. To explain this, 
an unstirred water layer adjacent to the microvilli was proposed. An unstirred 
water layer refers to a layer of water adjacent to a biological membrane that is 
not at equilibrium with the bulk of the surrounding water. Unstirred water layers 
exist adjacent to cell membranes in the lumen of the human colon and 
contribute significantly to the absorption of molecules through the membrane 
(Dietschy et al., 1971). An unstirred water layer has been shown to exist in rat 
colon that contains a pH microclimate (Titus & Ahearn, 1992). This 
microclimate maintains a different pH to that of the central part of the lumen, at 
which the SCFA are protonated to a higher degree (Bugaut, 1987; Barry& 
Smyth 1960). However, there are several observations that can not be 
explained by this theory. SCFA are still absorbed in the absence of Na/H 
exchange and bicarbonate. The degree of protonation and absorption of SCFA 
is too small to account for the rapid influx of SCFA from the lumen. Finally a 
decrease in luminal pH would be expected with rapid transport of SCFA due to
Table 1.3 pKa values for SCFAs
Carbon
No. Formula IUPAC name common name pKa
1 HCOOH Methanoic Formic 3.55
2 CH3COOH Ethanoic Acetic 4.56
3 C2H5COOH Propanoic Propionic 4.67
4 C3H7COOH Butanoic n-Butyric 4.63
4 (CH3)2CHCOOH 2-Methylpropanoic iso- Butyric 4.63
5 C4H9COOH Pantanoic n-Valeric 4.64
5 (CH3)2CHCH2COOH 3-methylbutanoic /'so-Valeric 4.58
6 C5H11COOH Hexanoic n-Caproic 4.63
SCFA IUPAC and common names (with acid omitted) and their pKa at 25 
strength 0.1 mol/l. Adapted from Fukushima, (1995).
°C, ionic
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the movement of protons into the lumen, however this is not seen (Titus & 
Ahearn, 1992).
1.4.2 Carrier-mediated transport
Carrier-mediated transport can be characterised with the observation of the 
substrates being transported against a chemical or electrochemical gradient, 
saturation kinetics, energy requirements for the carrier operation and 
competitive substrate inhibition (Bugaut, 1987; Titus & Ahearn, 1992). Studies 
carried out on guinea-pig isolated colon in Ussing chambers showed 
bicarbonate dependent SCFA transport that was explained as a SCFA/HC03- 
exchanger (Engelhardt et al., 1989). Studies carried out using luminal 
membrane vesicles isolated from rat distal colon, characterised an anion 
exchange process in which SCFAs were transported into the vesicles in 
exchange for bicarbonate (Mascolo et at., 1991; Stein et al., 1995). SCFA 
transport into pig and human colonic luminal membrane vesicles has also been 
investigated (Harig et al., 1996; Ritzhaupt et al., 1998a). Transport studies of 
SCFAs using luminal membrane vesicles showed that SCFA transport 
demonstrated saturation kinetics, was stimulated by an outward bound HC03- 
gradient and inhibited by other SCFAs (Harig et al., 1996; Ritzhaupt et al., 
1998a; Stein et al., 1995); all characteristics of a carrier-mediated transport 
system. Furthermore, transport of butyrate into Caco-2 cells - a colonic 
adenocarcinoma cell line that forms viable monolayers of polarised cells - 
showed butyrate transport that demonstrated saturation kinetics, was 
stimulated by low pH, inhibited by other SCFAs and demonstrated SCFA/HC03 
exchange (Stein et al., 2000). Transport of propionate into human ileal brush- 
border membrane vesicles has also been shown to follow saturation kinetics,
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enchanced by intra-vesicle HC03' and low pH and was inhibited by other 
SCFAs (Harig et al., 1991).
1.4.3 Identification of SCFA transport by MCT1
Work carried out by Rizthaupt et a/., (1998a) on butyrate transport into porcine 
and human colonic luminal membrane vesicles, characterised butyrate 
transport as a pH-activated electroneutral anion exchange mechanism. 
Transport of butyrate into colonic LMVs showed saturation kinetics and was 
stimulated by an outward directed anion gradient in the order of butyrate > 
bicarbonate > propionate > chloride. Furthermore, butyrate transport into 
colonic LMVs was enhanced at low pH but was not dependent on a pH 
gradient, with butyrate transport being inhibited by other SCFAs, namely 
propionate and lactate (Ritzhaupt et al., 1998a). The protein responsible for 
butyrate transport into porcine and human colonic LMVs was determined to be 
the monocarboxylate transporter isoform 1 (MCT1). Northern blotting for MCT1 
showed the presence of a single transcript of 3.3 kb in porcine and human 
colonic tissue. Western blotting using an antibody to MCT1 gave a single band 
of 40 kDa in purified and well-characterised human and porcine colonic LMVs 
that was enriched 15- to 20-fold. Furthermore, injection of MCT1 mRNA into 
oocytes of Xenopus laevis, demonstrated transport of butyrate and L-lactate 
into the oocytes that was inhibited by butyrate, L-lactate and pyruvate 
(Ritzhaupt etal., 1998b).
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1.5 Monocarboxylate transporter (MCT) family
1.5.1 The MCT gene family
To date the MCT family consists of 14 members, with all members sharing at 
least 20 -  25 % amino acid sequence homology (Hediger et al., 2004). 
Hydrophobicity plots predict 1 0 - 1 2  a-helical trans-membrane (TM) domains 
for the MCT family with a large hydrophilic loop between TM domains 6 and 7, 
and the N- and C-terminus located in the cytoplasm (Enerson & Drewes, 
2003); this topology has been confirmed experimentally for MCT1 in rat 
erythrocytes (Poole et al., 1996) and is illustrated in figure 1.5. The TM 
domains have high sequence homology between family members and across 
species. However, the large intracellular loop between TM domains 6 and 7 
differs greatly between members (Haiestrap & Meredith, 2004).
1.5.2 Identification of MCT1
MCT 1 was the first member of the MCT family to be identified. MCT1 was 
discovered in 1992 by Kim et al., (1992) as the transporter responsible for the 
movement of mevalonate across the plasma membrane in a mutant line of 
Chinese hamster ovary (CHO) cells. At the time, the transporter was given the 
name Mev. Sequence analysis of Mev cDNA and wild type cDNA showed a 
point mutation in the Mev cDNA conferring a change from phenyalanine (wild- 
type) to cysteine (Mev) (Kim et al., 1992). The wild-type protein was found to 
transport mevalonate to a much smaller degree and exhibited the classical 
properties of the monocarboxylate transporter (MCT) that was
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Figure 1.5 Predicted topology of MCT1
Adapted from Halestrap & Price, (1999).
responsible for the transport of lactate into erythrocytes. After sequencing and 
functional testing the transporter was given the name MCT1 (Garcia et al., 
1994a). MCT1 has the gene symbol SLC16A1, is a member of the SCL16 
monocarboxylate cotransporter gene family, and human MCT1 is mapped to 
locus 1p13.2-p12 on chromosome 1 (Garcia eta!., 1994b).
1.5.3 Characterisation of MCT1
MCT1 has a wide tissue distribution; to date MCT1 has been found expressed 
at the level of mRNA in mouse, rat and human, skeletal muscle, heart, kidney, 
brain, small intestine, colon, testis and red blood cells (Dubouchaud et al., 
2000; Halestrap & Price, 1999; Lambert et al., 2002; Philp et al., 2003; Price et 
al., 1998). Equally, the substrates available for transport by MCT1 are wide 
ranging. Short chain (C2-C5) unbranched aliphatic monocarboxylates such as 
acetate and butyrate and substituted C2 or C3 monocarboxylates such as
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pyruvate, L-lactate, acetoacetate and D-p-hydroxybutyrate are all transported 
(Halestrap & Meredith, 2004). Expression of MCT1 in rat skeletal muscle has 
83 % and 86 % homology with human MCT1 nucleotide and amino acid 
sequences respectively (Jackson et al., 1995). MCT1 has been found to 
transport L-lactate in erythrocytes (Halestrap & Price, 1999) and ketone bodies 
and L-lactate in sheep ruminal epithelium (Muller et al., 2002). MCT1 catalyses 
net transport of one carboxylate with a proton, exchange for one 
monocarboxylate with another (Halestrap & Meredith, 2004) or exchange for a 
monocarboxylate with bicarbonate (Ritzhaupt et al., 1998b).
1.5.4 Characterisation of other MCTs
Human MCT2 (SLC16A2) shares 49 % amino acid sequence homology with 
MCT1 (Lin et al., 1998). MCT2 transports pyruvate (Lin et al., 1998; Garcia et 
al., 1995) and L-lactate (Broer et al., 1999) that is stimulated at low pH (Broer 
et al., 1999; Lin et al., 1998). The expression of MCT3 (Human gene name 
SLC16A8) has been localised to the retinal pigment epithelium in rat, mouse 
and chicken (Philp et al., 2003) and in the choroid plexus epithelium in mouse 
brain (Philp et al., 2001). MCT3 shares 43 % amino acid homology with MCT1, 
transports lactate and pyruvate and is inhibited by a-cyano-4- 
hydroxycinnamate, a known MCT inhibitor (Yoon et al., 1997). MCT4 (Human 
gene name SLC16A3) is expressed in mouse neural retina (Philp et al., 2003). 
MCT4 has been shown to catalyse the proton-linked transport of L-lactate 
(Halestrap & Price, 1999) and is up regulated in skeletal muscle after exercise; 
that is consistent with it being an L-lactate transporter in this tissue 
(Dubouchaud et al., 2000).
Information on MCT5 -  MCT8 (Human gene name SLC16A4 - SLC16A6) is 
limited to expression analysis with MCT5 -  MCT8 being expressed in various
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tissues throughout the human body (Price et al., 1998). TATI is the only MCT 
that does not transport monocarboxylates and was identified as a member of 
the MCT superfamily through amino acid sequence homology. Human TAT1 
(SCL16A10) transports aromatic amino acids in a sodium- and proton- 
independent manner. The remaining family members MCT9, MCT11, MCT12, 
MCT14 and MCT15 (SCL16A9, SCL16A11 -  15) were identified through 
searching of the human genome and EST databases and there is currently no 
expression analysis or characterisation data available for these MCTs 
(Halestrap & Meredith, 2004).
1.5.4 Regulation of colonic MCT1
Human colonic MCT1 was found to be regulated by butyrate but not acetate 
and propionate; butyrate was demonstrated to up-regulate MCT1 in a 
concentration- and time-dependent manner (Cuff et al., 2002). This regulation 
involved transcriptional and post-transcriptional processes. Butyrate up 
regulates the transcription of MCT1 and stabilises the MCT1 transcript, which 
in turn increases the transcript half-life (Cuff et al., 2002). MCT1 has been 
localised to the luminal membrane in human colon (Lambert et al., 2002). 
Using in situ hybridisation and northern and western blotting MCT 1 expression 
in human colon has been shown to decline in the colon during development 
from normality to malignancy (Lambert et al., 2002).
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1.6 In vivo and In vitro effects of Butyrate
1.6.1 Butyrate effects in  v ivo
There have been a great number of studies investigating the effects of SCFAs, 
in particular butyrate, in vivo. It is generally accepted that butyrate increases 
colonic mucosal proliferation and reduces apoptosis in vivo (Macfarlane & 
Cummings, 1991; Lupton, 1995).
In vivo investigations are difficult to carry out and control, especially in human 
subjects and much work has centred on animal studies. Animals fed a high 
fibre diet have higher rates of colonic mucosal proliferation than animals fed 
elementary diets. This increase is abolished in germ free animals indicating 
fermentation of fibre and the down stream products are important (Johnson, 
1995). Feeding of fibres promoting stable butyrate production to rats increase 
the length of the mucosa and the depth of the crypts in the caecum and colon. 
This effect was only seen with fibres known to produce high levels of butyrate. 
Furthermore, the high butyrate-producing fibres decreased the rate of aberrant 
crypt foci in rates preceding injection with azoxymethane (Perrin et al., 2001). 
Direct instillation of SCFAs into caecectomised rats fed a fibre-free diet 
stimulated increased mucosal mass and DNA content. Moreover an increase 
was also seen after colonic installation with butyrate to a similar level as 
installation with total SCFAs (Johnson, 1995). Perfusion of individual SCFAs 
into the gastrointestinal (Gl) tract of rats has shown a dose-dependent 
stimulatory effect on epithelial cell production rates in the jejunum and distal 
colon (acetate only showed an effect in the colon) in the order of butyrate > 
propionate > acetate (Sakata, 1995).
Feeding of high amylase cornstarch, a form of resistant starch, to rats showed 
increased production of butyrate, increased faecal weight, reduced pH and 
increased apoptosis (Le Leu et al., 2003). Apoptosis has been also shown to
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be linked to butyrate. Perfusion studies in Ussing chambers using guinea-pig 
colonic tissue showed increase apoptosis, and in particular increased bax (a 
proapoptotic gene) expression after 45 minutes post withdrawal of butyrate 
(Hass et al., 1997; Luciano et al., 1996).
Intervention studies in humans have shown that dietary wheat bran 
supplements, that are known to raise colonic luminal butyrate levels, can inhibit 
DNA synthesis and epithelial cell proliferation in the rectal crypts of patients 
with a resected colon or colorectal cancer (Clausen, 1995). Perfusions of 
butyrate into the colon of patients with ulcerative colitis has been shown to 
reduce inflammation and the associated symptoms (Johnson, 1995; Young & 
Gibson, 1995). Overall, conditions that reduce the production of SCFAs, 
especially butyrate, can depress epithelial cell proliferation in the large and 
small intestine. These include bypass surgery, parental nutritional feeding, 
feeding of a substrate free diet and germ free conditions. The result is 
depressed mitotic activity and mucosal atrophy in the colon mucosa (Sakata, 
1995; Young & Gibson, 1995).
1.6.2 Butyrate effects in  v itro
Salts of butyrate act on abnormal and transformed cells to bring about a 
change to a more normal phenotype. Treatment of cultured cells with butyrate 
is associated with decreased cell growth, bringing about differentiation and 
increasing apoptosis (Lupton, 1995). The in vitro observations seen with 
butyrate treatment of cultured cell lines are discussed in more detail below.
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1.6.2.1 Butyrate and proliferation
Cdks are serine/threonine kinases that require binding of their cyclin partner for 
activation; the exception being cdk5, which is activated by the non-cyclins p35 
and p39 (Loyer et al., 2005). Different cyclin-cdk complexes are activated at 
different points within the cell cycle and cyclins have to be destroyed in order 
for the cell to exit mitosis (Murray, 2004). Progression through Gt requires the 
D-type and E-type cyclins and their respective cyclin-dependent kinases 
(Diehl, 2002). Cyclins D1, D2 and D3 bind to cdk4 and cdk6 while cyclin E1 
and E2 bind with cdk2 (Sherr & Roberts, 2004). D-type cyclin-cdk complexes 
are involved in the G^S checkpoint; activation leads to phosphorylation and 
activation of the retinoblastoma protein (pRb), the so called gate keeper of the 
Gt phase, which in turn dissolves complexes of pRb with members of the E2F 
family of transcription factors and associated chromatin-modifying enzymes. 
The downstream result is activation of the genes required for DNA synthesis 
and key steps of cell proliferation (Deshpande et al., 2005; Fu et al., 2004). 
Cyclin-cdk complexes are negatively regulated by the CIP/KIP and INK family 
of inhibitors. CIP/KIP members include p2 iWAF1/Cip1 (p21) and p27KIP1 (p27), 
while INK members include p16INK4a (p16) and p19INK4c (p19) (Sherr, 1996). 
p21 and p27 inhibit CD/cdk4 kinase, CD/cdk5 kinase, CE/cdk2 kinase and 
CA/cdk2 kinase activities to varying degrees (Siavonshian et al., 2000; Sherr, 
1996); p21 is the main inhibitor of the CD/cdk4 and CD/cdk6 complexes 
(Coradini et al., 2000).
The addition of butyrate to cultured cells inhibits proliferation, leading to an 
arrest of cell growth, which in many cases involves arrest early on in the G! 
phase of the cell cycle (Kruh et al., 1995). See Table 1.4 for a list of genes that 
are modulated by butyrate. Treatment with sodium butyrate (NaBut) also
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suppresses cell proliferation and colony formation in agarose (Lupton, 1995). 
Butyrate reduces proliferation in HT-29, Caco-2 and SW-1116 colonic epithelial 
cells with the largest inhibition of proliferation in HT-29 cells, an 
adenocarcinoma cell line, resulting in 76 % inhibition achieved with 2 mM 
NaBut. The anti-proliferative effect was similar in Caco-2 cells but stronger in 
SW-1116 cells, a differentiated cell line, indicating that inhibition is independent 
of the differentiation state of the cells (Siavoshian et al., 1997). Butyrate- 
modulated arrest in HT-29 cells is time- and concentration-dependent, occurs 
prior to the Cyclin E restriction point and is associated with an increase in the 
number of cells in G0/G, phase of the cell cycle (Coradini et al., 2000; lacomino 
et al., 2001). Butyrate modulates the expression of many regulators of the cell 
cycle. The cyclin-dependent kinase inhibitors p16, p19 and p27 are all up- 
regulated by butyrate in HT-29 cells (lacomino et al., 2001); moreover p27 
along with p21 was found to be up-regulated, in response to butyrate treatment 
in Caco-2 cells, in a dose- and time-dependent manner (Litvak et al., 1998).
G2 phase
M phase,
G0 phase, 
Quiescence
Figure 1.6 Schematic illustrating the cell cycle
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Butyrate induces p21 in HT-29 and Caco-2 cells as early as 2 and 3 hours 
respectively upon butyrate treatment (5-20 mM) that lasts for 48 hours (Orchel 
et al., 2003). However Coradini et al., (2000) found that while a concentration 
of 1 mM NaBut induced p21, higher doses above 4 mM down-regulated p21 in 
HT-29 cells. Butyrate negatively modulates the expression of p53 in HT-29 
cells in a dose-dependent manner; p53 is a regulator of p21 transcription 
indicating that butyrate modulation of p21 is linked to p53 expression (Coradini 
et al., 2000). Butyrate induces p21 through the P21WAF1/Clip1 promoter at Sp1 
sites in human colonic adenocarcinoma WiDr and oteosarcoma MG63 cell 
lines at Sp1 sites -82 to -77 and -69 to -64, relative to the transcription start 
site. The Sp1 site at -82 to -77 was found to strongly activate p21 while the 
Sp1 site at -69 to -64 was partially responsible. MG63 cells contain a p53 
rearrangement, therefore indicating that the activation of the promoter was 
independent of p53; however, it should be noted that these cells, are not colon 
derived (Nakano et al., 1997). The relationship between butyrate anti­
proliferative effect and p21 was further supported by Hinnebusch et al., (2000). 
The authors treated a p21-deleted HCT-116 colonic adenocarcinoma cell line 
with NaBut and showed no reduction in proliferation. The wild type HCT-116 
p21-containing cell line did respond to NaBut treatment, indicating that p21 is 
required for the butyrate mediated response in HCT-116 cells (Hinnebusch et 
al., 2002).
Butyrate-induced cell cycle arrest has also been linked to CKII expression. 
CKII is a serine/threonine protein kinase that requires phosphorylation for 
activation and regulates transcription factors such as Jun and Myc. Moreover, 
CKII is vital for cell cycle progression in yeast Saccharomyces cerevisiae. 
Treatment of NaBut to HT-29 cells significantly down-regulates CKII activity at
- 2 9 -
CHAPTER 1: INTRODUCTION
the post-translational level indicating that butyrate may modulate CKII 
expression through changes in its phosphorylation state (Russo et al., 1997).
Table 1.4 Butyrate-induced modulation of genes associated with 
proliferation, differentiation and apoptosis
Positively modulated Negatively modulated
Proliferation
p16 p53
p19 CB1
p21 CD1
p27 Cdx2
CD3 Ckll
Differentiation
Glycoprotein synthesis
Carcino-embryonic antigen
DPP IV
IAP
Apoptosis
Bak Survivin
FAST B c I-x l
Caspase-1 Bcl-xs
Cspaspe-3 Bcl-2
The intestinal Cdx2 homeobox gene encodes an intestinal transcription factor 
that is a key regulator of intestinal mucosal homeostasis by inhibiting cell 
proliferation and inducing differentiation. Butyrate modulates the expression of 
Cdx2 mRNA and protein through increased transcriptional activity of the Cdx2 
promoter in a time- and concentration-dependent manner (Domon-Dell et al., 
2002) .
CD1 reaches maximal expression during Gi phase and is a key regulator of 
Gi/s progression (Kong et al., 2000). Furthermore, CD1 is frequently 
associated with human malignancies (Diehl, 2002). Butyrate was found to 
positively modulate the expression of CD3 and negatively modulate the 
expression of CD1 and CB1 in HT-29 and HCT-116 cells (Hinnebusch et al., 
2002; Siavoshian et al., 2000) Butyrate modulated CD1 at level of mRNA but
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not the protein, while CD3 protein was up-regulated by butyrate but not the 
CD3 mRNA (Siavoshian et al., 2000).
1.6.2.2 Butyrate and differentiation
Butyrate has been found to induce differentiation in a number of non- 
cancerous cells promoting erythropoiesis and kératinocyte differentiation. 
(Lupton, 1995) Moreover butyrate treatment to cultured cells increases net 
production of glycoprotein synthesis, carcino-embryonic antigen (Johnson, 
1995), dipeptidyl-peptidase (DPP) IV (Siavoshian et al., 1997) and intestinal 
alkaline phosphatase (IAP) (Kruh et al., 1994), all markers of differentiation 
(see table 1.4). The regulation of carcino-embryonic antigen by NaBut involves 
transcriptional and post-transcriptional mechanisms (Saini et al., 1990). 
Treatment of NaBut can stimulate mucin production of cultured mucosa 
obtained from cancer patients (Johnson, 1995), while IAP is up-regulated by 
butyrate in HT-29 and Caco-2 cells (Ding et al., 2001). Butyrate induced 
differentiation in HT-29 is linked to p27 expression. HT-29 cells that 
overexpressed p27 had a marked increase (2-3 fold) in sensitivity to induction 
of differentiation with 2 mM NaBut (Yamamoto et al., 1999). Yamamoto et al., 
(1999) used IAP expression as a marker for differentiation.
1.6.2.3 Butyrate and apoptosis
Apoptosis, or programmed cell death, is a naturally occurring process that 
occurs in all tissues and has an essential role in maintaining tissue 
homeostasis throughout the body. Cells undergoing apoptosis show 
characteristics of shrinkage and blebbing of cell membranes, chromatin 
condensation and DNA fragmentation. Moreover these characteristics are very
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distinct from cells undergoing necrosis (Renehan et at., 2001; Thomson, 2001). 
Apoptosis is principally mediated by a family of cysteine protease caspases 
that are constitutively present in most cell types. Once activated, caspases 
activate each other and co-operate in an intra-cellular cascade that results in 
the release of cytochrome C from the mitochondria and cell death (Thomson, 
2001; Sjostrom & Bergh, 2001). Apoptosis is initiated by a wide range of 
external and internal sources including anticancer drugs, gamma and 
ultraviolet irradiation, deprivation of survival factors such as interleukin-1, and 
various cytokines that activate extra-cellular death-receptors such as the Fas 
and tumour necrosis factor receptors (Renehan et at., 2001; Sjostrom & Bergh, 
2001).
The bcl-2 family of genes contains at least 20 members which are either pro- 
or anti-apoptotic. Pro-apoptotic members include Bax, Bak, Bcl-xs, BNIP3 and 
Bnip3L; anti-apoptotic members include Bcl-2, Bcl-xL and survivin (Thomson, 
2001). Survivin is a bifunctional member of the inhibitor of apoptosis gene 
family that counteracts cell death and controls mitotic progression. Survivin is 
present during embryonic development but is undetectable in most healthy 
human tissues (Kim et at., 2003).
Butyrate treatment to cultured cells brings about changes in the expression of 
many apoptotic genes, some of which are discussed below. See table 1.4 for a 
summary of the genes whose expression is modulated by butyrate. Survivin 
expression in the normal human colon is localised to the crypt base, 
decreasing up the crypt and is inversely proportional to APC expression 
(Zhang et at., 2001). The expression of survivin in HT-29 cells is markedly 
reduced upon treatment with butyrate (Daly et at., 2005). HT-29 butyrate 
treated cells show a marked over expression of FAST, a serine/threonine
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kinase that is rapidly activated during Fas-mediated apoptosis, compared to 
untreated cells (lacomino et al., 2001). Caspase-1 expression is enhanced in 
Caco-2 cells after treatment with NaBut. Caspase-3 is also up-regulated in 
Caco-2 cells as well as a RSB cell line (the latter obtained from a colonic 
tumour of an ulcerative colitis patient), although butyrate modulation of 
caspase-3 in RSB cells is to a lesser extent. Bak is strongly up-regulated in 
butyrate treated Caco-2 cells, while Bcl-2 is down-regulated, and Bak is up- 
regulated in butyrate treated RSB cells without an accompanying change in 
Bcl-2 (vivi-Green et al., 2002). Bcl-2 was shown to be negatively modulated by 
butyrate when primary invasive human colonocytes were treated in vitro with 
SCFAs (Emenaker et al., 2001). The expression of Bcl-2, Bcl-xL, Bcl-xs and 
Bak was found to decrease in Caco-2 cells after treatment with NaBut. The 
authors used a ribonuclease protection assay to identify apoptotic mRNA 
transcript expression but no protein expression was determined (Litvak et al., 
1998). BcI-Xl has been shown to be negatively modulated by butyrate and Bak 
positively modulated by butyrate in HT-29, HCT-116 and AA/C1 cells; butyrate 
induced apoptosis in these three cell lines was demonstrated using a TUNEL 
assay (Cuff et al., 2005). Modulation of Bcl-2 and Bak has also be shown in 
butyrate induced apoptosis in AA/C1, RG/C2 and PC/JW/F1, colonic adenoma 
cell lines (Hague & Paraskeva, 1995). Butyrate induced apoptosis in these cell 
lines was found to be p53-independent (Hague et al., 1993) and 
overexpression of Bcl-2 did not protect against Bak-mediated apoptosis 
(Hague et al., 1997). Furthermore, over-expression of Bcl-2 results in 
suppression of butyrate-induced apoptosis in DiFi, SW-480 and HCT-116 
human colorectal carcinoma cell lines (Mandal et al., 1997).
Treatment of bile acids has been shown to have a protective effect over 
butyrate-induced apoptosis. Treatment of secondary bile acids deoxycholic
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add and ursodeoxycholic acid markedly inhibited butyrate-induced apoptosis 
in AA/C1 cells, however no effect was shown in HT-29 cells. Secondary bile 
acids are known colonic tumour promoters and here the authors used 
concentrations of secondary bile acids that are typical of those found in the 
human colon (McMillan et ai, 2000). In summary, butyrate appears to play an 
important role in regulating proliferation, differentiation and apoptosis of colonic 
epithelial cells.
1.6.2.4 Other SCFAs
Treatment of propionate and valerate causes growth inhibition in HT-29, CaCo- 
2 and SW-1116 colonic epithelial cells and induced IAP and DPP IV activity; 
however this is to a lesser extent than butyrate treatment of the same 
concentration (Siavoshian et al., 1997). Propionate and valerate induce IAP in 
HT-29 to a similar extent of butyrate. Propionate down-regulates CB1 but not 
to the same extent as butyrate, and valerate also down-regulates CB1 to a 
similar extent as butyrate (Hinnebusch et al., 2002). The SCFAs propionate 
and acetate have been shown to induce apoptosis in three colonic adenoma 
cell lines (AA/C1, RG/C2 and PC/JW/F1). Propionate induced apoptosis to a 
lesser extent than butyrate with acetate even less, requiring 40 mM to induce 
apoptosis (Hague & Paraskeva, 1995).
1.7 Colorectal cancer
Colorectal cancer (CRC) has affected mankind for millennia; the earliest 
discoveries of CRC have been found in Egyptian and Peruvian mummies 
dating back to 3000 B.C. CRC, after lung (in men) and breast (in women) 
cancer, is the third most common cause of cancer related death in the world,
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representing the second most common cause of cancer in the US (Rupnarain 
et al., 2004). There are 30,000 new cases of CRC diagnosed in the UK every 
year which account for approximately 17,000 deaths per annum (Ilyas et al., 
1999). CRC is predominantly a disease of the Western world with the highest 
incidence rates found in North America, Australia and New Zealand. Africans, 
Asians and Latin Americans have the lowest rates of incidence and Western 
Europeans show higher rates of incidence over their Eastern counterparts 
(Ilyas et al., 1999; Rupnarain et al., 1991). CRC is influenced by diet and age 
and genetic predisposition (Rupnarain et al., 2004); World wide research is 
now centred on elucidating the mechanisms involved in the activation and 
development of the disease in man. The various forms of CRC, its 
epidemiology and the aberrant gene-expression associated with the disease 
are ail discussed below.
1.7.1 The adenoma to carcinoma sequence
The progression of a tumour is referred to as the adenoma to carcinoma 
sequence and outlines the progression of a colorectal cancer from normal 
mucosa through benign polyps, early and advanced adenoma to an invasive 
and metastatic adenocarcinoma (Renehan et al., 2002). Tumour progression 
can be characterised with the development of qualitatively different stages, in a 
stepwise fashion, with each step involving one or multiple genetic alterations 
(Nowell, 2002). In total there are seven distinct events that characterise the 
progression from adenoma to carcinoma that are illustrated in figure 1.7. The 
latent interval for medium sized adenomas to develop malignancy is 5 to 7 
years. Many small tumours (0.5 -  1 cm diameter) contain benign adenomas 
while large tumours are totally carcinomas (Eastwood, 1991). Aberrant crypt 
foci (ACF) are involved in the earliest steps in colorectal carcinogenesis. The
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aberrant crypts appear larger, thicker and darker than normal and are found in 
clusters within the mucosa. ACF are divided into two types. Hypercellular ACF 
are the more common and have K-ras mutations, but are unlikely to progress 
to neoplastic lesions. Dysplastic ACF contain mutations of the adenomatosis 
polyposis coli (APC) gene and are precursors to adenomas (Renehan et al., 
2002). Polyps are outgrowths from the mucosa into the luminal space. Not all 
polyps progress to carcinoma or are considered neoplastic as some retain a 
benign status. Adenomatous and villous polyps are considered neoplastic and 
are commonly believed to be precursors to large intestine carcinomas 
(Shamsuddin, 1990). The development of polyps to carcinomas is correlated 
with inactivation of chromosome 18-associated, deleted-in-colorectal-cancer 
tumour suppressor gene (DCC). Inactivation/mutation of chromosome 17 p53 
suppressor gene and the ras genes follow. The order of gene inactivation is 
always followed albeit not precisely (Rupnarain et al., 2004; Nowell, 2002).
Benign
Malignant
nr_ I
Normal epitheiia
X
▼ — — —APC or p-catenin mutation
Dysplastic epithelia
— K-ras activation-mutation 
Adenoma n r
...— DCC & p53 inactivation-mutation 
Carcinoma
»
Metastatic cancer
'J' <^S
te  « H r
Figure 1.7 Illustration of the adenoma to carcinoma sequence
Adapted from Rupnarain ef al., (2004).
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1.7.2 Familial CRC
Hereditary colorectal cancers are indicative of germ-line mutations that result 
in hereditary predispositions to cancer (Vogelstein & Kinzler, 2004). 20 % of 
CRC patients have a first or second degree relative with the disease, with 
hereditary patients making up 5 -  10 % of all CRC patients (Lynch & de la, 
2003). There are two major forms; familial adenomatous polyposis (FAP) and 
hereditary non-polyposis colorectal cancer (HNPCC).
FAP is characterised by a mutation in one APC allele predisposing FAP 
patients to CRC. FAP patients only require inactivation of the wt-APC allele to 
initiate tumourigenesis (Vogelstein & Kinzler, 2004), bringing early onset of 
cancer at around 20 -  30 years. APC controls the p-catenin-TCF pathway, a 
complex pathway that modulates cell proliferation and may play a role in the 
modulation of differentiation (Augenlicht et al., 2002). The colon of FAP 
patients is littered with polyps that are adenomatous in type, with the number 
of polyps present, ranging from a few, to hundreds and thousands. In extreme 
cases the mucosa is not visible due to the numbers of polyps present 
(Shamsuddin, 1990). FAP patients have an almost 100 % risk of developing 
CRC, as the risk of developing cancer increases with the number of adenomas 
present (Eastwood, 1991). For each carcinoma present there may be up to a 
thousand benign adenomatous polyps (Knudson, 2002).
HNPCC patients have early onset of the disease which averages 
approximately 45 years. The HNPCC syndrome is an autosomal dominant 
condition that accounts for approximately 5 % of all colorectal cancers in the 
Western world (Ilyas et al., 1999). HNPCC develops through germ-line 
mutations in any of the mismatch repair genes, which encode gene-products 
responsible for the repair of DNA base pair mismatches formed during DNA 
replication (Ilyas et al., 1999; Knudson, 2002). The mismatch repair genes
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MLH1 and MSH2 account for 90 % of HNPCC tumours, with a predominance 
for the disease in the right side of the colon (Lynch & de la Chapelle, 2003)
1.7.3 Sporadic CRC
Sporadic colorectal cancers represent the majority of colorectal tumours and 
are associated with late onset, usually 1 tumour over 6 to 7 decades of a life 
time. The onset of sporadic colorectal tumours requires the loss of both APC 
alleles, a factor adding to the increased onset compared to familial CRC 
(Augenlicht et a/., 2002). Sporadic CRC is characterised by mutations in a 
single somatic cell, usually epithelial in origin, resulting in the progression to a 
malignant and invasive tumour (Vogelstein & Kinzler, 2004).
1.7.4 Colorectal tumourigenesis and associated aberrant gene 
expression
The balance between proliferation and apoptosis is critical for the steady-state 
production of cell populations within the colon and in maintaining colonic tissue 
homeostasis. When rates of colonic cell proliferation increase and cell death is 
attenuated or inactivated, the risk of developing cancer is increased. In general 
deregulations of this mechanism can disrupt homeostasis, resulting in clonal 
expansion, with the resultant overproduction of affected cells (Lupton, 1995). 
The human APC gene is localised to chromosome 5q21 in FAP patients. A 
mutation cluster region (MCR) has been identified in exon 15 of the APC gene 
in both familial and sporadic tumours, between codons 1286 and 1513. The 
MCR comprises only 10 % of the APC gene yet 90 % of all familial and 
sporadic APC mutations are found in this region (Smith et at., 2002; Ilyas et at., 
1999). The majority of APC mutations are loss of function truncating mutations,
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which result in the loss of APC activity and subsequent failure to modulate the 
p-catenin-TCF4 pathway (Ilyas et al., 1999). Wt-APC transfected into HT-29 
cells inhibits cell growth through increased apoptosis (Morin et al., 1996). 
Alterations in the machinery that controls whether the cell exits the resting 
phase and re-enter the cell cycle (G0/G1 phase), or progress from Gi into S 
phase are found in virtually all tumour cells (Deshpande et al., 2005). P53 acts 
as a suppressor of transformation in conjunction with ras oncogene (Finlay et 
al., 1989). Functional inactivation of p53 by protein degradation or mutations 
within the gene are found in 70 % of CRC cases resulting in deregulation of 
p53-dependent apoptosis (Smith et al., 2000; Sherr, 1996), aneuploidy and 
loss of p53 (Taylor et al., 1999); p53 mutations are found to occur late in the 
adenoma-carcinoma sequence, (Kim et al., 2001). Furthermore, loss of p53 
predisposes cells to drug-induced gene amplification and aberrant 
chromosomal segregation during mitosis (Sherr, 1996). Mutations in K-ras are 
found in the majority of colorectal tumours. 50 % of colorectal tumours contain 
mutations in a ras gene, with 40 % of colorectal tumours containing a ki-ras 
mutation (Augenlicht, 1989).
Loss of pRb or hyperactivation of cdk4 and/or cdk6 are found in most human 
tumour cells. Hyperactivation can be achieved through loss or deregulation of 
CD expression, p16 or other INK4 family members (Deshpande et al., 2005). 
The expression of p16 is disrupted in many cancers. INK4a'/‘ null mice 
spontaneously develop a multitude of cancers at six months old (Sherr, 1996). 
The proto-oncogene c-myc is deregulated in a wide variety of cancers and has 
been found to down-regulate p15, p21 and p27, with p21 being a major target. 
The regulation involves increased (3-catenin-TCF4 activity and is correlated 
with increase c-myc expression (Gartel & Radhakrishnan, 2005). The anti- 
apoptotic gene BIRC5 (survivin) is re-expressed in most human carcinomas.
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Furthermore, survivin expression increases gradually from normal colorectal 
mucosa to adenomas with low grade dysplasia, adenomas with high grade 
dysplasia to carcinomas (Lin et al., 2003).
CD1 is overexpressed in many cancers as a result of gene amplification or 
translocations targeting the CD1 locus, on human chromosome 11 q13. 
Moreover, aberrant over expression of CD1 is seen in many CRC tumours 
(Sherr, 1996). Furthermore, approximately 50 % of HNPCC tumours exhibit 
overexpression of CD1. An early onset of HNPCC correlates with a 
polymorphism in CD1. The polymorphism (G870A) encodes an alternative 
splicing site that encodes a CD1 protein, which does not contain sequences 
involved in the turnover of the protein (Diehl, 2002). Investigations into the 
polymorphism found that HNPCC patients who were homozygous or 
heterozygous for the mutant allele developed colorectal cancer on average 11 
years earlier (Kong et al., 2000).
Table 1.5 some of the de-regulated genes during CRC
development
Up-regulated in CRC Down-regulated in CRC
Survivin p53
c-myc pRb
CD1 p15
K-ras p16
Ki-ras p21
P-catenin-TCF4 p27
1.7.5 Epidemiology of CRC and dietary fibre
The importance of dietary fibre was first identified by Burkitt in the 1970s. 
Burkitt observed a correlation between the high-fibre, low-fat diets, and low 
CRC incident rates in black Africans, compared to their white counterparts on
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low-fibre, high-fat diets (Burkitt, 1971). Since the first observations by Burkitt 
into dietary fibre and CRC, there have been a great number of epidemiological 
studies performed investigating the link between high-fibre, low-fat diets and 
reduced CRC risks. Some cohort and human-intervention studies have found 
only a 50 % protective effect against CRC or no effect at all (Lipkin et al., 1999; 
Topping & Clifton, 2001). A prospective study involving 88,757 women with a 
16 year follow up period found no correlation between intake of dietary fibre 
and risk of CRC, when the first 6 follow up years were excluded (Fuchs et al., 
1999).
In general case-controlled studies have provided the most convincing results. 
In an analysis of 19 case-controlled studies, 13 showed a protective effect of 
dietary fibre against CRC. Fibre from cereals and pulses had the highest 
correlation (Lipkin et al., 1999). An analysis of 13 case-controlled studies 
identified 12 which showed a decreased risk of CRC with increased dietary 
fibre intake. On average there was a 26 % reduced risk of CRC per 27 g of 
dietary fibre consumed per day (Howe et al., 1992). A population based study 
involving 1993 CRC patients and 2410 controls in three areas of the U.S.A., 
showed a correlation between increased dietary fibre intake and reduced CRC 
risk. The study also found that increase fat intake from pre-prepared food also 
increased the risk of CRC. Furthermore, women with family histories of CRC 
had an increased risk of developing CRC compared to women on similar diets 
with no family history of CRC (Slattery et al., 1997). A randomised-controlled 
study performed in the U.S.A., screened patients on the prostate, lung, 
colorectal and ovarian cancer screening study (PLCO study). In total 33971 
patients were screened with 3591 adenomas discovered in the distal bowel 
(descending and sigmoid colon and rectum). The study identified a correlation 
between a high fibre diet and low colorectal adenomas. Furthermore the
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correlation was highest with fibres from fruits and grains (Peters et al., 2003). 
An EPIC cohort-study involving 519,978 people across 10 European countries 
(Denmark, France, Italy, Germany, Greece, Netherlands, Norway, Spain, 
Sweden and UK) showed an inverse correlation between total fibre intake and 
reduced CRC risk. The correlation was strong for the left side of the colon, but 
could not identify which fibres had the highest protective nature (Bingham et 
al., 2003). A case control study performed in North Carolina, USA, found a diet 
high in fat and salt gave an increased risk of adenomas, whereas a diet high in 
fibre and fruit reduced the risk of adenomas. The risk of adenomas was also 
correlated with high secondary bile acids (Sandler et al., 1993). A population 
(cohort) study in Japan observed CRC mortality rate decrease with increased 
rice and wheat consumption. However, a study in Hawaian Japanese observed 
no significant differences between colonic adenoma incident rate and intake of 
dietary carbohydrate (Young-in Kim, 2000).
A link between starch intake and reduced CRC risk has also been identified. 
High starch intake and reduced CRC risk has been observed in Africa and 
Australia, which have the same fibre intake but very different CRC incidence 
rates. Australians have higher CRC incidence rates compared to Africans but 
lower starch intake (Topping & Clifton, 2001). In general, incidences of CRC 
are inversely related to stool weight (Kirtchevsky, 1995), and a correlation 
exists between increased stool weight and increased intake of dietary fibre 
(Eastwood, 1991). However, the relationship between dietary fibre and cancer 
is a complex one. For example, faecal bile acid concentrations are higher in 
cancer patients (Bingham et al., 2003), and the addition of bran to the diet has 
been found to reduce bile acid concentrations in the faeces, whereas pectin 
has been found to increase faecal bile acid concentrations (Eastwood, 1991). 
CRC patients tend to exhibit high faecal pH. Moreover, a study into CRC
- 42-
CHAPTER 1: INTRODUCTION
incidences in African subpopulations found that faecal pH was highest in 
subpopulations with the highest CRC incidences rates. Intriguingly, the 
subpopulations all had approximately the same total fibre intake (Kritchevsky, 
1995). Dietary fibre is not the only nutritional substance with implications in 
colon carcinogenesis; other factors are also important and include fat, bile 
acids, cholesterol plus minerals such as calcium (Bugaut & Bentejac, 1993; 
Eastwood, 1991).
Cancer is a multistage process that is likely to be affected at different stages 
by different dietary patterns, but as the discussion above demonstrates, the 
inclusion of high amounts of fibre in the diet does, in general, have a protective 
effect again colon carcinogenesis (Hill, 1995b).
1.8 Mechanistic action of butyrate
1.8.1 Intracellular Mechanism of butyrate action
Butyrate treatment of cultured cells results in modulation of multiple genes. 
The exact down stream processes by which butyrate modulates the vast 
number of genes is unclear; however some proposed methods through which 
butyrate’s effects are mediated are discussed below.
Histones are acetylated by histone transacetylases on lysine residues and 
deacetylated by histone deacetylase. There is a correlation between the extent 
of histone acetylation and template activity of chromatin (Kruh et al., 1994). 
Hyperacetylation of histones H3 and H4 leads to changes in chromatin 
structure; unfolding the chromatin and allowing access to the DNA by 
transcription factors and DNases (Hague & Paraskeva, 1995). Treatment of 
butyrate to cultured cells results in general histone acetylation through the 
inhibition of nuclear histone deactylases resulting in increase gene expression
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(Clausen, 1995; Hague & Paraskeva, 1995). Increased DNA cleavage and 
micrococcal nuclease has been found to digest chromatin from butyrate 
treated cells in vitro to a much higher extent than untreated cells (Kruh et al., 
1994). Tricstatin A (TSA) is a known histone deacetylase inhibitor; treatment of 
cultured cells with TSA at concentrations that are known to inhibit histone 
deacetylase, has no effect on expression of p21. Moreover induction of IAP 
and DPP IV by TSA was significantly lower than that modulated by butyrate 
indicating that butyrate modulates p21 by some other means (Siavoshian et 
al., 2000). Hyperacetylation of histones explains the global changes in gene 
expression seen in butyrate-treated cultured cells. Butyrate though, is able to 
modulate genes with a more discrete effect; hyperacetylation of histones does 
not explain this (Kruh et al., 1995).
A family of nonhistone nuclear proteins known as the high mobility group 
(HMG) proteins have 3 subfamilies. One such subfamily, namely HMG-N1/N2 
bind a 146 bp nucleosome core particle. Binding of HMG-N1/N2 to 
nucleosomes unfolds the higher order chromatin structure and enhances 
various DNA-dependent activities such as transcription and replication. 
Acetylation of HMG-N2 reduces its binding activity to chromatin. Butyrate 
treatment of HT-29 cells increased acetylation on HMG-N2 (Hinnebusch et al., 
2002) linking butyrate modulation of gene expression to unfolding of chromatin 
and increased gene expression.
Histone méthylation and phosphorylation is also linked to modulation of 
chromatin structure. Histones méthylation is inhibited in a concentration- 
dependent manner by butyrate. Butyrate has also been shown to inhibit the 
phosphorylation of histones H1 and H2A in HeLa cells (Boffa et al., 1981). 
Moreover there is evidence indicating that histone H1 phosphorylation is 
required for G1/s progression (Boffa et al., 1981; Clausen, 1995) and that
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butyrate modulated inhibition of histone H1 phosphorylation and increased H3 
phosphorylation is mediated by a calcium-dependent protein kinase (Kruh et 
ai, 1994).
Méthylation of cytosine in the regulatory sequence of a gene prevents the 
expression of a gene. Treatment with butyrate has been shown to decrease 
DNA méthylation (Clausen, 1995). Moreover, butyrate’s effect on DNA 
méthylation, whether to increase or decrease méthylation, in dependent on cell 
type (Kruh et ai, 1994), illustrating another route by which butyrate’s 
modulation of gene expression is mediated within the cell.
1.8.2 Mechanism of butyrate action at the plasma membrane
The mechanisms of butyrate regulation of gene expression discussed in 
section 1.8.1 are dependent on the presence of butyrate within the cell. There 
is evidence however, that butyrate is able to modulate the expression of 
certain genes extracellularly (Cuff et ai, 2005). As discussed previously, MCT1 
is responsible for the transport of butyrate across the luminal membrane of 
colonocytes. Cuff et ai, (2005) knocked down the expression of MCT1 in three 
colonic cell lines (AA/C1, HT-29 and HCT-116) to investigate the effect on 
butyrate-induced gene expression on a variety of genes. After treatment of the 
colonic cell lines with small interfering RNA (siRNA) to MCT1, a decrease in 
MCT1 protein expression of up to 80 % was seen. A corresponding decrease 
in butyrate transport into colonic LMVs isolated from the MCT1 siRNA treated 
cells was also observed (Cuff et al., 2005). Silencing MCT1 expression 
prevented butyrate-induced regulation of p21, IAP and CD1, in all three cell 
lines. However, the butyrate-induced modulation of the apoptotic genes bak1 
and bcl-xL was not inhibited by the knock-down of MCT1 (Cuff et ai, 2005). 
This finding has led to the hypothesis of the presence of a butyrate sensor
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located on the luminal membrane of colonocytes. The putative butyrate-sensor 
senses butyrate in the lumen resulting in the downstream regulation of bak1 
and bcl-xL (Cuff et a!., 2005).
1.9 Nutrient sensing
1.9.1 Nutrient sensing and regulation of gene expression
The intestinal lumen is a constantly changing environment responsive to the 
diet. The intestine is at constant equilibrium between the nutrients available in 
the lumen and the extra- and intra-cellular metabolic systems that are 
regulated by these nutrients. Nutrient-induced signalling pathways allow for 
optimal nutrient consumption through adaptations in metabolism and the 
associated adjustments in growth properties (Swinnen et al., 2006). 
Polyunsaturated fatty acids (PUFA) bind intra-cellularly to members of the 
peroxisome proliferator-activated receptor (PPAR) family of transcription 
factors. Binding of PUFAs to PPARa induces up-regulation in p-oxidation 
enzymes (Al-Hasani & Joost, 2005). The intestine is also capable of sensing 
nutrients available in the lumen. Long-chain fatty acids are sensed (Raybould, 
1999) and amino acid transporters are regulated via extra-cellular sensors 
(Hyde et al., 2003). Glucose and galactose are sensed in the small intestine 
via a G-protein coupled receptor (GPCR) linked to the a-subunit of a G-protein, 
Gustducin, and a cAMP-PKA pathway (Dyer et al., 2003); the activation of the 
sensor results in the downstream enhancement in expression of the intestinal 
sodium/glucose co-transporter, SGLT1 (Dyer et al., 2003). The intestinal 
glucose sensor is thought to be a heterodimer of GPCRs T1R2 and T1R3 that 
are found in the taste buds on the tongue and the palate, sensing 
monosaccharides and artificial sweeteners. Furthermore, T1R2 and T1R3
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have been found to be expressed along the axis of the mouse small intestine 
and in STC-1 cells, a mouse enteroendocrine cell line (Dyer et al., 2005). The 
bitter taste receptors of the TR2 family have also been found to be expressed 
in mouse small intestine and STC-1 cells (Wu et al., 2002). An extra-cellular 
calcium-sensing receptor (CaR) has been identified in the gastrointestinal tract 
(Hebert et al., 2004). Upon activation, the receptor initiates intracellular 
pathways involving phophoinositide turnover, increased concentration of intra­
cellular calcium and production of inositol trisphosphate (Riccardi & 
Maldonado-Perez, 2005). CaR is a member of the GPCR superfamily and is 
expressed along the entire length of the gastrointestinal tract (Kirchhoff & 
Geibel, 2006). CaR is not only activated by Ca2+ but by other divalent cations 
including Zn2+, Ni2+, Co2+, Ba2+, Sr2* and Pb2+; L-amino acids and small 
peptides; as well as the polyamines spermine and spermidine (Riccardi & 
Maldonado-Perez, 2005). Furthermore, CaR is expressed in the human large 
intestine on the apical and basolateral membranes of crypts as well as certain 
enteroendocrine cells (Hebert et al., 2004). Colonic CaR regulates fluid 
secretion in colonic crypts through cAMP and cGMP pathways (Geibel et al., 
2006).
1.9.2 The SCFA receptors GRP41 and GPR43
Investigations carried out during the human genome project identified many 
orphan G-protein coupled receptors (GPCR); so called due to the lack of 
knowledge concerning their activating ligand. Brown et al., (2003) discovered 
that the orphan GPCRs, GPR41 and GPR43, are activated by short chain 
carboxylic anions in a dose-dependent and dose-specific manner (Brown et al., 
2003). A carbon chain length of between one to six carbons is required for 
activation, and the presence of two or more carboxylic groups fails to activate
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the receptors (Le Poul et al., 2003). Short-chain fatty acids, acetate, 
propionate, butyrate and pentanoate have been found to stimulate leptin 
production in adipocytes through GPR41, although acetate was found to be 
less potent than propionate, butyrate or pentanoate (Xiong et al., 2004). 
Furthermore, GPR41 has been shown to induce apoptosis via a p53/Bax 
pathway during reoxygenation after ischemic hypoxia in HT-29 cells (Kimura et 
al., 2001). The activation of GPR41 and GPR43 by SCFAs makes them 
excellent candidates for the putative human colonic butyrate sensor.
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1.8 Aims and objectives
1.8.1 Synopsis
Butyrate is transported across the colonic luminal membrane predominantly by 
the monocarboxylate transporter isoform 1, MCT1. Silencing of MCT1 
expression has been shown to have a profound inhibitory effect on the ability 
of butyrate to regulate some key butyrate responsive genes controlling 
proliferation and differentiation of colonic epithelial cells.
In contrast, inhibition of MCT1 expression has had no effect on the ability of 
butyrate to modulate the expression of genes regulating apoptosis; implying 
that for some butyrate responsive genes there is a need for butyrate entry into 
the cell, and for some butyrate may exert its effect via a plasma membrane 
butyrate sensor (Cuff et al., 2005).
1.8.2 Aims
The aims of this study were to (i) synthesise a membrane impermeable 
butyrate analogue (disodium PEG6ooa,co-di(4-butyrate)) (ii) assess the structure 
and purity of the compound (iii) investigate whether the expression of genes 
regulating apoptosis of colonic epithelial cells are responsive to the membrane 
impermeable butyrate analogue and (iv) examine the significance of response 
in terms of butyrate regulation of gene expression.
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2.1 Materials
2.1.1 Chemicals and radioisotopes
All chemicals and solvents were o f the highest analytical grade and obtained 
from Sigma-Aldrich (Poole, Dorset, UK), Fisher Scientific (Leics., UK), B.D.H 
Chemicals Ltd (Poole, Dorset, UK) or BioRad Laboratories (Herts., UK) unless 
otherwise stated.
[a-32P]dCTP (specific radioactivity 3000 Ci mmol'1) was obtained from the 
Radiochemical Centre (Amersham, Bucks., UK) and used within 1 half-life of 
the stated activity date. Sodium [U-14C]butyrate was obtained from Sigma- 
Aldrich with a specific radioactivity of 16 mCi mmol'1.
2.1.2 Antibodies
Antibodies to MCT1 were raised in rabbits against a peptide 
(CQKDTEGGPKEEESPV) corresponding to the C-terminus region of human 
MCT1. Monoclonal antibodies to human villin and human p-actin were 
purchased from the Binding Site (UK) and Sigma-Aldrich respectively. 
Polyclonal antibodies to human alkaline phosphatase were purchased from 
Abeam (UK). Polyclonal antibodies to Rat glut II were a kind gift from Prof. 
Bernard Thorens (University of Lausanne, Switzerland). Monoclonal antibodies 
to human Bcl-xL and polyclonal antibodies to human Bak were purchased from 
Santa Cruz Technology Inc (UK). Mouse monoclonal antibodies to human 
HMC I (HLA-1); goat anti-mouse and swine anti-rabbit secondary antibodies 
conjugated to horseradish-peroxidase were purchased from Dako Ltd (UK).
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2.2 Chemical Synthesis
2.2.1 Chemicals
4-Bromobutyronitrile and Polyethylene glycol)60o were purchased from 
Lancaster Synthesis, Morecambe, UK. 1,8-Diazabicyclo[5.4.0]undec-7-ene, 
Diethylaminoethyl (DEAE) Sephadex A50, Triethylamine (99.5 %) and 1,4- 
dioxane (anhydrous Sure-seal™) were all obtained from Sigma-Aldrich, UK. All 
general solvents used were of Analar grade or equivalent.
2.2.2 Equipment and buffers
2.2.2.1 NMR
Analytical 1H NMR and 13C NMR spectra were obtained on a Bruker AMX400 
(400 MHz) NMR spectrometer (Bruker BioSpin Limited, Coventry, UK). 
Samples were run in deuterated methanol (CD4OD) against an internal 
standard of tetramethylsilane (TMS). All chemical shifts are reported in ppm.
2.2.2.2 Mass spectrometry
Mass spectra were obtained on a Micromass LCT mass spectrometer (Waters 
Ltd, Herts., UK) using electrospray ionisation (El) and direct infusion syringe 
pump sampling. All samples were diluted in methanol.
2.2.2.3 IR spectroscopy
Samples were prepared in nujol and held between NaCI discs. IR spectra were 
obtained using a Perkin-Elmer Spectrum RX1 FT-IR spectrometer 
(PerkinElmer Life And Analytical Sciences, Inc. Wellesley, MA, USA).
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2.2.2.4 Preparation of triethylamine bicarbonate
Triethylamine bicarbonate (TEAB) was prepared according to (Eccleston & 
Trentham, 1977). A 1 M solution of TEA in distilled H20  was prepared and 
carbon dioxide bubbled through the TEA solution for approximately three 
hours. The reaction was stopped once an approximate pH 7.5 was reached.
2.2.3 Thin Layer Chromatography
Aluminium-baked silica plates (Fisher, Leics., UK) were used, with an eluant 
consisting of ethyl acetate:methanol:27 % (w/w) concentrated ammonia:water 
(65:20:10:5 v/v/v/v).
The following stains were used:
■ Iodine vapour; gave brown spots on a yellow background
■ Potassium permanganate; gave yellow spots on a purple background
■ Bromocresol green; gave blue spots on a pale blue/green yellow 
background
For use of the potassium permanganate and bromocresol green stains, the 
TLC plates were dipped into the corresponding stain and dried using a heat 
gun until spots were detected. When using iodine vapour, the TLC plate was 
left in a sealed container containing iodine for approximately 5 minutes.
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2.2.4 The synthesis of di(4-butyronitrile)poly(ethylene glycol)6oo
4-Bromobutyronitrile (BBN) (9.07 g, 61 mmol) was added to a stirred solution 
of polyethylene glycol) with an average molecular weight of 600 gmol'1 (6.0 g, 
10 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (6.0 g, 39 mmol) in 
10 ml dry 1,4-dioxane. The reaction mixture was heated at 110 °C at reflux for 
approximately 4 weeks until no starting material remained. The reaction was 
followed using TLC and an iodine vapour or potassium permanganate stains.
1H NMR: 5h (400 MHz, DMSO) 1.80 (PEG-BN, 4H, m, H2 and H3, J3.4 = 6.2),
2.01 (BBN, 2H, m, H3, J3.2 = 7.0 Hz, J3.4 = 6.51 Hz), 2.13 (BBN, 2H, t, H1, J2.3 
= 7.0 Hz), 3.42 (PEG-BN, 2H, t, H4, J4.3 = 5.88), 3.48 (BBN 2H, t, H4, J4.3 = 
6.50 Hz), 3.57 (PEG600 , 2H, t, H1'), 3.51 (PEG backbone, 4H, t, CH2-CH2-0). 
3.57 (PEGeoo, 2H, t, H2\ J2,r  = 6.51)
Mass spectra: found (m/z) (4-butyronitrile)PEG60o [M + Na]+ n=10, 548.3; 
n=11, 592.3; n=12, 636.4; n=13, 680.4; n=14 724.4; n=15, 768.4; n=16, 812.5. 
di(4-butyronitrile)PEG6oo [M + Na]+ n=9, 571.3; n=10, 615.3; n=11, 659.4; n=12, 
703.4; n=13, 747.4; n=14, 791.4; n=15, 835.5. PEG600 [M + Na]+n=7, 349.2; 
n=8, 393.2; n=9, 437.2; n=10, 481.3; n=11, 525.3; n=12, 569.3; n=13, 613.4; 
n=14, 657.5; n=15, 701.5.
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2.2.5 Hydrolysis of di(4-butyronitrile)poly(ethylene glycol)6oo
o
OH
The crude PEG6oobutyronitrile was added to aqueous NaOH (20 ml 4 M) and 
stirred at 120 °C. The reaction was initially followed with TLC using iodine 
vapour, K2Mn04 and bromocresol green stains and then mass spectrometry. 
The reaction mixture was neutralised using 1 M HCI and concentrated prior to 
purification using anion-exchange column chromatography.
Mass spectra: found (m/z) (4-butyric acid)PEG600 [M + Na]+ n=7, 435.2; n=8, 
479.2; n=9, 523.2; n=10, 567.2; n=11 611.3; n=12, 655.3; n=13, 699.3; n=14, 
743.2; n=15, 787.4; n=16, 831.4. di(4-butyic acid)PEG600 [M + Na]+ n=6, 477.2; 
n=7, 521.2; n=8, 565.2; n=9, 609.2; n=10, 653.3; n=11, 697.3; n=12, 742.3; 
n=13, 785.3; n=14, 824.4; n=15, 868.4. (4-butyronitrile,4'-butyric acid)PEG60o 
[M + Na]+ n=8, 546.2; n=9, 590.3; n=10, 634.3; n=11, 678.3; n=12, 722.3; 
n=13, 766.3.
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2.2.6 Anion-exchange chromatography
Diethylaminoethyl (DEAE) Sephadex A50 (Sigma-Aldrich, UK) was used as 
the anion exchange resin. The concentrated reaction mixture (5 ml, ~5g) was 
added onto the column with dH20. The column was washed using dH20, to 
remove unreactive starting material and eluted using 1 M triethylamine 
bicarbonate (TEAB). The fractions containing PEG6ooOc,a>-di(4-butyric acid), as 
determined using TLC, were pooled and the solvent removed by rotary 
evaporation, to yield a light brown oil.
1H NMR: SH (400 MHz, CD3OD) 1.28 (TEAH, 3H, t, H2", Jr .r  = 7.31 Hz), 1.67 
(PEG-BN, 4H, m, H2 and H3, J3-4 = 7.47), 1.86 (PEG-ba, 2H, m, H3', J3,2. = 
6.83 Hz, J3'_4' = 7.47 Hz), 2.21 (PEG-ba, 2H, t, H2\ J2,3. = 7.29 Hz), 3.25 
(TEAH, 2H, q, H2", J2.,3» = 7.15 Hz), 3.46 (PEG-BN, 2H, t, H4, J4.3 = 7.15 Hz), 
3.51 (PEG-ba, 2H, t, H3\ J4,3. = 6.52 Hz), 3.67 (PEG backbone, 4H, t, Chh- 
CH2-0).
Mass spectra: found (m/z) (4-butyric acid)PEG600 [M + Na]+ n=7, 435.2; n=8, 
479.2; n=9, 523.2; n=10, 567.2; n=11 611.3; n=12, 655.3; n=13, 699.3; n=14, 
743.2; n=15, 787.4; n=16, 831.4. di(4-butyic acid)PEG600 [M + Na]+ n=6, 477.2; 
n=7, 521.2; n=8, 565.2; n=9, 609.2; n=10, 653.3; n=11, 697.3; n=12, 742.3; 
n=13, 785.3; n=14, 824.4; n=15, 868.4. (4-butyronitrile,4'-butyric acid)PEG600
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[M + Na]+ n=8, 546.2; n=9, 590.3; n=10, 634.3; n=11, 678.3; n=12, 722.3; 
n=13, 766.3.
2.2.6.1 Extraction of di(4-butyric acid)poly(ethylene glycol)6oo
A portion of the crude product (approximately 50 g) from the anion exchange 
chromatography was stirred for 48 hours in a large excess of acetone (400 ml). 
The acetone was filtered to remove the precipitated TEAH and the filtrate 
evaporated to yield a light brown oil. Another volume of acetone was added to 
precipitate more TEAH salt before filtering and evaporating the filtrate. The 
washing and filtering was repeated several times to reduce the amount of 
TEAH to a minimum. The amount of TEAH present was constantly monitored 
using 1H NMR.
Cellex-P, hydrogen ion form (BioRad, UK) was mixed with aqueous NaOH (0.5 
M, ~ 25 ml) and stirred at room temperature for 15 minutes to produce the 
sodium ion form of the resin. The Cellex-P sodium form (~ 30 ml) was poured 
into a column and cleaned by washing the column three times with dH20, 
which also removed excess sodium ions. The PEG600a,(o-di(4-butyric acid) 
TEAH salt ( ~ 5 g) was dissolved into a small volume of dH20  before loading
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on to the column and eluted with dH20. The fractions containing di(4-butyric 
acid)PEG6oo, as determined using TLC, were pooled and the solvent removed 
to yield a brown oil. The volume of deionised distilled water was added to 
prepare a 200 mM solution of disodium PEG600di(4-butyrate) and aliquoted into 
1 ml conical microcentrifuge tubes, afterwhich the deionised distilled water was 
removed in vacuo.
1H NMR: 8h (400 MHz, CD3OD) 1.85 (PEG-ba, 2H, m, H3, J3.2- = 7.4 Hz, J2.3. 
= 6.83 Hz), 2.26 (PEG-ba, 2H, t, H2', J2.3. = 7.4 Hz), 3.48 (PEG-ba, 2H, t, H4\ 
J4'-3' = 6.45 Hz), 3.64 (PEG backbone, 4H, t, (CH2-CH2-0)n).
13C NMR: 8C (400 MHz, CD3OD) 18.8 (C2), 24.4 (C3'), 27.2 (C3), 32 (C2'), 
71.3 (CH2-CH2-0-), 71.9 (C4'), 73.5 (C4), 180 (C1').
Mass spectra: found (m/z) (4-butyric acid)PEG6oo [M + Na]+ n=7, 435.2; n=8, 
479.2; n=9, 523.2; n=10, 567.2; n=11 611.3; n=12, 655.3; n=13, 699.3; n=14, 
743.2; n=15, 787.4; n=16, 831.4. di(4-butyic acid)PEG600 [M + Na]+ n=6, 477.2; 
n=7, 521.2; n=8, 565.2; n=9, 609.2; n=10, 653.3; n=11, 697.3; n=12, 742.3; 
n=13, 785.3; n=14, 824.4; n=15, 868.4. (4-butyronitrile,4'-butyric acidPEG600) 
[M + Na]+ n=8, 546.2; n=9, 590.3; n=10, 634.3; n=11, 678.3; n=12, 722.3; 
n=13, 766.3.
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2.3 Tissue and cell culture
2.3.1 Tissue collection
Porcine colonic samples were taken from adults pigs at an abattoir. Sections of 
the intestine were removed, divided into proximal, middle and distal sections 
and rinsed in ice-cold saline (0.9 % (w/v) NaCI pH 7.4). The sections were cut 
open and blotted with paper towels to remove excess mucous. The mucosa 
was scraped off with a glass slide, wrapped in aluminium foil and immediately 
frozen in liquid nitrogen. Upon returning to the laboratory the mucosal 
scrapings were stored at -80 °C until use.
2.3.2 Routine maintenance of cell lines
AA/C1, a human colonic epithelial non-tumorigenic adenoma-derived cell line 
(Williams et a/., 1990), was a kind gift from Professor C. Paraskeva, University 
of Bristol, UK. AA/C1 cells were maintained at 37 °C with 5 % C 02 in 
glutamine-free Dulbecco’s modified eagle’s medium (DEME; Sigma-Aldrich, 
UK), supplemented with, 20 % (v/v) foetal bovine serum (Sera Labs., UK), 100 
pg ml'1 streptomycin, 100 units ml'1 penicillin, 1 pg ml'1 hydrocortisone sodium 
succinate, 0.2 units ml'1 human Actrapid insulin (Novo Nordisk, Switzerland) 
and 2 mM glutamine.
HT-29 cells, an adenocarcinoma cell line, were also a kind gift from Professor 
C. Paraskeva and were maintained at 37 °C with 5 % C02 in DEME, 
supplemented with 10 % (v/v) foetal bovine serum, 100 pg ml'1 streptomycin, 
100 units ml'1 penicillin and 2 mM glutamine.
Cells were routinely passaged using a solution of 0.1 % (w/v) tripsin, 
phosphate buffered saline (Sigma-Aldrich, UK) and 0.1 % (w/v) EDTA. AA/C1
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cells were used between passage numbers 83 and 90; HT-29 cells were used 
between passage numbers 13 and 34.
2.3.3 Treatment of cultured cells
Cells were grown to either 70 % confluency (HT-29) or 100 % confluency 
(AA/C1) for treatment. Sodium butyrate (Sigma-Aldrich), sodium 
heptafluorobutyrate (Sigma-Aldrich), polyethylene glycol)600 (Lancaster 
synthesis, UK) and disodium PEG60oa,ro-di(4-butyrate) were prepared using 
ddH20  to a final concentration of 200 mM. Cells were treated with compounds 
(2-5 mM) for up to 48 hours and resupplemented after 24 hours. After the 
elapsed time of treatment, cells were washed three times with phosphate 
buffered saline (PBS) and harvested with a cell scraper. Cells were collected 
by centrifugation and either used immediately or stored at -80 °C until use.
2.4 Preparation of protein samples
2.4.1 Preparation of whole cellular homogenate from cultured cells
Cell pellets were resuspended in lysis buffer (10 mM Hepes/tris pH 7.4, 150 
mM NaCI, 10 mM EDTA, 0.1 % (w/v) SDS, 1 x Complete protease inhibitor 
(Boehringer Mannheim, Germany) and 0.2 mM PMSF), transferred to a 1.5 ml 
microfuge tube and mixed 10 times using a 1 ml pipette. The cells were 
homogenised using either a 27 G needle or a 100 pi Hamilton syringe 
(Scientific Glass Engineering, PTY, Ltd, Australia), depending on the volume of 
lysis buffer used, by drawing the cellular suspension through the needle 10 
times. Whole cell homogenates were stored at -20 °C.
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2.4.2 Preparation of porcine colonic luminal membrane vesicles
Mucosal scrapings were defrosted on ice in a hypotonic buffer, buffer 1 (100 
mM mannitol, 2 mM Hepes/tris pH 7.1, 0.2 mM benzamidine, 0.2 mM PMSF, 
0.2 mM DTT). Approximately 10 ml buffer per 1 g tissue was used. The 
scrapings were homogenised using an Ystral polytron (Ystral Scientific 
Instruments, Cambridge, UK) with a medium probe on setting 4 for 2 x 30 
seconds with the sample kept on ice during the interval. The homogenate was 
filtered through 2 layers of gauze and made up to 100 ml total volume with 
buffer 1 before centrifuging at 500 x g for 10 minutes at 4 °C (SS34 rotor, 
Sorvall RC 5C Plus, Kendro Laboratory Products, USA) to remove nuclei. The 
supernatant (S1) was decanted and placed on ice. MgCI2 was added to a final 
concentration of 10 mM and left to stir for 20 minutes before centrifuging at 
3000 x g for 10 minutes at 4 °C (SS34 rotor) to remove organelles and 
solublised membranes. The supernatant (S2) was centrifuged at 39,000 x g for 
30 minutes at 4 °C (SS34 rotor) to collect the luminal membranes. The pellet 
(P3) was resuspended in 6 ml buffer 2 (100 mM mannitol, 20 mM Hepes/tris 
pH 7.4, 0.1 mM MgS04) and homogenised using a Dounce homogeniser 
(Jencons Ltd, UK) with a tight fitting Teflon pestle for 60 strokes, before 
centrifuging at 39,000 x g for 45 minutes at 4 °C (SS34 rotor) to yield the 
purified luminal membranes. The pellet (P4) was resuspended in 50 |il buffer 3 
(300 mM mannitol, 20 mM Hepes/tris pH 7.4, 0.1 mM MgS04) and 
homogenised using a 25 G needle. The colonic luminal membrane vesicles 
were either used on the day or stored under liquid N2 until further use.
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2.4.3 Quantification of protein: micro assay.
Protein concentrations were determined by the Bio-Rad assay technique 
based on the method of (Bradford, 1976), exploiting the shift in absorbance 
from 465 nm to 595 nm when proteins bind to Coomassie blue. A commercially 
available dye was used (BioRad, Herts, UK) and a standard curve prepared (3 
pg to 24 pg) using porcine y-globulin (1.5 mgml'1) as the standard in 800 pi 
buffer 3. 1 pi of sample was diluted in 800 pi of buffer 3 (see section 2.4.2) and 
200 pi of protein dye was added to all samples and standards before leaving 
for 15 minutes at room temperature. The absorbance of samples and 
standards was read at 595 nm on a UV spectrophotometer (Hitachi U-200 
Spectrophotometer, UK).
2.5 Enzyme Assays
2.5.1 Measurement of cysteine-sensitive alkaline phosphatase 
activity
The activity of cysteine-sensitive alkaline phosphatase, a luminal membrane 
marker, was measured according to the procedure of Brasitus & Keresztes, 
(1984), with p-nitrophenylphosphate (PNPP) as the substrate.
Samples (50 pg) were incubated at 37 °C and the reaction started with the 
addition of 900 pi of reaction buffer (32 mM glycine pH 9.3, 3.2 mM MgCI2, 
0.32 mM ZnS04, 15 mM PNPP). The samples were incubated for 15 minutes 
in the presence or absence of 10 mM L-cysteine before stopping the reaction 
with the addition of 2 ml of 1 M NaOH. The absorbance was read at 410 nm 
(EmM = 17) against a buffer blank. Specific activity was expressed as nmol, min' 
1 (mg protein)'1. The appearance of p-nitrophenol was shown to be linear with 
time and protein concentration under the parameters of the assay.
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2.5.2 Measurement of a-mannosidase activity
The activity of a-mannosidase, a marker for the golgi apparatus, was 
measured according to the procedure of Tulsiani et al., (1977), with p- 
nitrophenol-a,D-mannoside (PNPM) as the substrate.
Colonic LMV fractions (50 pg) were incubated at 37 °C in 500 pi of a citrate 
buffer (50 mM citric acid, 50 mM sodium citrate, pH 4.5). The reaction was 
started with the addition of 500 pi of substrate (10 mM PNPM) and incubated 
for 30 minutes at 37 °C. The reaction was terminated with the addition of 2 ml 
of a borate buffer (0.2 mM boric acid pH 9.8 with 2 M NaOH) and the fractions 
were left for 15 minutes for the yellow colour to develop before the absorbance 
was read at 410 nm (EmM = 18.5) against a buffer blank. Specific activity was 
expressed as nmol, min'1 (mg protein)'1. The appearance of p-nitrophenol was 
shown to be linear with time and protein concentration under the parameters of 
the assay.
2.5.3 Measurement of Succinate dehdrogenase activity
The activity of succinate dehydrogenase, a marker of the mitochondria, was 
measured according to the procedure of Pennington, (1961) with p- 
iodotetrozolium succinate (INT) as the substrate.
A 2x Reaction buffer was prepared consiting of: 100 mM sodium succinate, 50 
mM sucrose, 50 mM potassium dihydrogen phosphate (KH2P04) and 50 mM 
dipotassium phosphate (K2P04) pH 7.4
On the day of the experiment the 2x reaction buffer was diluted two fold and 
substrate was added to a final concentration of 1 mg/ml. Colonic LMV fractions 
(30-40 pg) were incubated at 37 °C in glass tubes; the reaction started with the 
addition of 750 pi of the reaction buffer and left to incubate until a rose colour
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appeared. 3 ml of ethyl acetate was added to each sample and mixed to 
extract the tétrazolium dye product before reading the upper phase at 490 nm 
(EmM =20.1) against a buffer blank. The appearance of the tétrazolium product 
was shown to be linear with time and protein concentration under the 
parameters of the assay.
2.5.4 Measurement of tris-resistant-a-glucosidase activity
The activity of tris-resistant-a-glucosidase, a marker for the endoplasmic 
reticulum, was assayed according to Peters, (1976), with p-nitophenyl-atD- 
glucoside (PNPG) as the substate. 50 pg of sample were incubated on ice in 
50 pi of tris buffer (35 mM tris/HCI pH 8.0, 5 mM glutathione) for 15 minutes. 
The samples were then incubated at 37 °C and the reaction was started by the 
addition of 250 pi phosphate buffer (0.1 mM Na2HP04, 0.21 mM p-nitophenyl- 
a,D-glucoside, 0.1 % (v/v) triton X-100). After 30 minutes the reaction was 
stopped by the addition of a glycine buffer (5 mM glycine pH 10.4) and the 
absorbance read at 410 nm (EmM = 18.5) against a buffer blank. Specific 
activity was expressed as nmol, min'1 (mg protein)'1. The appearance of p- 
nitrophenol was shown to be linear with time and protein concentration under 
the parameters of the assay.
2.5.5 Measurement of H+/K+, Na+/K+-ATPase activity
The activity of the H+/K+ ATPase was measured using an assay adapted from 
Sarkar (2002). All solutions were prepared fresh on the day of the assay. A 2 x 
assay mix consisting of 240 mM NaCI, 8 mM Na2ATP, 8 mM MgCI2, 120 mM 
tris/HCI pH 7.5 and 2 mM EDTA was prepared and diluted 2 fold to produce 2 
reaction solutions:
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Solution A (Total ATPase activity): 1 x assay mix with 20 mM KCI 
Solution B (K+ insensitive): 1 x assay mix
Protein samples (50 pi) were permeablised with saponin (0.05 % (w/v) final 
concentration) and incubated at 37 °C. The reaction was started with the 
addition of 400 pi of either solution A or B and left to incubate for 10 minutes. 
The reaction was stopped by the addition of 1 ml developing solution (1.15 M 
H2S04, 1 % (w/v) ammonium molybdate, 4 % (w/v) ferrous sulphate) and left to 
develop for 1 hour. The developing solution has a light grey colour that 
changes to a deep blue during development. A standard curve of K2HP04 was 
also prepared from 0 to 720 pM, to calculate the Pi release, which was 
developed at the same time as the samples. Buffer blanks were used for each 
solution (A and B) that consisted of 50 pi ddH20  and 400 pi of the 
corresponding solution. The absorbance was measured at 690 nm and specific 
activity was expressed as the amount of Pj released in nmol, min'1 (mg 
protein)'1. The activity of H+/K+-ATPase was determined by subtracting the 
specific activity of solution B from solution A.
2.5.6 Measurement of alkaline phosphatase activity.
The total activity of alkaline phosphatase was measured based on the method 
of Shirazi et al., (1981) with PNPP as the substrate. A reaction buffer was 
prepared in advance consisting of: 10 mM sodium bicarbonate (NaHC03), 10 
mM disodium carbonate (Na2C03), 0.1 mM magnesium sulphate (MgS04).
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On the day of the assay the reaction buffer was mixed 9:1 (v/v) with 10 mM 
PNPP. Samples were incubated at 37 °C along with the reaction buffer and the 
reaction started by the addition of 1 ml reaction buffer. The reaction preceded 
for 10 minutes at 37 °C and was terminated by the addition of 1 ml 0.5 M 
NaOH and the absorbance read at 410 nm (EmM = 17) against a buffer blank. 
Specific activity was expressed as nmol, min'1 (mg protein)'1.
2.6 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
and western blotting
2.6.1 Preparation of samples
Protein samples ( 1 0 - 3 0  pg) were diluted, usually 1:4 (v/v), with denaturing 
sample buffer (2 % (w/v) SDS, 62.5 mM tris/HCI pH 6.8, 10 % (v/v) glycerol, 5 
% (v/v) p-mercaptoethanol and 0.01 % (w/v) bromophenol blue) and heated in 
boiling water for 4 minutes. The samples were centrifuged briefly (Eppendorf 
bench top centrifuge 5415C, UK) before loading into the wells.
2.6.2 Separation of proteins on SDS-PAGE gels.
SDS-PAGE gels were prepared based on the method of (Laemmli, 1970). The 
Bio-Rad mini PROTEAN II apparatus was used (Bio-Rad, Herts., UK). 2 glass 
plates and 2 spacers (0.75 mm thick) were cleaned with ethanol and 
assembled with the spacers lining the outside edge of the plates. The Running 
gel was prepared according to table 2.1 and poured in between the glass 
plates to a distance of 2 cm from the top, bubble free. A thin layer of butanol- 
saturated water was added and the gel was left to polymerise for 30 minutes. 
After polymerisation the butanol-saturated water was removed and a plastic
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comb inserted into the top of the plates. The stacking gel was prepared 
according to table 2.2 and poured onto the top of the running gel bubble free 
and left to polymerise for 30 minutes.
Table 2.1 Preparation of running gel
8 % 10 % 12 %
ddH20  (ml) 5.4 4.9 4.4
0.5 M tris/HCI pH 6.8 (ml) 2.5 2.5 2.5
40 % (v/v) acrylamide/BIS (ml) 2 2.5 3
20 % (w/v) SDS (ml) 0.05 0.05 0.05
TEMED (ml) 0.005 0.005 0.005
20 % (w/v) APS (ml) 0.05 0.05 0.05
The polymerised gels were placed into a buffer chamber containing 1.44 % 
(w/v) glycine, 0.3 % (w/v) tris base and 0.1 % (w/v) SDS. The gels were loaded 
with the protein samples and a molecular weight marker ladder and run at 11 
mA/gel until the dye front had reached the bottom of the gel.
2.6.3 Electrotransfer of proteins to PVDF membrane.
Polyvinyldifluoride (PVDF) membrane (Imunno-Blot PVDF, BioRad, UK) was 
equilibrated in transfer buffer (0.15 M glycine, 20 mM Trizma base and 20 % 
(v/v) methanol). The polyacrylamide gels were carefully removed from the 
glass plates and the stacking gel discarded. The running gel was placed into 
transfer buffer before placing into the transfer cassette bottom up in the 
following order: sponge pad, foam pad, 3 MM filter paper, running gel, PVDF 
membrane, 3 MM filter paper, foam pad and sponge pad. The cassette was 
closed and squeezed to remove bubbles before placing into the transfer tank. 
The transfer tank was filled with transfer buffer and electrotransfer took place
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at 100 V for 60 to 90 minutes depending on the acrylamide percentage of the 
running gel.
Table 2.2 Preparation of stacking gel
4%
ddH20  (ml) 6.4
0.5 M tris/HCI pH 6.8 (ml) 2.5
40 % (v/v) acrylamide/BIS (ml) 1
20 % (w/v) SDS (ml) 0.05
TEMED (ml) 0.01
20 % (w/v) APS (ml) 0.05
2.7 Detection of Proteins
2.7.1 Staining with Ponceau Red S.
In order to assess successful protein transfer the PVDF membranes were stained 
with Ponceau Red (1 % (w/v) Ponceau S Red and 3 % (w/v) TCA). The 
membranes were removed from the PROTEAN II apparatus and rinsed in 
ddTEO before covering with Ponceau Red for 30 seconds to 1 minute. The 
membranes were washed carefully with a small volume of ddFEO to remove 
background staining and to visualise the protein bands. The membranes were 
de-stained with sequential washes in ddKbO. The clean membranes were 
trimmed and either used immediately or air dried, wrapped in paper towel and 
frozen at -20 °C until use.
-68-
CHAPTER 2: METHODS
2.7.2 Immuno-detection of MCT1 protein in porcine colonic luminal 
membrane vesicles
Non-specific proteins were blocked by incubating the membranes at room 
temperature in buffer consisting of PBS, 5 % (w/v) skimmed milk powder 
(Oxoid Ltd, UK), 0.05 % (v/v) tween-20 for 1 hour at room temperature. The 
membranes were washed with incubation buffer (PBS, 1 % (w/v) skimmed milk 
powder, 0.05 % (v/v) tween-20) for 10 minutes before incubating at room 
temperature in fresh incubation buffer; with the primary antibodies at a dilution 
of 1:5000. Following incubation the membranes were washed 3 times with 
incubation buffer. Incubation at room temperature with secondary antibodies, 
affinity purified swine anti-rabbit, at a dilution of 1:2000 then followed for 1 
hour. The membranes were then washed 3 times as above before developing 
the signal and exposing to film (section 2.7.6).
2.7.3 Immuno-dection of MCT1 protein in cultured cells
Immuno-dection of MCT1 in cultured cells was carried out using the same 
protocol for the detection of MCT1 protein in colonic luminal membrane 
vesicles with the following exceptions: all incubations were carried out in 
TTBS pH 7.4 (0.05 % (v/v) Tween 20, 0.5 M NaCI, 10 mM Trizma base) with 5 
% skimmed milk powder.
Non-specific proteins were blocked by incubating the membranes at room 
temperature in incubation buffer (TTBS pH 7.4 (0.05 % (v/v) Tween 20, 0.5 M 
NaCI, 10 mM Trizma base) with 5 % skimmed milk powder) at room 
temperature. The membranes were incubated at room temperature in fresh 
incubation buffer; with the primary antibodies at a dilution of 1:5000. Following 
incubation the membranes were washed 3 times with incubation buffer.
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Incubation at room temperature with secondary antibodies, affinity purified 
swine anti-rabbit, at a dilution of 1:2000 then followed for 1 hour. The 
membranes were then washed 3 times as above before developing the signal 
and exposing to film (section 2.7.6).
2.7.4 Immuno-detection of Villin and p-Actin proteins
Non-specific proteins were blocked by incubating the membranes at room 
temperature in a buffer consisting of PBS, 5 % (w/v) skimmed milk powder, 0.1 
mM EDTA and 0.5 % (v/v) triton X-100 for 1 hour. The membranes were 
washed in incubation buffer consisting of PBS, 1 % (w/v) skimmed milk 
powder, 0.1 mM EDTA and 0.5 % (v/v) triton X-100 for 10 minutes. The 
membranes were incubated in fresh incubation buffer for 1 hour at room 
temperature with the primary antibodies at a dilution of 1/2000, anti-villin; and 
1:10000, anti-p-actin. Following incubation the membranes were washed 3 
times with incubation buffer. Incubation at room temperature with secondary 
antibodies, affinity purified goat anti-mouse, then followed at a dilution of 
1:2000 for 1 hour. The membranes were then washed 3 times as above before 
developing the signal and exposing to film (section 2.7.6).
2.7.5 Immuno-detection of HLA-1 protein
Non-specific proteins were blocked by incubating the membranes at room 
temperature in a buffer consisting of TTBS (500 mM NaCI, 10 mM Trizma 
base, 0.05 % (v/v) tween-20 pH 7.4) and 5 % (w/v) skimmed milk powder for 1 
hour at room temperature. The membranes were washed in incubation buffer 
consisting of TTBS and 1 % (w/v) skimmed milk powder for 10 minutes. The 
membranes were incubated in fresh incubation buffer for 1 hour at room
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temperature with the primary anti-HLA-1 antibodies at a dilution of 1:1000. 
Following incubation, the membranes were washed 3 times in incubation 
buffer. The membranes were incubated with the secondary antibodies, affinity 
purified goat anti-mouse, at a dilution of 1:2000 for 1 hour at room 
temperature. The membranes were then washed 3 times as above before 
developing the signal and exposing to film (section 2.7.6).
2.7.6 Immuno-detection of Bcl-xL and Bak proteins
Non-specific proteins were blocked by incubating the membranes at room 
temperature in a buffer consisting of TBS-TM (100 mM NaCI, 10 mM Trizma 
base, 0.1 % (v/v) tween-20 pH 7.4, 5 % (w/v) skimmed milk powder) for 1 hour 
at room temperature. The membranes were incubated in fresh. incubation 
buffer for 1 hour at room temperature with the respective primary antibodies at 
a dilution of 1:200. Following incubation, the membranes were washed 3 times 
in incubation buffer. The membranes were incubated with the secondary 
antibodies, affinity purified goat anti-mouse, bcl-xL; swine anti-rabbit, bak, at a 
dilution of 1:2000 for 1 hour at room temperature. The membranes were then 
washed 3 times as above before developing the signal and exposing to film 
(section 2.7.6).
2.7.7 Immuno-detection of p21 protein
Non-specific proteins were blocked by incubating the membranes at room 
temperature in TBS-TM buffer for 1 hour at room temperature. The 
membranes were washed in incubation buffer (100 mM NaCI, 10 mM Trizma 
base, 0.1 % (v/v) tween-20 pH 7.4, 1 % (w/v) skimmed milk powder) for 10 
minutes before incubated in fresh incubation buffer for 1 hour at room
-71 -
CHAPTER 2: METHODS
temperature with primary antibodies at a dilution of 1:500. Following 
incubation, the membranes were washed 3 times in incubation buffer. The 
membranes were incubated with the secondary antibodies, affinity purified 
goat anti-mouse at a dilution of 1:2000 for 1 hour at room temperature. The 
membranes were then washed 3 times as above before developing the signal 
and exposing to film (section 2.7.6).
2.7.8 Development of immunoblots
The antigen-antibody binding was detected using the Enhanced 
Chemiluminescence (ECL) system (Amersham International, UK) following the 
manufacturers instructions. The membranes were incubated in developer 
solution (equal volume of solution 1 and solution 2) for 1 minute. Excess 
developer solution was removed by blotting the corner of the membrane on 
paper towel before wrapping the membrane in Saran Wrap. The membranes 
were exposed to BioMax-ML (Kodak, UK) film for 5 seconds -  15 minutes 
before developing the film. The bands present on the film were quantified using 
scanning densitometry computer software (Phoretix ID quantifier, Non-linear 
Dynamics).
2.7.9 Stripping and reprobing of PVDF membranes.
PVDF membranes were stripped of the primary and secondary antibodies in 
order to reprobe the membrane with a different primary antibody. Membranes 
were washed 3 times in an acidic stripping buffer (137 mM NaCI and 20 Mm 
glycine pH 2.5) for 15 minutes on a rocking platform; followed by a 10 minute 
wash in the buffer of the proceeding antibody. Following stripping of the
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membranes, immunoblotting for a second protein was carried out as described 
previously.
2.8 Transport studies with butyrate into colonic LMVs
The transport of butyrate into colonic LMVs was carried out using the rapid 
filtration technique as described by (Shirazi et al., 1981). On the day of the 
experiment, LMV were thawed on ice and 50 pg of protein (2.5-7 pi) per assay 
were aliquoted. The uptake was carried out at 37 °C; started with the addition 
of 100 fil of uptake buffer (see figure legends for exact buffer composition) and 
incubated for 5 s. The uptake was stopped with the addition of 1 ml of ice cold 
stop buffer (100 mM mannitol, 100 mM sodium gluconate, 20 mM Hepes/tris 
pH 7.5, 1 mM sodium butyrate). The solution was immediately mixed using a 
whirly mixer before 900 pi were removed and filtered through pre-wetted 0.2 
pm filters (Millipore GSTF02500 Millipore, Herts., UK). The filter was washed 
five times using 1 ml of ice cold stop buffer to remove excess radio-labelled 
butyrate before placing into a scintillation vial with 4 ml scintillation cocktail 
(OptiPhase ‘HiSafe’ 2 Liquid Scintillation Cocktail, PerkinElmer, Leics, UK). 
The samples were counted in a liquid scintillation counter (LS 6500 Multi- 
Purpose Scintillation Counter, Beckman Coulter, CA, USA). Zero time blanks 
were performed to account for non-specific binding of the radio-labelled 
butyrate to the vesicles; here stop solution was added to the vesicles first, 
before the uptake buffer. The values obtained were subtracted from the 
corresponding 5 s uptake. An internal standard (50 pi of a random unfiltered 
stopped reaction mixture) was used to calculate the concentration of butyrate 
uptake. Butyrate uptake was measured in the presence of 1 mM sodium 
butyrate with tracer amounts of [U-14C]-butyrate to give final counts of 30,000
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cpm in 50 pi standards. Results of butyrate uptake are expressed as pmol. (mg 
protein)'1 (unit time)'1.
2.9 Isolation of total RNA
Total RNA was isolated using the Qiagen RNeasy Kit (Qiagen Ltd, Crawley, 
West Sussex, UK), following the manufacturers’ instructions. Briefly: cell 
pellets, if frozen, were defrosted at room temperature for no more than five 
minutes before 600 pi of lysis buffer was added. The pellets were quickly 
resuspended in lysis buffer before removing to a 1.5 ml microfuge tube and 
mixed with a 10 ml pipette 10 times. The pellets were homogenised using a 25 
G needle before 600 pi of 70 % (v/v) ethanol was added; the suspension was 
mixed with a pipette ten times. The solution was transferred to an RNeasy 
column, and centrifuged for 15 s at 15800 x g. The flow through was discarded 
and the column was washed using the manufacturers’ buffers. The column 
was centrifuged for 2 minutes at 15800 x g to remove any excess ethanol 
before eluting the RNA with 40 pi of RNase free water and storing at -80 °C. 
RNA was quantified with UV spectrometry (see section 2.10).
2.10 Quantification of nucleic acids
The concentration of RNA and cDNA was calculated by measuring the optical 
density (O.D.) of the nucleic acid in question using UV spectroscopy. One O.D. 
unit is equivalent to 40 pg ml"1 single stranded RNA and 33 pg ml'1 single 
standed cDNA. Sample nucleic acid (1 pi) was diluted into 100 pi ddH20  and 
the absorbance read at 260 and 280 nm on a UV spectrophotometer. The
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absorbance ratio of 260 nm / 280 nm was used as a measure of purity. A ratio 
of 1.8 -  2 was seen as an acceptable level of protein contamination.
2.11 Quantitative PCR
2.11.1 First strand cDNA synthesis
RNA samples (3 pg) were placed into 500 pi PCR tubes and incubated with 
0.5 pi random primers (500 ng ml"1) at 70 °C for 10 minutes then cooled to 25 
°C for 2.5 minutes. The contents of table 2.3 were then added and the samples 
incubated at 25 °C for a further 2.5 minutes. The samples were then incubated 
at 50 °C for 90 minutes, 70 °C for 10 minutes and then cooled to 37 °C for 1 
minute. 0.5 U RNase H (USB Europe GmBH, Staufen, Germany) was added 
and the samples incubated at 37 °C for a further 29 minutes. Samples were 
purified using the Qiagen PCR clean up Kit (see section 2.11.2).
Table 2.3 Preparation of first-strand reaction mixture
vol / pi
5x reaction buffer 4
0.1 M DTT 2
10 mM (each) dNTPs 1
40 U/pl RNase out 0.6
200 U/pl Superscript III 1
2.11.2 Purification of cDNA
cDNA was purified using a PCR clean up kit (Qiagen, UK). The reaction 
mixture was mixed with 5 volumes of buffer PB and loaded onto the column. 
The column was centrifuged at 18000 x g to bind the cDNA. The column was 
washed with 0.75 ml buffer PE and centrifuged at 15800 x g for 1 minute. The
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eluant was removed and the column centrifuged at 15800 x g for 2 minutes to 
dry the column. The cDNA was eluted in 30 |jl of buffer EB (10 mM Tris/HCI pH 
8.5) and stored at -20 °C. The cDNA was quantified using UV spectrometry 
(see section 2.10).
2.11.3 Real-Time PCR
Real-time PCR was used to measure the abundance of particular mRNAs from 
treated cell lines. The primer/probe sets used were either commercially bought 
(Assays on demand, Applied Biosystems, UK) or designed in-house using a 
primer design program (Primer Express, Applied Biosystems, UK) and 
manufactured by Eurogentec (UK). The assays for the genes of interest were 
matched with assays for the loading controls as follows: Bcl-xL, GAPDH; IAP, 
(3-actin; Bak, PRP2; MCT1, PRP2. The matched assays were then performed 
in a multiplex reaction with the abundance of mRNA for the gene of interest 
and the loading control being determined at the same time.
Each PCR reaction was prepared in a 20 pi volume and consisted of: 12.5 pi 
reaction buffer (Taq-Man Jump start ready mix, Sigma, UK), 1.25 pi gene of 
interest primers and probe assay mix (900 nM final concentration), 1.25 pi 
loading control primers and probe assay mix (300 nM final concentration) and 
5 pi ddH20. 5 pi of sample cDNA (10 ngpl'1) or ddH20  (for no template 
controls) was then added. The cycling parameters for the reaction were: an 
initial 2 mins at 95 °C to activate the DNA polymerase followed by 95 °C, for 15 
seconds and 60 °C for 1 minute repeated for approximately 60 cycles. The 
PCR was carried out on a Rotor-Gene 3000 (Corbett Research, Mortlake, 
NSW, Australia) and analysis performed using the Rotor-Gene 3000 computer 
software (Corbett Research, Australia).
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2.12 Northern Analysis
2.12.1 Agarose gel electrophoresis of RNA
RNA samples were resolved using 1 % (w/v) agarose denaturing gels. 0.4 g 
agarose was added to 33.8 ml ddH20  and 4 ml 10x MOPS (0.2 M MOPS, 50 
mM sodium acetate, 5 mM EDTA, pH 7), and heated in a microwave to 
dissolve the agarose. The solution was left to cool to 50 °C (hand hot) to which 
2 ml formaldehyde was added. The gel was poured into a gel rig (Hoefer Inc, 
San Francisco, CA, USA) and left to set at room temperature for 30 minutes. 
RNA samples (10 pg) were diluted 1:1 with RNA denaturing sample buffer (50 
% (v/v) formmide, 20 % (v/v) formaldehyde, 20 % (v/v) 10x MOPS) and heated 
to 65 °C for 5 minutes before cooling on ice for 2 minutes. 6x RNA loading dye 
(50 % (v/v) glycerol, 1 mM EDTA, 0.4 % (w/v) bromophenol-blue, 0.4 % (w/v) 
xylene cyanol) was added to each sample before loading on to the gel. High 
range RNA markers (Fermentas International Inc, Burlington, Ontario, Canada) 
were used and treated in the same regard as the RNA samples above. 
Electrophoresis was carried out at 80 volts until the bromophenol-blue dye 
reached the end of the gel.
2.12.2 Transfer of RNA to nitrocellulose membrane
After electrophoresis, the gel was rocked in ddH20  for 15 minutes to reduce 
the amount of formaldehyde. The RNA was transferred to nitrocellulose 
membrane (Hybond N+, Amersham Pharmacia Biotech, UK) using capillary 
action. Into a plastic dish went the following: sponges, 3 pieces of 3 MM paper, 
the RNA gel upside down, the membrane, 2 pieces of 3 MM paper, paper 
towels, a glass plate and a 0.5 kg weight. The RNA was left to transfer over
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night in 10x SSC (3 M NaCI, 0.3 M sodium citrate pH 7.0). Following transfer 
the RNA was fixed to the membrane by UV cross-linking (UV Stratlinker-2400, 
Stratagene, UK). Transfer efficiency was assessed by staining the membrane 
with a methylene-blue reversible stain (0.02 % (w/v) methylene blue, 0.3 M 
sodium acetate, pH 5.5) and destained using a buffer consisting of 0.2x SSC 
and 1 % (w/v) SDS. The membranes were either used on the same day or 
stored at -20 °C until further use.
2.12.3 Hybridisation of radiolabelied probe to the northern 
membrane
The membranes were pre-wetted with 2x SSC before pre-hybridising at 42 °C 
for 3 hours with hybridisation solution (25 mM sodium MES, 2.5 mM sodium 
pyrophosphate, 50 % (v/v) deionised formamide, 10 % (w/v) dextran sulphate, 
5x SSC, 3x Denhardt’s (1 % (w/v) BSA, 1 % (w/v) PPP, 1 % (w/v) Ficoll® 400), 
0.2 % (w/v) SDS, 0.1 % (v/v) Antifoam B (Sigma-Aldrich, UK)) in a rotating 
hybridisation oven. The membranes were incubated at 42 °C for 16 hours in 
the same buffer containing a radiolabelied cDNA probe. Labelling was carried 
out with [a-32P]-dCTP using a HexaLabel Oligolabelling kit (Amersham 
Pharmacia Biotech, UK). Following incubation the membranes were washed 
with increasing stringency to remove unbound probe. Low stringency washes 
were carried out with 5x SSC, 1 % (w/v) SDS and 0.25 % (w/v) SARKOSYL at 
42 °C; medium stringency with 1x SSC and 0.1 % (w/v) SDS at 42 °C; and 
higher stringency washes using 0.1x SSC and 0.1 % (w/v) SDS at 55 °C. 
Excess buffer was removed by dabbing the corner of the membrane on tissue 
paper. The membranes were wrapped in saran wrap and Tracker Tape 
attached (Amersham Ltd., UK) before subjecting to autoradiography.
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2.12.4 Autoradiography
The wrapped membranes were placed into an X-ray cassette (Sigma, UK) 
fitted with a Trans-Screen (Anachem Ltd., UK) intensifying screen. The 
membranes were exposed to BioMax-MS film (Kodak, UK) at -80 °C from 12 to 
48 hours before developing the film. The intensity of the bands was determined 
by scanning densitometry (Phoretix ID quantifier, Non-linear Dynamics).
2.12.4 Stripping and re-probing of the nitrocellulose membrane
In order to re-probe the membrane for another transcript of interest, the 
membranes were stripped by washing 3 times in a boiling solution of 0.1 x 
SSC and 0.1 % (w/v) SDS. The membranes were rinsed in 2 x SSC before 
carrying out hybridisation with another radiolabelled probe to the transcript of 
interest as described previously.
2.13 Statistical analysis
Statistical analyses were performed using a paired student t test. Results were 
considered to be significant (*) if a p-value <0.05 were obtained; very 
significant (**) if a p-value <0.01 were obtained and extremely significant (***) if 
a p-value of ¿0.001 were obtained.
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Synthesis of disodium poly(ethylene glycol)6ooot,
di(4-butyrate)
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3.1 Introduction
Coupling of biologically active compounds to membrane-impermeable 
molecules allows researchers to discriminate between the effects induced by 
biological active agents on the surface of plasma membranes, and intra­
cellular effects resulting from entry into the cell. Chemical modification of 
biologically active compounds to produce membrane-impermeable analogues 
can be achieved through a variety of means. These include: production of 
charged derivatives (Marrero-Alonso et al., 2006; Zhang et al., 1999), 
increasing the hydrophobicity of the compound through methylation (Wittekindt 
et al., 2006) and coupling the molecule of interest to a larger compound that is 
already membrane-mpermeable. In the latter case, the choice of membrane 
impermeable compound can also be varied and specific examples include: 
acetyl co-enzyme A (Dutta et al., 2002); biotin, either alone (Mahfoud et al., 
2006), or as biotin derivatives (Pardridge, 1999; Pavlov & Glaser, 2002), the 
protein bovine serum albumin (Arima, 2006; Gatson et al., 2006) and 
polyethylene glycol (Lee et al., 2003).
Polyethylene glycol (PEG) is a long chain polymer of repeating ethylene oxide 
groups that have the general formula of H0-(CH2CH20)n-H with n ranging from 
6 to 1000. PEGs are molecules which appear as transparent oils in the low 
molecular weight range to waxy solids in the high molecular weight range and 
can withstand high temperatures and pressures. The ethylene oxide back­
bone of PEG allows the molecule to be soluble in aqueous as well as protic 
and aprotic organic solvents such as acetone, benzene, chloroform, 
dichloromethane, dimethylsulphoxide, ethanol and toluene (Hinds & Kim, 2002; 
Kodera etal., 1998; Zalipsky, 1995).
PEG is relatively inert biologically and its low immunogenicity and non- 
antigenic properties have attracted the interest of many researchers. The use
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of PEG in PEG-compound conjugates, refered to as PEGylation, is a vast and 
growing field with the largest focus being on protein PEGylation (Fee & Van 
Alstine, 2006; Kodera et al., 1998; Roberts et al., 2002; Veronese & Pasut, 
2005; Zalipsky, 1995). PEGylation involves the coupling of single or multiple 
PEGs to biologically active compounds which then take on the properties of 
the PEG. The resulting compounds have increased molecular weights 
reducing the amount of the compound subjected to the reticuloendothelial 
system of the spleen, liver and kidneys; thereby increasing the circulation in 
the blood and so too the drugs half-life (Hinds & Kim, 2002; Xu et al., 2005; Yu 
et al., 2005). The low immunogenicity and non-antigenic properties of PEG 
are transferred to the compound of interest during PEGylation, lowering the 
host animal’s immune response towards the compound of interest (Roberts et 
al., 2002). Indeed, The Food and Drug Administration (FDA) in The United 
States of America have approved PEG for human internal consumption and 
there are several drug-PEG conjugates on the market. These include: PEG- 
asparaginase (Oncaspar®), PEG adenosine deaminase (Adagen®) and PEG a- 
interferon (PEG-intron®) (Veronese & Pasut, 2005; Fee & Van Alstine, 2006). 
PEG has been used in biochemical research as a membrane impermeable 
anchor in many PEG-compound conjugates including: radioimmunoimaging of 
liver metastases (Li et al., 2006); proteins, camptothecin (Yu et al., 2005) and 
superoxide dismutase (Wang et al., 2006); and the drug ibuprofen (Davaran et 
al., 2006). Previous work carried out in this laboratory involved the synthesis of 
a PEG-glucose conjugate, a,co-di(glucos-6-yl)PEG60o- a,co-di(glucos-6- 
yl)PEG600 was subsequently used in in vivo and in vitro studies to help identify 
and characterise a glucose sensor in the small intestine (Dyer et al., 2003). 
a,co-di(glucose-6-yl)PEG60o was synthesised according to the scheme in Figure
3.1 and involved a three step synthesis. The hydroxyl groups on the end of
- 8 2 -
CHAPTER 3
PEG were first halogenated using CBr4 in CH2CI2 before coupling the 
halogenated PEG with methylated D-glucose in DMSO. The resulting product, 
a,co-di(methylglucos-6-yl)PEG6oo was hydrolysed under acidic condition in 4 M 
H2S04 to produce a,(o-di(glucos-6-yl)PEG6oo-
Under the conditions outlined by Dyer et al., (2003) the methyl D-glucose was 
used as the nucleophile to replace bromine/chlorine from the halogenated 
PEG. Based on the work of Dyer et al., (2003), a two step procedure was 
developed as outlined in the scheme in Figure 3.2, for the synthesis of a PEG 
butyrate conjugate, disodium PEG6ooa,co-di(butyrate). PEG was used in its
CBr4/CH2CI2
40 °C/4 days
PEGeoo (n = 13) X = Br or Cl
OH OH
OH OH
a,co-di(glucos-6-yl)PEG6oo
Figure 3.1 Schematic illustrating the synthesis of 
di(glucose-6-yl)PEG6oo
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standard form, with the hydroxyl groups acting as nucleophiles.
Bromobutyronitrile was used as the substrate, eliminating the need to 
brominate the PEG and reducing the synthesis to a two step process. 
Bromobutyronitrile was used instead of bromobutyric, acid to prevent any by­
product from a reaction with the carboxylic acid moiety (lactonisation). Once 
coupled to the PEG, the butyronitrile can be hydrolysed to butyric acid under 
either acidic or basic conditions.
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Poly(ethylene glycol)60o 4-Bromobutyronitrile
1,4-dioxane 
DBU, 110°C
a,co-di(butyronitrile)PEG600
4 M NaOH 
100 ° C I
DEAE-Sephadex 
1 f chromatography
Acetone
extraction/Na+ exchange 
chromatography
O
a,oo-di(butyric add)PEG60o disodium salt
Figure 3.2 Schematic illustrating the synthesis of 
disodium PEG6oo a,co-di(4-butyrate)
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3.2 Results
3.2.1 The synthesis of di(4-butronitrile)PEG6oo
4-Bromobutyronitrile was added to a stirred solution of PEG60o and DBU in 1,4- 
dioxane and left to stir at 110 °C for a total of 4 weeks. The reaction was 
initially followed for 2 months by TLC. Staining of the TLC plates was carried 
out with iodine vapour and K2Mn04, using separate plates for each stain. The 
loss of PEGeoo, which produced a large elongated spot (average Rf = 0.26), 
and the formation of a,co-di(4-butyronitrile)PEG60o, which produced a small 
discrete spot (average Rf = 0.72) were followed by TLC. After the 
approximately 3 months, TLC showed complete loss of PEG60o. The reaction 
was left to stir for a further 4 weeks while the formation of di(4- 
butyronitrile)PEG60o was confirmed by mass spectrometry. However PEG600 
was also present on the mass spectra with (4-butyronitrile)PEG60o- The 
reaction time, albeit very long, was in part due to the scheduling of the 
chemical synthesis around biochemical work being carried out in parallel (see 
chapter 5) that was favourable at the time.
3.2.2 Hydrolysis of di(4-butronitrile)PEG6oo
In order to generate the carboxylic acid, the nitrile group was hydrolysed under 
basic conditions. The crude PEG60oa,co-di(4-butyronitrile) was added to 20 ml 4 
M NaOH and left to stir at 100 °C for 4 weeks. The formation of a,co-di(4- 
butyric acid)PEG600 was followed using TLC, that gave a small discrete spot 
just above the base line of the TLC plate with an average Rf = 0.02. Once 
hydrolysis of a,co-di(4-butyronitrile)PEG60o was complete, as determined by 
mass spectrometry of the crude reaction mixture, the solution was neutralised
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with 1 M HCI and concentrated before purifying with diethylaminoethyl (DEAE)- 
Sephadex.
3.2.3 DEAE-Sephadex chromatography
The hydrolysis of a,(o-di(4-butyronitrile)PEG6oo had taken place without any 
prior purification. Anion exchange chromatography was selected for the 
purification media as this would give specific purification of products containing 
a carboxylic acid function.
The crude product was concentrated to approximately 5 ml and added onto a 
DEAE-sephadex (bicarbonate form) column equilibrated with distilled water. 
The column was washed with distilled water until the filtrate ran clear. TLC 
confirmed the present of DBU and PEG6oo in the distilled H20  fractions. The 
a,co-di(4-butyric acid)PEG6oo was then eluted with 1 M triethylammonium 
bicarbonate (TEAB) to give the product as the triethylammonium salt. The 
fractions containing a,co-di(4-butyric acid)PEG60o, as determined by TLC, were 
pooled and dried by rotary evaporation to yield a pale yellow solid. 1H NMR 
determined this to be a mixture of triethylammonium (TEAH) salts and a,co- 
di(butyric acid)PEG60o-
The TEAB contaminant was removed using a series of acetone extractions. 
Thus solid TEAH a,co-di(4-butyric acid)PEGeoo mixture was stirred in acetone to 
dissolve the a,co-di(4-butyric acid)PEG6oo and filtered to remove the 
undissolved TEAB salts. The TEAB a,co-di(4-butyric acid)PEG600 was then 
washed several times, each wash reducing the amount of TEAB present. The 
level of TEAH present was continually followed by 1H NMR until a required 
stoichiometric ratio of TEAH and a,co-di(4-butyric acid)PEG600was observed.
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3.2.4 Na+ exchange chromatography
Final purification of a,co-di(4-butyric acid)PEG6oo was carried out with sodium 
exchange chromatography resulting in the isolation of the sodium salt of the 
butyric acid. Cellex-P exchange resin, hydrogen ion form, was stirred in 0.5 M 
NaOH for 15 minutes to produce the Na+ ion form. The resin was poured into a 
column and washed 3 times with dH20  before loading the concentrated a,co- 
di(4-butyrate)PEG6oo triethylammonium salt onto the column. The a,co-di(4- 
butyric acid)PEG6oo was eluted from the column using distilled water and dried 
using a rotary evaporator with a “cold finger”, to give the disodium PEG60oa,co- 
di(4-butyrate) as a brown oil.
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3.3 Discussion
3.3.1 The synthesis of di(4-butronitrile)PEG6oo
The reactions conditions first employed in the synthesis of a,co-di(4- 
butronitrile)PEG60o (PEG-BN) were based on the approach outlined by Dyer et 
al., (2003) in the synthesis of a,co-di(glucose-6-yl)PEG6oo, a membrane 
impermeable glucose analogue. In the Dyer approach, polyethylene glycol 600 
was first brominated then reacted with methylated D-glucose in an SN2 
reaction. Under the reaction conditions, the methylated D-glucose reacted by a 
nucleophilic attack on the brominated PEG, displacing bromine for methylated 
D-glucose.
For the synthesis of a,co-di(4-butyronitrile)PEG6oo (PEG-BN), PEG was used in 
its unmodified form with hydroxyl groups intact, reversing the role of PEG from 
the electrophile to the nucleophile. In this case, PEG acting as the nucleophile, 
makes a nucleophilic attack on the fourth carbon of bromobutyronitrile, 
displacing bromine, to form an ether linkage. By using PEG as the nucleophile 
and a commercially available brominated substrate, the synthesis was reduced 
to a two stage process. The remaining reaction conditions outlined by Dyer et 
al., (2003) were followed; these included dimethyl sulphoxide (DMSO) as 
solvent, potassium hydroxide as base and stirring the reaction mixture at room 
temperature in the dark for approximately four days for each step. The starting 
and revised reaction conditions for the synthesis of a,co-di(4-butyric 
acid)PEG6oo can be seen in figure 3.3; figures 3.3A1 and 3.3B1 show the 
changes made in the synthesis of a,co-di(4-butyronitrile)PEG60o.
Following the KOH/DMSO conditions employed by Dyer et al., (2003), resulted 
in a prolonged reaction with no product forming during several days after
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starting the reaction. After 4 weeks had elapsed, some reaction between the 
bromobutyronitrile and polyethylene glycol had taken place, however a large 
amount of PEG6oo was still present, as seen by TLC and mass spectrometry. 
The stoichiometry of the reaction was increased from a ratio of 1:3 to a ratio of 
1:6 (PEG:bromobutyronitrile) in an attempt to drive the reaction to completion. 
The increased amount of bromobutyronitrile in the reaction brought about a 
complication. Bromobutyronitrile is a liquid at room temperature and soluble in 
a water:DMSO (1:1, v/v) mixture. When the ratio of PEG to bromobutyronitrile 
was increased to 1:6 the volume of bromobutyronitrile present was too great to 
dissolve in the water:DMSO mixture and produced an organic layer thereby 
creating a two phase system. Stirring the reaction had no effect on mixing of 
the two layers, which separated immediately when stirring ceased. The 
water:DMSO mixture was used as a convenient method for the addition of 
KOH into the reaction. 2 M Potassium hydroxide was diluted 1:1 with DMSO, 
resulting in a 50 % aqueous solution. The hydroxyl ions introduced by water 
into the reaction mixture have a greater reactivity than the hydroxyl groups on 
alcohols such as PEG and can attack the bromobutyronitrile resulting in 
hydroxybutyronitrile (Clayden et al., 2001). This added to the problems caused 
with the BBN failing to dissolve in the water/DMSO solution. In an attempt to 
resolve this, potassium hydroxide was crushed under nitrogen
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Proposed Synthesis Actual Synthesis
Based on Dyer et al., (2003)
PEG600 + 4-BBN 
KOH/DMSO/40 °C
1
A1
r
Purify with Sephadex G-25
_1
A2
r
di(4-butyronitrile)PEG600 
H2S 04/100 °c
1
A3
f
Purify with Sephadex G-25
A4
r
disodium PEG600di(4- 
butyrate)
PEG600 + 4-BBN 
DBU/dioxane 110 °C
'
B1
r
di(4-butyronitrile)PEG600 
NaOH/100 °C
'
B2
r
Purify with DEAE-Sephadex
'
B3
r
Na+ exchange 
chromatography
1
B4
r
disodium PEG600di(4- 
butyrate)
Figure 3.3 Schematic outlining the synthesis of disodium 
PEG6ooa,o)-di(4-butyrate)
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and added directly to dry DMSO, thus limiting the availability of water in the 
reaction and allowed the BBN to fully dissolve.
DMSO has a boiling point of 189 °C and has low volatility. As a result, DMSO 
was retained on the TLC plates and chromatographs to give anomalous 
results. Accordingly the solvent was changed from DMSO to 1,4-dioxane 
(dioxane). Dioxane was chosen as it is a good aprotic organic solvent with a 
lower boiling point of 101.5 °C. Dioxane also has a low volatility but did not 
produce any discrete isolated spots on the TLC plates; however, it did elongate 
the spots produced from other compounds. Crucially no anomalous results 
were seen on the TLC plates when dioxane was used as the solvent. However, 
the solubility of potassium hydroxide in dioxane is considerable less than in 
DMSO and problems with dissolving the potassium hydroxide arose. Indeed, 
after 24 hours of stirring approximately half the potassium hydroxide had failed 
to dissolve in the dioxane and formed a solid layer at the bottom of the flask. 
Added to the problems with dissolving the potassium hydroxide in dioxane, the 
potassium ions were carried over in a work-up and purification of the di(4- 
butyronitrile)PEG60o. A strong base is required in the reaction in order to 
deprotonate the hydroxyl groups on the PEG, thus preparing the PEG alkoxide 
ion that will subsequently react with 4-BBN (Clayden et a/., 2001). 1,8- 
Diazabicyclo[5.4.0]undec-7-ene (DBU) is an organic compound which is a 
strong base, has low nucleophile properties and fully dissolves in dioxane. (see 
figure 3.2 A1 and 3.2B1)
Overall the reaction between PEG and 4-BBN was very slow. The rates of SN2 
reactions between primary alcohols and primary alkyl halides can be fast. 
However, the size of the nucleophile and substrate, the solvent used and 
temperature of the reaction all have an effect on the rate and yield of the 
reaction. Hydroxyl groups do not make good leaving groups in an SN2 reaction 
and are more often converted to a better leaving group; for the synthesis of
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di(methylglucos-6-yl)PEG6oo the hydroxyl group was converted to a halogen. 
Halogens make good leaving groups, with an iodide ion being the best leaving 
group and a fluoride ion the poorest. The general order in ease of leaving is as 
follows: r>Br'>CI»F' (March, 1985). Small, charged nucleophiles are solvated 
less in aprotic solvents compared to protic solvents, allowing more contact 
between the nucleophile and the solvent. However this solvent effect becomes 
less important as the size of the substrate and nucleophile increase (March, 
1985). Here steric effects become more important in affecting rate and yield of 
a reaction.
The choice of nucleophile in this synthesis might have an important effect on 
the reaction. Bulky nucleophiles are less reactive than small nucleophiles, due 
to the nonbonded repulsions that develop during the SN2 transition state 
(Carey & Sundberg, 1990). While PEG is a primary alcohol, the chain length of 
PEG is considerably long which could have had a significant effect on the rate 
of a reaction. The rate of an SN2 reaction generally decreases as the carbon 
chain length of the nucleophile increases. PEG has a chain length of between 
18 and 45 (counting the CH2-CH2-0 repeating monomer of the PEG backbone) 
making it considerable larger than the substrate it is attacking.
3.3.2 Workup and purification of PEG-BN
In order to simplify the purification of the end product, removal of any 
unreacted PEG, bromobutyronitrile and DBU is desirable before continuing on 
to hydrolyse the a,co-di(4-butyronitrile)PEG60o- Column chromatography using 
Sephadex G-15 media was first used, as this was the method of choice by 
Dyer et al., (2003) Sephadex G-15 is a size-exclusion solid media whose 
matrix excludes molecules above 1500 mw. When synthesising a,co- 
di(glucose-6-yl)PEG6oo, the reactions conditions were set up to ensure that the
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reaction went to completion and resulted in a very small amount of starting 
material present, with a yield of 98 %. The purpose of purification using 
Sephadex G-15 was therefore to remove excess K+ salts. Here however, 
starting material was still present. When purifying using Sephadex G-15, 
separation of the K+ salts from the PEG-BN was expected due to the size 
difference between the two species. However, some K+ salts were eluted in the 
fractions containing the PEG-BN together with some unreacted PEG thereby 
making purification of the PEG-BN extremely difficult.
During the initial reactions when DMSO and potassium hydroxide were used 
as the solvent and base respectively, purification with Sephadex G-15 was 
used. As the reaction conditions were changed, purification with Sephadex 
proved even more difficult. Changing the base from potassium hydroxide to 
DBU also brought more complications as the DBU eluted with the PEG-BN, 
resulting in a highly contaminated product. Increasing the amount of BBN to 
excess also meant that there was unreacted BBN in the reaction mixture that 
failed to separate from the PEG-BN when using Sephadex G-15. Using column 
chromatography to purify PEGs and PEG conjugates is a notoriously difficult 
procedure to master due to the heterogeneous mixture of polymers that make 
up PEG, (Fee & Van Alstine, 2006). Mass spectrometry showed a range of 
polymer chains from 400 to 1000 gmol'1. It was therefore decided to take the 
reaction mixture containing PEG-BN and use it directly in the hydrolysis 
reaction.
3.3.3 Hydrolysis of PEG-BN under acid and basic conditions
Hydrolysis of PEG-BN involves the hydrolysis of the nitrile initially to the amide 
and then to the carboxylic acid. Hydrolysis can occur under either acid or base 
catalysis. In order to establish which method to use, both acid- and base-
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catalysed reactions were examined using a small amount of the PEG-BN. In 
the trial reactions 0.5 g PEG-BN was placed into a 10 ml round bottom flask 
containing either 4 M HCI or 4 M NaOH and stirred at 50 °C (see Figure 3.3A3 
and 3.3B2). After approx. 2 weeks the acid-catalysed reaction failed to form 
appreciable quantities of the PEG-BN as seen by TLC. During the same period 
TLC of the base-catalysed reaction indicated that it had gone to completion. 
However, there was some of the intermediate amide present as seen by mass 
spectrometry. After a further 2 weeks the intermediate butyramide was still 
present. Increasing the temperature of the reaction to reflux produced a 
mixture of the mono-acid, mono-acid and amide or di-acid PEG-conjugates, as 
assessed by mass spectrometry. No peaks corresponding to the mono or di- 
substituted a,co-(4-butyronitrile)PEG60o were seen on the mass spectra 
confirming that hydrolysis of the nitrile group had taken place.
The reaction times reported for base-catalysed reaction include the time taken 
to assess progression of the reaction via mass spectrometry. All mass 
spectrometry was carried out in house by the mass spectrometry service 
where there were delays between submitting and receiving mass spectra. As 
the PEG-BN was not purified after synthesis, the exact amount present in the 
hydrolysis reaction was not known and consequently, the yield for the 
hydrolysis reaction can only be estimated. As no mono- or di-butronitrilePEG6oo 
products were seen by mass spectrometry, it is estimated that the hydrolysis of 
a,co-di(butyric acid)PEG6oo is > 95 %.
3.3.4 Anion Exchange Chromatography
Purification of a,co-di(4-butyric acid)PEG6oo was carried out using DEAE- 
sephadex. The DEAE residues bind negatively charged species which makes 
this an ideal method to purify a,co-di(4-butyric acid)PEG60o whose carboxylic
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residues will bind to the DEAE groups. Any unreacted starting material, DBU 
and dioxane will be washed through the column. Elution of the product from 
the column was carried out using TEAB with an initial gradient of 0 -  0.3 M 
TEAB, The elution of a,co-di(4-butyric acid)PEG60o was followed using TLC, 
using a bromocresol green stain with a,co-di(4-butyric acid)PEG600 being eluted 
in the fractions that proceeded the addition of TEAB onto the column. 
a,co-Di(4-butyric acid)PEG6oo was not completely eluted from the column using 
0.3 M TEAB; increasing the gradient to 0.5 M TEAB also proved unsuccessful 
in eluting all the a,co-di(4-butyric acid)PEG60o as seen by the present of ot,co- 
di(4-butyric acid)PEG6oo in the last fraction eluted from the column. The 
gradient was thus increased to 1 M TEAB whereby all a,co-di(4-butyric 
acid)PEG600 was eluted from the column. Subsequent batch purifications did 
not use a TEAB gradient; after washing the DEAE-sephadex column with 
distilled water, a,co-di(4-butyric acid)PEG6oo was eluted using 1 M TEAB 
reducing the total volume of TEAB required.
Purification of the a,co-di(4-butyric acid)PEG6oo with DEAE-sephadex resulted 
in a yellow solid that was, according to theoretical yield calculations, 4 times 
greater than expected. 1H NMR analysis confirmed the presence of a large 
amount of TEAH salt present in the yellow solid. Elution of acid products from 
DEAE-sephadex columns necessarily results in the TEAH salt of the acid. Any 
excess TEAH can be removed by repeated evaporation from water. In this 
case though, the amount of TEAH salt present was so great, that the volume of 
distilled water required made removal of the TEAH salt a slow and tedious 
process. Several co-evaporations of the a,co-di(4-butyric acid)PEG6oo salted 
product with dH20  did not make a significant impact on the amount of TEAH 
present. Removal of TEAH ions using column chromatography on silica was 
examined, but rejected due to the polar nature of the carboxylic acid groups in
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the product. A search for alternative methods for the removal of TEAH was 
subsequently performed.
Oishi et at. prepared PEGylated antisense oligonucleotides and used 
isopropanol precipitation as the purification method. The PEGylated antisense 
olidonucleotides were prepared using 4 kDa PEGs in THF and purified by 
pipetting the reaction mixture into cold (-15 °C) propan-2-ol (Oishi et at., 2005). 
The PEGylated antisense oligonucleotides precipitated out in propan-2-ol and 
were collected via centrifugation. The isolation of a,co-di(4-butyric acid)PEG6oo 
using isopropanol precipitation was investigated. The solid a,ro-di(4-butyric 
acid)PEG60o TEAH salt mixture was dissolved into THF and added to 
isopropanol (cooled to approximately -15 °C in a NaCI-acetone-ice bath) 
whereby precipitation occurred. The a,co-di(4-butyric acid)PEG60o did not 
precipitate as a solid wax but rather as a semi-solid liquid that would mix with 
the isopropanol upon attempted removal of the isopropanol. The semi-solid 
nature of the a,co-di(4-butyric acid)PEG6oo is perhaps, not unexpected, due to 
its substantially lower molecular weight ( ~ 600 Da) as compared to the 4 kDa 
PEG used by Oishi et at. Although the isopropanol precipitation failed to 
adequately purify the a,co-di(4-butyric acid)PEG60o, the TEAH ions did 
however dissolve in the isopropanol, and this presented the idea of using a 
solvent that would selectively dissolve the a,co-di(4-butyric acid)PEG60o in the 
presents of the TEAH salts.
Thus crude TEAH a,co-di(4-butyric acid)PEG6oo product was stirred in a large 
excess of acetone (approximately 400 ml per 4 g) for 1 hour. The acetone, now 
yellow in colour, was filtered through Whatman paper and evaporated to yield 
a brown oil. The brown oil was further stirred in acetone to remove more TEAH 
salt, which was collected and subjected to further acetone washes in an 
attempt to extract as much a,codi(4-butyric acid)PEG6oo as possible. Figure. 3.4
- 9 7 -
CHAPTER 3
illustrates the stages involved in extracting the a,(o-di(4-butyric acid)PEG6oo 
from the TEAH salt. The removal of TEAH was continually followed with 1H 
NMR. The TEAH ions showed two distinct peaks; a triplet at 1.28 ppm, 
representing the terminal methyl group and a quartet at 3.25 ppm, representing 
the methylene group adjacent to nitrogen. The removal of TEAH continued 
until the amount of TEAH ions present was reduced to a minimum as 
determined by comparing the corresponding peaks present of TEAH and 
butyric acid on the 1H NMR spectra; this being approximately 10 washes. At 
this time the a,co-di(4-butyric acid)PEG6oo TEAH salt was converted to the 
sodium salt using sodium-exchange chromatography.
Figure 3.4 Schematic illustrating the removal of excess TEAH
salt
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4.3.5 Sodium-exchange chromatography
The exchange of TEAH for sodium ions was conducted in order to standardise 
the biological testing that was to be carried out using a,co-di(4-butyric 
acid)PEG6oo- The other substrates being tested were bought in in the form of 
sodium salts. TEAH a,to- di(4-butyric acid)PEG6oo was dissolved into 
approximately 4 ml distilled water and added onto the sodium-exchange resin. 
The a,co-di(4-butyric acid)PEG6oo was drawn through the column and eluted 
with distilled water. The water was evaporated off in vacuo to give a brown oil 
with a yield for disodium PEG6ooa,®-di(4-butyrate) of 13.2 %. 1H NMR 
confirmed the absence of TEAH ions and butyronitrile. The peaks present on 
the 1H NMR speactra that represented the butyric acid showed the correct 3JHh 
coupling; which was confirmed using 2D 1H NMR correlated spectroscopy 
(COSY). As expected, no signals were seen on the 1H NMR corresponding to 
the carboxylic acid group, which are expected to have a chemical shift around 
11 ppm.
All expected signals for a,co-di(4-butyric acid)PEG6oo were seen on the 13C 
NMR spectra, although the peak at 181 ppm representing the carboxylic acid 
carbon had a smaller peak than the corresponding peaks for C2-C4. Signals 
for C2-C4 of (4-butyronitrile)PEG6oo were seen on the 13C NMR but not the 
signal for the carbon of the nitrile group. Mass spectrometry confirmed the 
presence of the heterobifunctional PEG600 containing a butyric acid group and 
a butyronitrile group at either end of the PEG molecule. Signals were seen 
representing mono- and di-substituted (4-butyric acid)PEG6oo on the mass 
spectra. No signals corresponding to PEG6oowere seen by either 1H NMR or 
mass spectrometry confirming that all the PEG600 had been removed by the 
anion exchange chromatography. No peaks relating to (4-butyronitrile)PEG6oo 
or a,co-di(4-butyronitrile)PEG60o were present on the 1H NMR or mass spectra.
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Furthermore, no peaks relating to a,co-(4-butyronitrile,4-butyrate)PEG6oo were 
seen on the 1H NMR; therefore, the amount of the butyronitrile group present is 
likely to be less than 5 %.
The idea of coupling butyric acid to PEG is not a new suggestion. Wakselman 
et al., (1990) synthesised PEG-dibutyrate analogues that were coupled to PEG 
via an ester bond. This strategy was based on the principle that the butyric 
acid would be released at the site of action through cleavage of the ester bond. 
Wakselman et al., (1990) found that PEG100o dibutyrate had very good anti­
tumour activity; determined by inoculating mice with 180 TG Crocker sarcoma 
cells followed by treatment of the a,co-di(butyrate)PEG10oo- The a,co- 
di(butyrate)PEG100o was injected 3 days preceding inoculation and had a 
protective effect on the mice compared to the control mice (Wakselman et al., 
1990).
Overall coupling of butyric acid to PEG6oo through a stable ether linkage has 
proved successful. Extensive characterisation including 1H and 13C NMR, IR 
and mass spectrometry showed the formations of a mono- and di-substituted 
butyric acid conjugated PEG60o- The membrane-impermeable butyrate 
analogue can now be used as a tool in determining the mechanism for butyrate 
regulation of gene expression in the large intestine. Here in vitro testing of 
disodium PEG6ooa,®-di(4-butyrate) will be carried out on the colonic epithelial 
cell lines, AA/C1 and HT-29. Known butyrate responsive genes will be assayed 
to investigate the need for butyrate entry into the cell, in order for butyrate to 
modulate the expression of the genes assayed (see chapter 4).
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CHAPTER 4
Treatment of human colonic epithelial cell lines 
with disodium PEG6ooa,G)-cli(4-butyrate)
CHAPTER 4
4.1 Introduction
Butyrate regulates a number of genes associated with differentiation, 
proliferation and apoptosis of colonic epithelial cells. Transport of butyrate 
across the colonocyte luminal membrane is mediated by MCT1 (Cuff et al., 
2002), the expression of which is dramatically down regulated during colon 
carcinogenesis (Lambert et al., 2002). It has been proposed that the decline in 
MCT1 expression during colon carcinogenesis may reduce the intracellular 
availability of butyrate required to regulate expression of genes associated with 
the processes maintaining tissue homeostasis within the colonic mucosa. To 
test this hypothesis previous work in our laboratory employed the technique of 
RNA interference to specifically inhibit MCT1 expression, and determined the 
consequences of this inhibition for the ability of butyrate to exert its recognised 
effect in vitro. It was demonstrated, that inhibition of MCT1 expression, and 
hence butyrate uptake, has profound inhibitory effects on the ability of butyrate 
to regulate expression of key target genes; CDKN1A (p21), ALP1 (IAP) and 
cyclin D1, and their associated processes of proliferation and differentiation. It 
was proposed that the ability of butyrate to induce cell cycle arrest and 
differentiation is dependent upon the transport of butyrate into the cell via 
MCT1 (Cuff et al., 2005). In contrast, inhibition of MCT1 expression had no 
effect on the ability of butyrate to modulate the expression of either bak1 or 
bcl-xL, and this was reflected in a corresponding lack of effect on butyrate- 
induction of apoptosis. It was suggested that the potential mechanism by which 
butyrate regulates genes controlling apoptosis is independent of expression of 
MCT1. The proposed mechanism was that butyrate is sensed by a plasma 
membrane butyrate sensor expressed on the luminal membrane of 
colonocytes initiating a signalling pathway controlling the expression of genes 
such as bak1 and bcl-xL.
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In the present study in order to assess the potential presence of the butyrate 
sensor and its effect on gene expression, a membrane impermeable butyrate 
analogue was synthesised. Butyrate was linked to polyethylene glycol)600, the 
latter has been shown to be membrane impermeable (Lloyd, 1998) (See 
chapter 3 for the detailed synthesis). The aim was to treat colonic epithelial 
cell lines with butyrate and the membrane impermeable butyrate analogues, 
and determine their effects on the expression of candidate genes, ALP1, 
CDKN1A, bak1 and bcl-xL, To this end, the butyrate analogue disodium 
PEG6o0a,co-di(4-butyrate) was used in in vitro studies using two well- 
characterised human colonic epithelial cell lines, AA/C1 and HT-29 cells. Two 
cell lines were used in order to eliminate a single cell type specific effect. HT- 
29 are fast growing, poorly differentiated human colon adenocarcinoma cells 
which have been used as models of colonic epithelial cells. When exposed to 
butyrate these cells differentiate, and revert back to normality. In contrast 
AA/C1 cells are derived from a non-tumourigenic human colonic adenoma, are 
slow growing, and possess structural and functional properties modelling the 
differentiated absorptive cells of the normal colonic epithelium (Cuff et al., 
2002; Wiliams et a., 1990).
During the synthesis of the butyrate analogue characterisation of the final 
product revealed that some butyronitrile was still present that had failed to be 
hydrolysed during synthesis (See chapter 3). The butyronitrile was determined 
to be part of a biheterofunctional PEG60o with butyrate and butyronitrile coupled 
to either end of PEG molecule (sodium PEG60oa,co-(4-butyrate,4-butyronitrile). 
Coupling of butyrate to PEG600 did not result in the exclusive formation of di- 
substituted PEG, but a mixture of of mono- and di- substituted PEG6oo(4- 
butyrate) as well as sodium PEG6ooa,co-(4-butyrate,4-butyronitrile), see figure
4.1 below. For simplicity the mixture of mono- and di- sodium PEG6oo(4-
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butyrate) and sodium PEG6oo a,co-(4-butyrate,4-butyronitrile) will be referred to 
as PEG-ba throughout the reminder of this thesis.
Na Na
disodium PEG600oc,it>-di(4-butyrate)
HO
o
sodium PEG600(4-butyrate)
sodium PEG600a,©-(4-butyronitrile,4-butyrate)
Figure 4.1 schematic illustrating the structural formula of PEG-ba
Schematic showing the structural formula of disodium PEG60odi(4-butyrate), sodium 
PEG60o(4-butyrate) and sodium PEG60o(4-butyronitrile,4-butyrate). PEG-ba refers to a 
mixture of all three compounds utilised in the treatment of the colonic epithelial cell 
lines.
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4.2 Results
HT-29 and AA/C1 colonic epithelial cells were treated with, i) sodium butyrate, 
ii) PEG-ba, iii) PEG6oo or iv) butyronitrile. Sodium butyrate was used as a 
positive control, whilst PEG600 and butyronitrile were employed in order to 
assess any potential effect that they may have on the pattern of gene 
expression. Expression of IAP, p21, bak and bcl-xL were determined at mRNA 
levels using either northern blot analysis or quantitative real time PCR, as 
appropriate. Protein expression for p21, bak and bcl-xL were determined using 
western blot analysis with the specific antibodies. For alkaline phosphatase, 
due to the lack of a specific antibody to human alkaline phosphatase, the 
activity of IAP was determined enzymatically.
It is worth mentioning that the synthesis of PEG-ba proved to be a challenging 
task and took a large proportion of the time allocated to this study. In addition, 
the AA/C1 cell line is a very slow growing cell, this is in contrast to HT-29 cells 
which take approximately 1 week to reach confluency, allowing a greater 
number of passages to be utilised. Consequently, the number of experiments 
involving the AA/C1 cells had to be restricted to cover the essential work 
needed. For the above reasons the potential effect of butyronitrile on gene 
expression was only carried out using HT-29 cells
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4.2.1 Regulation of intestinal Intestinal alkaline phosphatase
and P21WAF1/Cip1
IAP is a classical marker of differentiation, well-established to be up-regulated 
in response to butyrate treatment of HT-29 and other cells (Kruh et al., 1995). 
P21 is a cell cycle Inhibitor, the expression of which is responsive (up- 
regulated) to butyrate (lacomino et al., 2001; Litvak et al., 1998). Previous work 
in the laboratory had shown that butyrate transport into the cell, via the MCT1, 
is required for butyrate to regulate IAP and p21. Therefore, it is expected that a 
membrane impermeable, non-transportable butyrate analogue would not be 
able to modulate the expression of IAP and p21. To test this, AA/C1 cells were 
grown to confluency, and were then either left untreated or treated with NaBut, 
PEG-ba, PEG6oo, for 48 hours each at 5 mM concentration. In addition, HT-29 
after reaching 80 % confluency were either left untreated or treated with 2 mM 
solutions of either NaBut, PEG-ba, PEG600 or butyronitrile for 24 hours. 
Different concentrations and incubation times selected were based on the 
previous work in the laboratory indicating the optimum conditions for butyrate 
effect using AA/C1 and HT-29 cells (Cuff et al., 2005). Figure 4.2 shows that 
treatment of AA/C1 cells with NaBut, as expected, upregulated IAP mRNA 
expression and activity by 1.5 ± 0.22 and 1.2 ± 0.08 fold respectively. However 
there were no effect on IAP expression at both mRNA and activity levels when 
AA/C1 cells were treated with PEG-ba. In AA/C1 cells treated with PEG there 
was no statistically significant change in IAP mRNA nor activity.
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A) Northern Blot B) IAP enzyme assay
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Figure 4.2 Expression of IAP in AA/C1 cells
AA/C1 cells were grown to 100 % confluency and either left untreated or treated with 
5 mM sodium butyrate, PEG-ba and PEG6oo for 48 hours, resupplementing after 24 
hours. A, northern analysis showing IAP mRNA levels with densitométrie analysis of 
abundance normalised to p-actin, as a histogram; B, histogram demonstrating IAP 
activity measured in the corresponding cell homogenate. Results are expressed, as 
abundance relative to untreated control; values represent mean ± S.E.M. of three 
separate cell treatments.
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Treatment of HT-29 cells with sodium butyrate resulted in 11 ±1.35 and 9.2 ± 
0.4 fold increase in IAP mRNA and activity (fig. 4.3). When HT-29 cells were 
treated with PEG-ba, a slight but not significant increase 1.4 ± 0.16 and 1.9 ± 
0.41 fold were observed in mRNA and activity. There was also a slight, but not 
significant increase in IAP mRNA and activity in response of cells to exposure 
to PEG6oo- However butyronitrile treatment of cells did not lead to any 
statistically significant change in IAP mRNA and activity.
It is worth mentioning that in response to butyrate treatment there was a 1.5 
fold increase in IAP expression in AA/C1 cells, compared to 11 fold increase in 
IAP expression in HT-29 cells. As mentioned before HT-29 ceil is an 
undifferentiated cell line which expresses negligible alkaline phosphatase. 
However in response to butyrate treatment it becomes differentiated and 
expresses high levels of the differentiation marker alkaline phosphatase. This 
is in contrast to AA/C1 cells, a differentiated phenotype, which expresses 
alkaline phosphatase; in response to butyrate treatment there is an additional 
increase in IAP but not as dramatic as seen in HT-29 cells.
As seen in figures 4.4 and 4.5 p21 expression is not also responsive to PEG- 
ba treatments. P21 expression is up-regulated 2 ± 0.7 and 1.6 ± 0.08 fold at 
mRNA and protein levels when AA/C1 cells are exposed to NaBut. However 
there is no enhancement in p21 in response to exposure of cells to either PEG- 
ba or PEGeoo-
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A) Real-time PCR B) IAP enzyme assay
Figure 4.3 Expression of IAP in HT29 cells
HT-29 cells were grown to 70 % confluency and either left untreated or treated with 2 
mM sodium butyrate, PEG-ba and PEGeoo for 24 hours. A, real-time PCR analysis 
showing IAP mRNA levels with densitométrie analysis of abundance normalised to 
(3-actin shown as a histogram; B, Histogram demonstrating IAP activity measured in 
the corresponding cell homogenate. Results are expressed as abundance relative to 
untreated control; values represent mean ± S.E.M. of three separate cell treatments 
(* = p-value £ 0.05 and ** = p-value s 0.005).
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A) Northern Blot
p21
p-actin
B) Western blot
mmmmtrnm .....
<uoc.
03■oc3JD
03
0)>
JO
<13cc
Figure 4.4 Expression of p21 in AA/C1 cells
AA/C1 cells were grown to 100 % confluency and either left untreated or treated with 
5 mM sodium butyrate, PEG-ba and PEG600 for 48 hours, resupplementing after 24 
hours. A, northern analysis showing p21 mRNA expression with corresponding 
densitométrie analysis shown as a histogram; B, Western analysis showing p21 
protein expression with corresponding densitométrie analysis displayed as a 
histogram. Results are normalised to p-actin and expressed as abundance relative to 
untreated control; values represent mean ± S.E.M. of three separate cell treatments. 
(* = p-value s 0.05, ** = p-value ^ 0.005).
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Treatment of HT-29 cells with sodium butyrate resulted in a 1.6 ± 0.06 fold 
increase in p21 mRNA, as assessed by real-time PCR, and 1.5 ± 0.13 fold 
increase in p21 protein abundance (fig. 4.5). Treatment of HT-29 cells with 
PEG-ba and butyronitrile did not result in any statistically significant change in 
the expression of p21 mRNA nor protein. Treatment of PEG600 to HT-29 cells 
did not follow that seen in AA/C1 cells. Indeed, the relative abundance of p21 
mRNA showed a 1.2 ± 0.04 fold decrease compared to untreated control. 
However there was a 1.4 ± 0.6 fold increase in protein abundance seen in 
PEG60o treated HT-29 cells compared to untreated control, resulting in 
conflicting data.
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A) Real-time PCR B) Western Blot
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Figure 4.5 Expression of p21 in HT-29 cells
HT-29 cells were grown to 70 % confluency and either left untreated or treated with 2 
mM sodium butyrate, PEG-ba and PEG600 for 24 hours. A, real-time PCR analysis 
showing p21 mRNA expression with the corresponding densiometric analysis shown 
as a histogram; B, Western analysis showing p21 protein expression with 
corresponding densiometric analysis shown as a histogram. Results are normalised 
to p-actin and expressed as abundance relative to untreated control; values 
represent mean ± S.E.M. of three separate cell treatments. (* = p-value < 0.05).
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4.2.2 Regulation of Bcl-xL and Bak
Previous work carried out in this laboratory has shown that knocking down the 
expression of the colonic butyrate transport, MCT1, had no effect on butyrate- 
regulation of BcI-Xl and Bak1 gene expression. Bak1, a pro-apoptotic gene is 
up-regulated by butyrate whilst bcl-xL, an anti-apoptotic gene is down-regulated 
by butyrate (Cuff et at., 2005). AA/C1 and HT-29 cells were treated with PEG- 
ba and the effect on the expression of Bcl-xL and Bak was investigated. 
Accordingly AA/C1 and HT-29 cells were treated with sodium butyrate, PEG- 
ba, PEG6oo and butyronitrile (5 mM, AA/C1; 2 mM, HT-29) as mentioned above 
(section 4.2.1).
Treatment of AA/C1 cells with NaBut resulted in a 2 ± 0.16 fold reduction in the 
abundance of Bcl-xL mRNA, examined by northern blotting, and 2.2 ± 0.03 fold 
reduction in the abundance of Bcl-xL protein abundance, relative to an 
untreated control (fig. 4.6). The effect elicited by sodium butyrate was not seen 
when AA/C1 cells were treated with PEG-ba. Here, there was a 1.1 ±0.1 fold 
and 1.4 ± 0.06 fold increase in the relative abundance of Bcl-xL mRNA and 
protein levels respectively; the latter being statistically significant. Treatment of 
AA/C1 cells with 5 mM PEG6oo had no effect on the abundance of Bcl-xL 
mRNA; no statistically significant difference was seen in the relative 
abundance of Bcl-xL protein compared to an untreated control (fig. 4.6).
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A) Northern Blot B) Western Blot
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Figure 4.6 Expression of Bcl-xL in AA/C1 cells
AA/C1 cells were grown to 100 % confluency and either left untreated or treated with 
5 mM sodium butyrate, PEG-ba and PEG600 for 48 hours, resupplementing after 24 
hours. A, northern analysis showing B c I-x l  mRNA expression with the corresponding 
densiometric analysis show as a histogram; B, western analysis showing B c I-x l  
expression and the corresponding densiometric analysis. Results are normalised to 
p-actin and expressed as abundance relative to untreated control; values represent 
mean ± S.E.M. of three separate cell treatments (* = p-value < 0.05, ** = p-value < 
0.005 *** = p-value < 0.001).
- 114-
CHAPTER 4
The pattern of expression for Bcl-xL seen in AA/C1 cells was similar to that 
seen in HT-29 cells. Treatment of sodium butyrate to HT-29 cells resulted in a 
1.45 ± 0.01 reduction in the abundance of Bcl-xL mRNA and a 1.3 ± 0.05 fold 
reduction in the level of Bcl-xL protein, compared to an untreated control (fig. 
4.7). When HT-29 cells were treated with PEG-ba the opposite pattern of 
expression for butyrate treatment was seen; a 1.6 ± 0.09 fold and 1.7 ± 0.11 
fold up regulation of Bcl-xL mRNA and protein, respectively, relative to an 
untreated control that are both statistically significant. Treatment of HT-29 cells 
with PEG60o and butyronitrile did not result in any statistically significant change 
in the expression of Bcl-xL mRNA or protein.
The pattern of expression for the pro-apoptotic gene Bak in AA/C1 and HT-29 
cells treated with PEG-ba was very similar to that observed when cells were 
treated with NaBut. As shown in figure 4.8, in AA/C1 cells treated with sodium 
butyrate, there was a 1.8 ± 0.12 fold up regulation in Bak mRNA expression, 
as seen by northern blotting, and a 1.9 ± 0.06 fold up enhancement in the level 
of protein. When AA/C1 cells were treated with PEG-ba a 1.8 ± 0.11 fold and 2 
± 0.08 fold increase in Bak mRNA and protein respectively was observed; 
clearly demonstrating that PEG-ba can mimic the effects of butyrate. 
Treatment of PEG6oo on AA/C1 cells resulted in a 1.3 ± 0.13 fold increase in 
the level of Bak mRNA. However, a smaller 1.1 ± 0.16 fold increase in the level 
of Bak protein was observed with PEG60o treatment; changes that are not 
statistically significant (fig. 4.8).
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A) Real-time PCR B) Western Blot
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Figure 4.7 Expression of Bcl-xL in HT-29 cells
HT-29 cells were grown to 70 % confluency and either left untreated or treated with 2 
mM sodium butyrate, PEG-ba and PEG600 for 24 hours. A, real-time PCR analysis 
showing Bcl-xL mRNA expression with the corresponding densiometric analysis 
shown as a histogram; B, western analysis showing Bcl-xL protein expression and 
the corresponding denoiometric analysis. Results are normalised to p-actin and 
expressed as abundance relative to untreated control; values represent mean ± 
S.E.M. of three separate cell treatments (* = p-value s 0.05 and *** = p-value < 
0.001) .
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Treatment of HT-29 cells with sodium butyrate and PEG-ba showed a 
similar pattern of expression for Bak. As figure 4.9 shows, when HT-29 
cells were treated with sodium butyrate, a 1.5 ± 0.05 fold increase in Bak 
mRNA and a 1.6 ± 0.07 fold increase in Bak protein were seen. 
Treatment of PEG-ba also increased the level of Bak mRNA and protein, 
albeit to a higher degree, with a 1.8 ± 0.05 and ± 0.12 fold increase in 
mRNA and protein respectively. Treatment of HT-29 cells with PEG6oo 
and butyronitile had no statistically significant effect on the level of Bak 
mRNA and protein expression, (fig. 4.9).
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Figure 4.8 Expression of Bak in AA/C1 cells
AA/C1 cells were grown to 100 % confluency and either left untreated or treated with 
5 mM sodium butyrate, PEG-ba and PEGeoo for 48 hours, resupplemented after 24 
hours. A, northern analysis showing Bak mRNA expression and the corresponding 
densiometric analysis shown as a histogram; B, western analysis showing Bak 
protein expression with the corresponding densiometric analysis shown as a 
histogram. Results are normalised to p-actin and expressed as abundance relative to 
untreated control; values represent mean ± S.E.M. of three separate cell treatments 
(* = p-value ^ 0.05, ** = p-value < 0.005).
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A) Real-time PCR B) Western blot
Figure 4.9 Expression of Bak in HT-29 cells
HT-29 cells were grown to 70 % confluency and either left untreated or treated with 2 
mM sodium butyrate, PEG-ba and PEG600 for 24 hours. A, northern analysis 
showing Bak mRNA expression with the corresponding densiometric analysis 
displayed as a histogram; B, western analysis showing Bak protein expression with 
the corresponding densiometric analysis displayed as a histogram. Results are 
normalised to p-actin and expressed as abundance relative to untreated control; 
values represent mean ± S.E.M. of three separate cell treatments (* = p-value s 0.05 
and ** = p-value s 0.005).
-119-
CHAPTER 4
4.2.3 Analysis of survivin, Bak and Bcl-xL mRNA expression in 
AA/C1 cells by quantitative PCR
4.2.3.1 Analysis of Bak and Bcl-xL mRNA expression
The mechanism by which butyrate regulates Bak and Bcl-xL mRNA in AA/C1 
cells was also investigated by real-time PCR. The results obtained were close 
to those obtained using HT-29 cells. As shown in figure 4.10, treatment of 
AA/C1 cells with sodium butyrate resulted in a 1.7 ± 0.04 fold enhancement in 
Bak mRNA expression. When AA/C1 cells were treated with PEG-ba a 2.1 ± 
0.24 fold induction in Bak mRNA was seen. While PEG6oo had no effect on the 
level of Bak mRNA expression. AA/C1 cells treated with sodium butyrate 
showed a 1.5 ± 0.02 fold down regulation of Bcl-xL mRNA while treatment of 
PEG-ba resulted in a 1.5 ± 0.3 up regulation. When cells were treated with 
PEG6oo, a smaller 1.2 ± 0.01 fold up regulation of Bcl-xL mRNA was seen (fig. 
4.10).
4.2.3.1 Analysis of survivin mRNA expression
Survivin is another anti-apoptotic gene known to be down-regulated by 
butyrate (Daly et al., 2005). To investigate whether PEG-ba was able to 
modulate survivin expression, AA/C1 cells were treated with 5 mM of either 
butyrate or PEG-ba for 24 hours. Upon harvesting the cells, total RNA was 
isolated and cDNA was prepared. The relative expression of survivin was then 
assessed using real-time PCR. As shown in figure 5.10, butyrate down- 
regulated survivin 2.5 ± 0.02 fold while PEG-ba down-regulated survivin 4 ± 
0.04 fold, compared to an untreated control.
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Figure 4.10 Real-time PCR analysis on AA/C1 cells
AA/C1 cells were grown to 100 % confluency and either left untreated or treated with 
5 mM sodium butyrate, PEG-ba and PEG600 for 48 hours, resupplemented after 24 
hours (Cells were treated for 24 hours for survivin, with no PEG6oo control). Real-time 
PCR analysis was carried out for: A, Bak; B, Bcl-xL; C, MCT1; D, Survivin. Results 
are expressed as abundance relative to untreated control; values represent mean ± 
S.E.M. of three separate cell treatments (* = p-value s 0.05, ** = p-value £ 0.005 *** = 
p-value s 0.001).
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4.2.4 Regulation of MCT1
The work described in this chapter clearly shows that PEG-ba, a membrane- 
impermeable, non-transportable butyrate analogue regulated the pro-apoptotic 
gene bak and the anti- apoptotic gene product survivin with the same pattern 
as butyrate. These finding supports our proposition that expression of these 
candidate genes controlling apoptosis may be regulated through “butyrate 
sensing”. Our proposition is further supported by the findings that the 
regulation of IAP and p21 that was dependent on the entry of butyrate into the 
cell via MCT1 were not regulated by PEG-ba.
We next asked the question what is the pattern of regulation of MCT1 by 
butyrate? MCT1 is the colonic butyrate transporter, and it has been shown to 
be regulated by butyrate at both transcriptional and post-transcriptional levels 
(Cuff et al., 2002). However, it is not known whether, for butyrate regulation of 
MCT 1, there is a need for butyrate entry into the cell.
AA/C1 cells express MCT1 protein on the luminal membrane (Rizhaupt et al., 
1998a; Lambert et al., 2002) and they have been used in studies assessing the 
regulation of MCT1 by butyrate (Cuff et al 2002). Accordingly, AA/C1 cells 
were grown to confluency and either left untreated or treated with NaBut or 
PEG-ba, 5 mM concentration, for 48 hours. Afterwards the cells were 
harvested and total RNA and cellular homogenates were prepared. Northern 
blot and real-time PCR were used to measure the abundance of MCT1 mRNA 
expression and western blot was employed to measure the MCT1 protein 
abundance.
Treatment of AA/C1 cells with NaBut resulted in a 1.6 ± 0.05 and 1.9 ± 0.01 
fold increase in MCT1 mRNA abundance compared to control as measured by 
northern blotting and the real time PCR respectively (see fig. 4.10 and 4.11). 
There was a co-ordinated 2 ± 0.16 fold increase in MCT1 protein abundance
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over the controls. No change was observed in either MCT1 mRNA or protein 
compared to controls when AA/C1 cells were treated with PEG-ba. In fact 
there was a reduction in MCT1 expression, at mRNA and protein levels in 
response to PEG-ba, indication that MCT1 regulation by butyrate requires 
butyrate entry into the cell.
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A) Northern blot B) Western blot
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Figure 4.11 Expression of MCT1 in AA/C1 cells
AA/C1 cells were grown to 100 % confluency and either left untreated or treated with 
5 mM sodium butyrate, PEG-ba or PEG6oo for 48 hours, resupplemented after 24 
hours. A, northern analysis showing MCT1 mRNA levels and the corresponding 
densiometric analysis, as a histogram; B, western analysis showing MCT1 protein 
levels with the corresponding densiometric analysis, as a histogram. Results are 
normalised to p-actin and expressed as abundance relative to untreated control; 
values represent mean ± S.E.M. of three separate cell treatments (** = p-value < 
0.05, *** = p-value s 0.001).
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4.3 Discussion
It has been shown by our laboratory and others that MCT1 is the protein 
responsible for the transport of butyrate across the colonic luminal membrane 
(Ritzhaupt et al., 1998a; Stern et al., 2000; Hadjiagapiou et al., 2000) 
Furthermore we have shown that MCT1 is regulated by its substrate butyrate, 
and that knocking down MCT1 expression in several colonic cell lines results in 
the loss of butyrate’s ability to regulate genes AIP1 (gene product IAP), 
CDKN1A (CD1) and CCDN1 (p21). In contrast the inhibition of MCT1 
expression had no effect on butyrate’s ability to up-regulate bak1 (bak) and 
down-regulate bcl-xL
We set out to synthesise a membrane-impermeable, non-transportable 
butyrate analogue to determine if extra-cellular butyrate can regulate the 
expression of bak1 and bcl-xL similar to that observed in response to butyrate. 
This objective was investigated because we hypothesised that for some genes 
to be regulated by butyrate, there is a need for butyrate entry into the cell, 
whilst for others butyrate may exert its effects via a “butyrate sensor” located 
on the external face of colonic luminal membrane. This hypothesis was 
strengthened not only by our previous findings but also by reports indicating 
the presence of G-protein coupled receptors, GPCR 41, and 43 that can act as 
butyrate sensors in the large intestine.
The membrane impermeable butyrate analogue was synthesised by coupling 
of the butyrate molecule, at the C4 position of butyrate, to either end of PEG6oo 
(see figure 4.1 for the structural formula). An average molecular mass of 600 
gmol'1 for PEG was chosen as this is known to be impermeable to the 
intestinal plasma membrane (Lloyd, 1998) and yet it is soluble. PEG-ba was 
fully characterised by 1H and 13C NMR and mass spectrometry.
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Human colonic cell lines AA/C1 (derived from non-tumourigenic Adenoma) and 
HT-29 (originated from an adenocarcinoma) were utilised to assess the effect 
of PEG-ba on gene expression. The expression of IAP, p21, bak and bcl-xL 
after treatment with PEG-ba was investigated in both cell lines; the expression 
of MCT1 and survivin after PEG-ba treatment was also investigated in AA/C1 
and HT-29 cell lines respectively. The change in the expression of each gene 
in response to PEG-ba treatment was determined relative to the untreated 
control cells. The levels of expression were then compared to that observed 
with cells treated with butyrate (positive control) and PEG60o and butyronitrile 
(negative controls).
The results indicated that PEG-ba had no regulatory effect on the expression 
levels of CDKN1A and ALP1 in both AA/C1 and HT-29 cells compared to the 
effects seen by butyrate treatment. We had shown previously that butyrate was 
not able to modulate the expression of the above genes when MCT1 
expression was silenced, using siRNA, in AA/C1 and HT-29 cells (Cuff et al 
2005).
PEG-ba was able to modulate the expression of bak at the level of mRNA and 
protein, and survivin at the mRNA level (due to the lack of antibody to survivin 
it was not possible to determine protein expression). In AA/C1 a 1.8 ± 0.11 
and 2 ± 0.08 fold enhancement in mRNA and protein were observed in 
response to PEG-ba treatments; values identical to the effect seen by butyrate. 
PEG-ba treatment of HT-29 cells resulted in a 1.8 fold ±0.11 and 0.16 increase 
in bak mRNA and protein. This increase was slightly higher to that observed 
for bak by butyrate, which resulted in a 1.5 ± 0.05 and 1.6 ± 0.07 fold increases 
in bak mRNA and protein respectively. In contrast PEG-ba down regulated 
survivin mRNA 4 ± 0.04 fold in AA/C1 cells compared to a 2.5 ± 0.02 fold 
reduction by NaBut. These data collectively indicate that p21 and IAP are only
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up-regulated in response to butyrate, and are not responsive to PEG-ba. In 
contrast, both butyrate and its membrane impermeable analogue PEG-ba 
regulate bak and survivin to an extent (bak expression is up-regulated by both 
butyrate and PEG-ba, whilst survivin is down regulated by both compounds); 
supporting the notion that for the latter genes, butyrate may exert its effect 
through a plasma membrane butyrate sensing molecule.
There were some changes in gene expression in response to PEG6oo 
treatments, more pronounced in HT-29 cells than AA/C1 cells, but by no 
means were the changes as dramatic as seen with PEG-ba. There are reports 
of PEG inducing differentiation in HT-29 cells in the literature. Laboisse et al., 
1988 reported that treatment of PEG100o on HT-29 cells brought about a 
differentiated subpopulation of cells with characteristics of mucous secreting 
goblet cells and endocytotic cells. Both subpopulations also showed reduced 
tumourogenicity than the parental HT-29 cell line (Laboisse et al., 1988). PEG 
has also been found to induce apoptosis in HT-29 cells (Roy et al., 2001). 
Parnaud et al., 2001 reported that treatment of PEG800o on HT-29 cells reduced 
proliferation through reducing the number of cells in S phase and increasing 
the number of cells in G0/Gi. The authors noted that the treatment of PEG80oo 
increased the number of floating cells within the medium. Upon further 
investigation, blebbing -  a characteristic of apoptosis -  was seen, and no 
necrotic cells were found (Parnaud et al., 2001).
It is worth noting that the up regulation in the abundance of p21 and IAP 
induced by PEG60o is not seen by PEG-ba. Furthermore, the level to which 
PEG6oo up regulates bak, a 1.3 fold induction in AA/C1 cells, is not statistically 
significant. Nor is it to the same level induced by PEG-ba that gave a 1.8 fold 
increase in bak mRNA in AA/C1 cells; an increase that was statistically 
significant. The size of PEG used seems to be crucial for inducing apoptosis
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with PEGs of around 8000 Da seeming to be the optimum size for inhibiting 
biomarkers for colon cancer (Roy et a/., 2001); this being well above the size of 
PEG used in this study.
Butyrate has been shown previously to regulate the expression of its 
transporter, MCT1. We sought to identify whether butyrate sensing or transport 
was responsible for MCT1 upregulation by butyrate. Treatment of AA/C1 with 
PEG-ba failed to modulate the expression of MCT1 indicating that butyrate 
entry is required for butyrate regulate of MCT1 expression.The data presented 
in this chapter clearly supports our previous results (Cuff et a!., 2005) 
indicating MCT1 expression and addressing its effects on butyrates ability to 
modulate the expression of key target genes. The combined data collectively 
support the suggestion for the presence of an extra-cellular “butyrate sensor” 
that senses luminal butyrate. The sensor may activate an intra-cellular 
pathway resulting in the downstream regulation of Bak, survivin and Bcl-xL.
There is evidence in the literature concerning nutrient sensing by the intestinal 
epithelium and the downstream pathways. Long-chain fatty acids, amino acids 
and sugars are sensed in the intestine while (Raybould, 1999) amino acid 
transporters and the sugar transporter, SGLT1, are regulated via extra-cellular 
sensors (Dyer et al., 2003; Hyde et at., 2003). The intestinal calcium-sensing 
receptor is activated by a multitude of divalent ions as well as L-amino acids, 
small peptides and polyamines (Riccardi & Maldonado-Perez, 2005) and is 
responsible for fluid secretion in the colon (Geibel et al., 2006).
Suitable candidates for the butyrate receptor are the G-protein coupled 
receptors, GPR41 and GPR43, which are activated by short chain carboxylic 
anions in a dose-dependent and dose-specific manner (Brown et al., 2003). 
Moreover, GPR41 and GRP43 have been found to induce various biological
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pathways upon activation by SCFAs (Kimura et al., 2001; Xiong et al., 2004). 
On going work in our laboratory has identified that the G-protein coupled 
receptors GPR41 and GPR43 are present in AA/C1 and HT-29 cell lines and 
on the luminal membrane of human colon. As GPR41 and GPR43 have been 
shown to be activated by butyrate, it is feasible that either GPR41 or GPR43 
are responsible for the regulation of bak and survivin in AA/C1 and HT-29 cells 
by butyrate.
In this study, PEG-ba was statistically unable to regulate the expression of IAP 
and p21; but was able to regulate the expression of Bak, to the same 
magnitude as NaBut treatment. The pattern of expression for p21, IAP and Bak 
in AA/C1 and HT-29 cells, after PEG-ba treatment agrees with the previous 
data obtained from silencing MCT1 using siRNA i.e. silencing of MCT1 
prevented butyrate’s ability to modulate the expression of p21 and IAP, but not 
Bak (Cuff et al., 2005). However, the up-regulation of Bcl-xL by PEG-ba does 
not conform to the expected pattern of expression determined after silencing of 
MCT1 expression.
Silencing of MCT1 had no effect on butyrate’s ability to modulate Bcl-xL, 
showing a 2 fold reduction in Bcl-xL expression, post butyrate treatment (Cuff 
et al., 2005). Treatment of AA/C1 and HT-29 cells by NaBut resulted in a 2 fold 
decrease in Bcl-xL expression compared to a 2 fold increase in Bcl-xL 
expression after PEG-ba treatment; both statistically significant. The data 
presented here shows that although PEG-ba can mimic butyrate in modulating 
bak expression in AA/C1 and HT-29 cells and survivin in AA/C1 cells, it is not 
entirely the case for bcl-xL.
Butyrate increases apoptosis by up regulating pro-apoptotic genes, such as 
Bak1 and down regulating anti-apoptotic genes, such as BIRC5 (survivin) and
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Bcl-xL. The up regulation of Bcl-xL seen here by PEG-ba does not fit with this 
pattern of expression and requires further investigation.
If the induction of Bak by PEG-ba does involve the sensing of PEG-ba by an 
extra-cellular nutrient sensor, then it is possible for Bak, survivin and Bcl-xL to 
be regulated by different sensors. If only one sensor was responsible for the 
induction of Bak and the inhibition of survivin and Bcl-xL then one would expect 
PEG-ba to mimic butyrate’s effect in modulating these three genes. If there are 
multiple sensors involved in the sensing of butyrate, then these may be 
differentially expressed with different affinities for butyrate. PEG-ba may not 
fulfil the requirement of butyrate to regulate the expression of Bcl-xL. One way 
to help clarify this issue would be to knock down GPR41 and GPR43 using 
siRNA, and determine if GPR41 and 43, or both, were responsible for sensing 
butyrate in the colon and if Bak, survivin and Bcl-xL expression was regulated 
by these GPCRs.
The 2 fold increase in Bcl-xL expression following PEG-ba treatment, may also 
be due to non-specific interactions between the PEG-ba and the putative 
‘butyrate sensor’. Co-treatment of NaBut and PEG-ba would help to determine 
whether the increased expression of Bcl-xL following PEG-ba treatment is a 
true result, or merely an anomaly. If co-treatment of NaBut and PEG-ba 
resulted in the down-regulation of Bcl-xL (i.e. mirroring NaBut treatment), then 
the PEG-ba-induced up-regulation of Bcl-xL would more likely be an 
anomalous result. Whereas, if no change in Bcl-xL expression was seen (i.e. 
NaBut-induced down-regulation being cancelled out by PEG-ba-induced up- 
regulation), then the up-regulation of Bcl-xL is probably a true result.
In summary, the work presented in this chapter demonstrates that the 
membrane-impermeable butyrate analogue is capable of mimicking butyrates 
ability to modulate butyrate-responsive genes such as bak1 and BIRC5.
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Furthermore, the data presented here supports the notion of the presence of 
an extra-cellular butyrate sensor(s) present on the plasma membrane of the 
two colonic cell lines, AA/C1 and HT-29. The potential mechanism could be 
that the sensor senses media butyrate activating a downstream pathway 
resulting in the regulation of the two apoptotic genes, bak1 and BIRC5.
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Exchange of butyrate/heptafluorobutyrate (HFB) 
across porcine colonie luminal membrane 
vesicles; treatment of human colonie epithelial
cell lines with HFB
CHAPTER 5
5.1 Introduction
As discussed in previous chapters, the experimental data have indicated that 
the ability of butyrate to modulate the expression of candidate genes p21 and 
IAP (involved in the control of proliferation and differentiation) is dependent on 
its transport into the cell. Butyrate serves as the principal source of energy for 
colonocytes (Roediger, 1980), a role for which cellular entry clearly is vital. It is 
feasible, therefore that the requirement for butyrate entry may reflect a 
metabolic dependency of its actions on proliferation and differentiation that is 
not required for modulation of apoptosis. Heerdt at al., (1994) investigated the 
effect of a non-metabolisable butyrate analogue heptafluorobutyrate, (HFB) on 
butyrate mediated differentiation and apoptosis in HT-29 and SW620 colon 
adenocarcinoma cell lines. They did not detect any modulations in apoptosis or 
differentiation of these cells by HFB. They concluded that butyrate-induced 
apoptosis and differentiation of HT-29 and SW20 colonic cell lines may be 
dependent on butyrate metabolism (Heerdt et al., 1994).
Although Heerdt et al., (1994) had used HFB as a nonmetabolisable butyrate 
analogue; there was no indication that HFB is transported into the cell. Fluorine 
has been used in a wide variety of metabolite analogues. Fluorine carbon bond 
energies are one of the highest found in natural products and known to be 
broken enzymatically (Goldman, 1969). The transport of HFB into the cell and 
the potential involvement of HFB as a non-metabolisable butyrate analogue 
regulating gene expression were investigated in the present study.
In order to investigate if HFB is transported across the colonic luminal 
membrane, we used porcine colonic tissue due to its functional similarity to 
human (Sullivan et al., 2001). Colonic mucosal scrapings were used to prepare
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colonic luminal membrane vesicles. The use of membrane vesicles to study 
the transport of nutrients and ions across plasma membranes is a well 
established technique that has many advantages over whole cell and tissue 
experiments. The transport of nutrients being investigated are not subjected to 
metabolism, and the extra and intra cellular composition can easily be 
manipulated to suit the experimental design (Murer et al., 1984). There are 
disadvantages to the use of membrane vesicles. Routine preparations are 
never free of contaminating membranes; during transport studies, the solute 
under investigation can bind to the membrane giving false positive results; and 
the membranes may become leaky. Control experiments are therefore carried 
out to assess and minimise the contribution of other factors (Murer & Kinne, 
1980). Purified colonic LMVs were prepared using cation precipitation and 
differential centrifugation technique as reported by Ritzhaupt et al., (1998a) 
and as discussed in the Methods.
Once isolated the colonic LMV are characterised in terms of purity and 
potential contamination by other membranes such as the basolateral and 
organelle membranes. Characterisation can be carried out by assessing the 
enrichment of marker proteins for the luminal and basolateral membranes 
using western blotting. Enzyme assays against marker enzymes for luminal, 
basolateral and organelle membranes are also utilised to assess any potential 
contamination by these membranes.
The purpose of work carried out in this chapter was not to characterise 
butyrate uptake, as this has been reported previously; the work carried out in 
this chapter set out to determine if HFB is transported into colonic LMVs, and if 
HFB could mimic the effects of butyrate on butyrate-responsive genes.
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5.2 Results
5.2.1 Characterisation of colonic luminal membrane vesicles
Characterisation of colonic LMVs was carried out by immunoblotting for marker 
proteins characteristic of the luminal and basolateral membranes of 
colonocytes.
5.2.1.1 immunodection of markers of colonic luminal membranes
Colonocytes have characteristic microvilli present on the luminal face of the 
epithelial cell. Villin is a 95 kDa protein that is associated with a-actin in the 
microvilli of epithelial cells, and is a reliable marker of the luminal membrane of 
colonoctyes (Robine et al., 1985). MCT1 is also another indicator of the luminal 
membrane of porcine and human colon (Ritzhaupt et al., 1998b) and has been 
shown to reside on the luminal membrane of the human colon by 
immunohistochemistry (Lambert et al., 2002).
In order to assess the abundance of luminal marker proteins, 20 |ig colonic 
LMV and homogenate were separated on 8 % SDS-PAGE gels and 
transferred to PVDF membrane before blotting with antibodies to villin and 
MCT1. As shown in figure 5.1 villin was enriched in the colonic LMV fraction by 
2.2 ± 0.33 fold, compared to homogenate. In addition MCT1 showed a 4 ± 1.5 
fold enrichment in the colonic LMV fraction, compared to the homogenate (fig. 
3.1).
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Figure 5.1 Enrichment of colonic luminal membrane markers in
porcine colonic LMVs
Porcine colonic LMV (20 pg) were separated on SDS-PAGE gels, transferred to 
PVDF membrane and immunoblotted for luminal membrane marker proteins villin 
and MCT1. H = crude cellular homogenate, V = purified colonic LMVs. A, western 
blot for villin showing two fold enrichment in colonic LMVs compared to homogenate. 
B, western blot showing a four fold enrichment of MCT1 in colonic LMV compared to 
homogenate. Results are expressed as mean ± S.E.M. of 3 separate LMV 
preparations (*  = p-value £ 0.05).
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3.2.1.2 Immunodetection of markers of colonic basolateral 
membranes
HLA-1 is a member of the human major histocompatibility (MHC) antigen 
family. Class I and II MHC antigens are known to play a central role in the 
response to antigens in the body (Gorvel et at., 1984). HLA class I (HLA-1) has 
been localised to the basolateral membrane of human jejunal enterocytes 
(Gorvel et a/., 1984) and porcine RLA class I has been localised to the 
basolateral membrane in pig colonocytes (Pinches et at., 1993). To assess any 
potential contamination with basolateral membranes in the colonic LMV the 
abundance of HLA-1 was measured using western blotting. As shown in figure 
3.2, HLA-1 displayed a 3.33 ±0.12 fold disenrichment in the LMV fraction 
compared to the homogenate, indicating that the colonic LMVs had hardly any 
basolateral membrane contamination.
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Figure 5.2 Enrichment of HLA-1 in porcine colonic LMVs
Porcine colonic LMV (20 jxg) were loaded on SDS-PAGE gels, transferred to PVDF 
membrane and immunoblotted for HLA-1, a marker of the basolateral membrane, 
showing 4 fold disenrichment in colonic LMV compared to homogenate. H = crude 
cellular homogenate, V = purified colonic LMVs. Results are expressed as mean ± 
S.E.M. of 3 separate LMV preparations.
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5.2.1.3 Assessment of LMV purity by enzyme assays
Cysteine-sensitive alkaline phosphatase (AP) is a membrane-bound 
glycoprotein with an approximate molecular mass of 66 kDa. It hydrolyses a 
wide variety of monophosphate esters at an alkaline pH (Malo et at., 2004). 
Cysteine-sensitive AP is a classical luminal membrane marker and its 
abundance was assessed using a cysteine-sensitive AP enzyme assay. 
Accordingly, the activity of cysteine-sensitive AP was assessed in the 
homogenate and LMV fraction to calculate the enrichment and recovery of this 
luminal membrane marker. As shown in table 5.1 cysteine-sensitive AP was 
enriched 7 fold in the colonic LMV fraction and had a recovery of 23 %. The 
activity of the luminal membrane marker, H+/K+-ATPase, was also assessed 
using a H+/K+-ATPase enzyme assay. As shown in table 5.1 the activity of 
H+/K+-ATPase was enriched 5 fold with a recovery of 15.9 %.
Contamination of colonic LMVs with organelle membranes was assessed by 
assaying for marker enzymes for the mitochondria, endoplasmic reticulum 
(ER) and Golgi apparatus. The enzymes succinate dehydrogenase, a marker 
for the mitochondria; tris-resistant-a-glucosidase, a marker for the ER; and a- 
mannosidase, a marker for the Golgi apparatus were assessed in the LMV 
fraction to assess any potential contamination by these membranes. The 
enrichment and recoveries of marker enzymes from organelle membranes 
were low. Tris-resistant-a-glucosidase was enriched 1.8 fold and had a 
recovery of 6.7 %. a-mannosidase and succinate dehydrogenase had small 
enrichments of 1.6 and 2 fold respecitively; with recoveries of 4.5 and 5.7 % 
respectively (see table 5.1).
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CHAPTER 5
5.2.3 Transport of sodium [U-14C]-butyrate
In order to assess the transport of the non-metabolisable butyrate analogue, 
HFB, we first set out to reproduce the typical butyrate uptake into porcine 
colonic LMV carried out previously in this laboratory (Ritzhaupt et al., 1998a).
5.2.3.1 Butyrate/'OH exchange
Butyrate/proton co-transport into LMV was investigated. Accordingly LMV were 
preloaded with 300 mM mannitol, 20 mM Hepes/tris pH 7.5 and 0.1 mM 
MgS04 Butyrate uptake was performed at 37 °C in a buffer consisting of 100 
mM mannitol, 100 mM Na gluconate, 1 mM butyrate with tracer amounts of [U- 
14C]-butyrate, 0.1 mM MgS04 and either 20 mM Hepes/tris pH 7.5 or 20 mM 
Mes/tris pH 5.5 for 5 s. As shown in figure 5.3 the rate of butyrate uptake at the 
extravesicular pH (pHout) of 7.5 was 17.31 ± 5.11 pmoles/5 s/mg protein 
compared to 382.4 ± 42.24 pmoles/5 s/mg protein when pH0Ut = 5.5. The rates 
for butyrate/proton co-transport (butyrate/hydroxyl exchange) in porcine colonic 
LMV were comparative to the rates determined previously.
-141 -
CHAPTER 5
450-1
T-v 400- c
^  4) 350-
S. o. 300- <r> ™
§ £ 250-
ffi ^2 0 0 - ro «
S . 150-
m "5 100-
Q- 50-
0
pHin = 7.5 pH
Figure 5.3 Uptake of Butyrate into Porcine colonic LMV
Vesicles were loaded with 300 mM mannitol, 20 mM Hepes/tris pH 7.5 and 0.1 mM 
MgS04. LMV (50 pg protein per assay) were incubated in 100 mM mannitol, 100 mM 
sodium gluconate, 1 mM butyrate, 0.1 mM MgS04 and either 20 mM Hepes/tris pH 
7.5 or 20 mM Mes/tris pH 5.5. Uptake was measured as described in section 2.8. 
(pHjn = intravesicular pH, pHout = extravesicular pH). Rates are expressed as mean ± 
S.E.M. for three separate LMV preparations (** = p-value ^ 0.05).
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5.2.3.2 Effect of intravesicular anion
We next set out to reproduce the uptake of butyrate into the LMV in exchange 
for intra-vesicle butyrate. Butyrate/butyrate exchange was determined using 
the same method as above with colonic LMV preloaded with 100 mM mannitol 
and 100 mM NaBut. Figure 5.4a shows the rates of butyrate uptake into 
colonic LMVs in exchange for butyrate, with a differing extravesicular pH of 7.5 
and 5.5. The rate of uptake into colonic LMVs loaded with butyrate was 436.7 
± 48.69 pmoles/5 s/mg protein at pH0Ut = 7.5 and 1239 ± 131.6 pmoles/5 s/mg 
protein at pH0Ut = 5.5.
We next set out to determine the rate of HFB transport into colonic LMVs. As 
no 14C radiolabelled HFB was commercially available, no direct tracer-labelled 
transport using a 14C-labelled HFB were possible. HFB transport was therefore 
determined using trans-stimulation of HFB in exchange for transport of radio- 
labelled butyrate into the vesicles. Accordingly, LMV were preloaded with 
either 300 mM mannitol or 100 mM mannitol and 100 mM NaBut or NaHFB. 
Butyrate uptake was performed in either extravesicular Hepes/tris buffer pH
7.5 or Mes/tris buffer pH 5.5. As shown in figure 5.4a the rate of butyrate 
uptake into colonic LMVs in exchange for HFB was 17.51 ± 3.0 and 247.9 ± 
44.55 pmoles/5 s/mg protein at pHout 7.5 and pH0Ut 5.5 respectively; a rate 
much smaller than butyrate/butyrate exchange and a smaller rate than 
butyrate/hydroxyl exchange (17.31 ± 5.11 and 382.4 ± 42.24 pmoles/5 s/mg 
protein at pH0Ut = 7.5 and pH0Ut = 5.5 respectively).
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Figure 5.4 Butyrate/butyrate exchange across porcine colonic
LMVs
Porcine colonic LMV were loaded with a buffer containing 20 mM Hepes/tris pH 7.5, 
0.1 mM MgSC>4 and 300 mM mannitol or 100 mM mannitol with 100 mM sodium 
butyrate or sodium HFB. LMV (50 pg protein per assay) were incubated in a buffer 
containing either 20 mM Hepes/tris pH 7.5 (□) or Mes/tris pH 5.5 (■) and 0.1 mM 
MgS04 and 1 mM sodium butyrate for 5 seconds. Uptake was carried out at 37 °C for
5 s as described in Methods (section 2.8). A, butyrate up at pH0Ut 5.5 and 7.5; B, pH 
stimulated butyrate uptake as determined by subtracting the uptake at pH 7.5 from 
the uptake at pH 5.5. Rates are expressed as mean ± S.E.M. 3 separate vesicle 
preparations.
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In order to establish a clear picture of butyrate/butyrate exchange versus 
HFB/butyrate exchange the pH stimulated butyrate uptake was calculated. 
This was determined by subtracting the uptake at pH0Ut 7.5 from the uptake at 
pH0ut 5.5. As seen in figure 5.4b butyrate/HFB exchange had a rate of 230.3 ± 
42.7 pmoles/5 s/mg protein; a rate significantly smaller than the rate observed 
for butyrate/butyrate exchange which had a rate of 946.8 ± 83.21 pmoles/5 
s/mg protein, and a smaller rate then butyrate/hydroxyl (368.4 ± 40.13 
pmoles/5 s/mg protein). The data indicated that HFB can directly exchange 
with butyrate, indicating that it is transported by the butyrate transporter but 
having possibly a lower affinity for the transporter compared to butyrate.
5.2.3.3 Inhibition of butyrate uptake by HFB
After determining that HFB is able to exchange with butyrate and be 
transported out of colonic LMVs, albeit at a lower rate, we next sought to 
determine if HFB could inhibit butyrate transport into the LMVs. Colonic LMVs 
were preloaded with 300 mM mannitol, 20 mM Hepes/tris pH 7.5 and 0.1 mM 
MgS04. Uptake of butyrate was carried out in an iso-osmolar buffer consisting 
of 100 mM mannitol, 100 mM Na gluconate, 20 mM Mes/tris pH 5.5, 1 mM Na 
butyrate and 0.1 mM MgS04 ± 5 mM NaHFB. Uptake of butyrate without 
addition of 5 mM NaHFB gave a rate of 385.7 ±44.14 pmoles/5 s/mg protein, 
which is in agreement with the rate obtained previously (see section 5.2.3.1). 
When the rate of butyrate uptake was determined in the presence of 5 mM 
HFB to the uptake medium, a rate of 194.8 ± 31.43 pmoles/5 s/mg protein was 
observed; a reduced rate of 49 %. This clearly shows that HFB can inhibit 
butyrate transport into porcine colonic LMV implying that HFB binds to the 
butyrate transporter.
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500-1
- HFB + HFB
5 mM HFB
Figure 5.5 HFB Inhibition of butyrate transport
Porcine colonic LMV were loaded with a buffer containing 300 mM mannitol, 20 mM 
hepes/tris pH 7.5 and 0.1 mM MgSC>4. LMV (50 pg protein per assay) were incubated 
in a buffer containing 100 mM mannitol, 100 mM Na glcuonate, 20 mM Mes/tris pH 
5.5, 0.1 mM MgS04 and 1 mM sodium butyrate ± 5 mM sodium HFB. Uptake took 
place at 37 °C for 5 s as described in Methods (section 2.8). Rates are expressed as 
mean ± S.E.M. 3 separate vesicle preparations (* = p-vaule < 0.05).
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5.2.4 Treatment of colonic epithelial cell lines with sodium HFB
After determining that HFB was transported into porcine colonic LMVs, we next 
set out to determine if HFB was able to mimic butyrates effects on gene 
expression; therefore assessing if some butyrate regulated gene expression 
may be responsive to butyrate metabolism. Two cell lines, a non-tumourigenic 
AA/C1, adenoma-derived cell line, and a HT-29, adenocarcinoma-derived cell 
line were used. These cells express MCT1 on their luminal membrane (Cuff et 
at., 2002; Lambert et at., 2002; Rizhaupt et at., 1998a) and it has been shown 
previously that the properties of butyrate transport in these cells is similar to 
that in porcine and human colonic luminal membrane vesicles (Rizhaupt et at., 
1998a). After reaching the desired confluency the cell lines were treated with 5 
mM NaBut and NaHFB for 24 hours, after which time the cells were harvested 
and total RNA isolated. Total cDNA was prepared and the expression of the 
butyrate-responsive genes p21, IAP, Bak and Bcl-xL mRNA was determined in 
both cell lines, while the expression of survivin and MCT1 mRNA was only 
determined in AA/C1 cells. The changes in the expression of the butyrate- 
responsive genes measured by real-time PCR are listed in table 5.2. 
Treatment of HT-29 cells with NaHFB resulted in no change in the expression 
of IAP or Bak compared to the untreated control. HFB treatment did result in a 
slight 1.1 fold increase in p21 mRNA expression; however this increase was 
far less than that observed in response to butyrate treatment (4.20 fold 
increase in p21 mRNA expression seen after butyrate treatment). NaHFB 
treatment of HT-29 cells resulted in a 1.3 fold increase in Bcl-xL mRNA 
expression, compared to the 1.7 fold decrease seen in Bcl-xL mRNA 
expression after butyrate treatment.
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5.3 Discussion
Porcine colonic LMVs were prepared using the cation-precipitation and 
differential centrifugation techniques from pig colonic mucosal scrapings. They 
were then characterised to assess the enrichment and recovery of the luminal, 
basolateral and organelle marker proteins. The results indicated negligible 
presence of organelles and basolateral membranes in the luminal membrane 
vesicles. Cysteine-sensitive alkaline phosphatase, a marker for the luminal 
membrane (Vengesa & Hopfer, 1979; Harig et al., 1990; Rizthaut et al., 1998a) 
was used to assess the origin of the LMVs. Cysteine-sensitive AP was 
enriched 6.99 ± 1.02 over the cell homogenate, with a recovery of 23.25 ± 3.59 
%, in agreement with enrichment and recoveries previously reported for 
colonic LMV preparations (Harig et al., 1990; Ritzhaupt, 1998a; Vengesa & 
Hopfer, 1979). Furthermore, the colonic LMVs were assessed using western 
blotting to determine the abundance of marker proteins in the luminal and 
basolateral membranes. Villin and MCT1, markers of the luminal membrane 
and HLA-1, a marker of the basolateral membrane were assessed. Villin and 
MCT1 were enriched 2 and 4 fold respectively; while HLA-1 was disenriched 3 
fold in the LMVs. The enrichment of villin in the LMV fraction is small compared 
to brush border membrane vesicles produced from the small intestine. Small 
intestinal enterocytes have more abundant microvilli compared to colonocytes, 
which corresponds to a higher abundance of villin (Dudouet et al., 1987). The 
microvilli of the enterocytes are also more tightly compacted allowing a higher 
recovery of the brush border member. The enzyme assays and immunoblots 
for membrane markers, showed high enrichment for the markers of the luminal 
membrane and negligible contamination of basolateral and organelle 
membranes in the LMVs.
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As there is no 14C radiolabelled HFB tracer commercially available, a different 
approach was used to investigate HFB transport into colonic LMVs. Butyrate is 
transported into the colonocytes using a pH dependent anion exchange 
process. Butyrate can be taken up into LMVs in exchange for intravesicular 
butyrate in the presence of a pH gradient. This trans-stimulation of butyrate 
allows studying the transport of butyrate/butyrate exchange from the inside to 
outside of the vesicle. Pre-loading the LMVs with HFB allowed an exchange 
between extravesicular butyrate and the intravesicular HFB to take place. The 
influx of the radiolabelled butyrate tracer was dependent on the efflux of the 
HFB, therefore allowing HFB transport to be studied indirectly. Transport of 
HFB via butyrate/HFB exchange was determined to be significantly lower than 
that for butyrate/butyrate exchange. Indeed, the transport rates obtained for 
HFB/butyrate exchange was slightly lower than butyrate/hydroxyl exchange. 
However, some transport of HFB did take place. Furthermore, this transport 
was stimulated at pH 5.5, a characteristic of butyrate transport into colonic 
LMVs (Rizhaupt, 1998a).
After determining that HFB is transported into porcine colonic LMVs we next 
set out to determine if butyrate metabolism plays a role in the regulation of 
some butyrate responsive genes. HFB failed to modulate the expression of 
p21, IAP, Bak, Bcl-xL, survivin and MCT1 in AA/C1 cells and IAP and Bak in 
HT-29 cells. A slight up-regulation of p21 and bcl-xL was seen when HT-29 
cells were treated with HFB. The slight up-regulation of p21 and Bcl-xL in HT- 
29 cells by HFB is probably coincidental. This conclusion is made due to the 
fact that butyrate down-regulated Bcl-xL in both cell lines while HFB treatment 
resulted in up-regulation of Bcl-xL in only one cell line. The modulation of p21 
expression seen in HFB-treated HT-29 cells is not seen in HFB-treated AA/C1
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cells compared to the modulation of p21 expression by butyrate, observed in 
both cell lines. Furthermore, as discussed in chapter 4, there is evidence that 
Bak and survivin as well as Bcl-xL are regulated by butyrate through a potential 
luminal membrane butyrate sensor(s). If HFB was able to mimic the effects of 
butyrate, via the putative butyrate sensor, one would expect HFB to interact 
with the extra-cellular sensor(s), resulting in the modulation of Bak, survivin 
and Bcl-xL.
The lack of effect of HFB can be interpreted in two ways; 1) that all the genes 
tested require butyrate metabolism for their regulation, 2) HFB is structurally 
different to butyrate and is unable to mimic any of butyrates effects. The van 
der waal’s radius of the fluorine atom (1.35 A) is close to that of hydrogen (1.1 
A) (Goldman, 1969), but is still larger. The difference in the chemical structure 
of butyrate and HFB may be sufficient for the lack of the effect.
3.3.1 Intracellular mechanisms involved in butyrate regulation of 
gene expression
Nutrients are known to be sensed intra-cellularly by binding to transcription 
factors within the nucleus. These transcription factors act as nutrient sensors 
by changing the level of DNA transcription. During ligand binding, these 
nuclear nutrient receptors undergo conformational changes that result in 
coordinated dissociation of co-repressor and recruitment of co-activator 
proteins. The transcription factors bind to specific nucleotide sequences in the 
promoter regions of a gene, known as response elements, to enable 
transcription activation (Afman & Muller, 2006). Butyrate is known to up- 
regulate the expression of numerous genes, many of which involve up-
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regulation of transcription. The activation of transcription by butyrate could 
involve butyrate alone or one or more of the downstream products of butyrate 
metabolism.
As shown in figure 5.6, butyrate undergoes metabolism by a complex pathway 
involving numerous enzymes. Silencing any one or a number of these 
enzymes would prevent the metabolism of butyrate and therefore the 
regulation of any gene that required a downstream metabolite of butyrate 
would be prevented. Targeting the machinery by which butyrate is metabolised 
is another route to discovering those genes that are dependent on butyrate 
metabolism.
CH3CH2CH2COOH
n-Butyrate
Butyrl-CoA synthetase HSCoA 
+ ATP
Crotonyl-CoA hydratase
3-Hydroxybutyrl-CoA
dehydrogenase
Acetyl-CoA
acetyltransferase
CH3CH2CH2COSCoA
Butyrl-CoA dehydrogenase 
(SCAD)
Butyryl-CoA
FAD
FADH,
CH3CH=CHCOSCoA
Crotonyl-CoA
H20
CH3CH(OH)CH2COSCoA
L-3-Hydroxybutyryl-CoA
—  NAD+
NADH
CH3COCH2COSCoA 
Acetoacetyl-CoA
H S C o A ------ -
CH3COSCoA + CH2COSCoA 
Acetyl-CoA Acetyl-CoA
Figure 5.6 Metabolism of butyrate in colonocytes
Adapted from Roediger, (1994)
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5.4 General discussion and future directions
Butyrate is a four carbon small chain monocarboxylate that is produced in the 
colon by the resident microflora through fermentation of dietary fibre and 
resistant starch. Butyrate plays an important role in maintaining colonic tissue 
homeostasis. Butyrate is the principle energy source for the colonocytes and 
has been shown to be responsible for the regulation of numerous genes 
associated with proliferation, apoptosis and differentiation. (Tan et al., 2002; 
Daly & Shirazi-Beechey, 2006). In many cases these genes have shown to be 
deregulated during colorectal tumorigenesis (Tabuchi et al., 2006). In order to 
understand the role butyrate plays in the regulation of the butyrate responsive 
target genes, how and why they are deregulated in CRC, one must first 
completely understand how butyrate modulates gene expression.
The mechanism by which butyrate regulates gene expression can be divided 
into two clear routes: 1) Butyrate-induced gene expression initiated by entry of 
butyrate into the colocytes; 2) Butyrate-induced gene expression initiated 
through the interaction of butyrate with the colonic luminal membrane butyrate 
receptor. Route one can be further subdivided into pathways that are directly 
affected by butyrate itself, such as its role as a histone deactylase inhibitor 
(Hague & Paraskeva, 1995); and others that are influenced by a metabolite of 
butyrate metabolism. Genes such as bak1, bcl-xL and BIRC5 appear to be 
regulated via a luminal membrane “butyrate receptor” such as GRP41 or 43. 
Whereas, the regulation of genes such as ALP1, p21 and mct1 are dependent 
on the entry of butyrate into the colocytes. However, whether the regulation of 
these genes is also dependent on butyrate metabolism is yet to be determined.
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The work presented in this thesis shows the successful synthesis of disodium 
PEG600a,co-di(4-butyrate). However, the problems faced during purification 
resulted in a small yield being obtained. As mentioned previously, disodium 
PEG6o0(x,a>-di(4-butyrate) can be utilised to identify further genes that do not 
require butyrate entry into the cell and may be regulated by the putative 
butyrate sensor. For the production of disodium PEG6ooa,co-di(4-butyrate) on a 
wide ranging scale, the synthesis of disodium PEG6ooa,©-di(4-butyrate) may 
have to be further modified to increase the yield.
Investigations into the effect on butyrate metabolism using HFB did not yield 
any concrete data on the effectiveness of HFB as a non-metabolisable 
butyrate analogue. The failure of HFB to induce apoptosis in HT-29 and 
SW620 colon adenocarcinoma cell lines led Heerdt at al., (1994) to propose 
that butyrate-induced apoptosis was dependent on the metabolism of butyrate. 
However, the authors did not show any positive regulation by HFB, i.e. no 
genes were shown to be modulated, either positively or negatively, by HFB.
As discussed in chapter 5, HFB did not modulate the expression of bak in 
either AA/C1 or HT-29 cell lines. It is proposed in this thesis that bak is 
modulated by butyrate through an extra-cellular sensor located on the luminal 
membrane of the colonocyte. In order for HFB to be classified as a non- 
metabolisable butyrate analogue, it is assumed that HFB is able to mimic any 
effects of butyrate that do not require the metabolism of butyrate; the 
modulation of bak expression by butyrate, through an extra-cellular sensor 
does not require butyrate metabolism. It was expected that HFB would 
modulate the expression of bak, mimicking butyrate. However, this is not the 
case.
-154-
CHAPTER 5
The lack of a positive control for HFB treatment in vitro and its failure to 
modulate the expression of bak, brings doubt on the appropriateness of HFB 
as a non-metabolisable analogue. This must be considered in the future for 
any use of HFB as a non-metabolisable butyrate-analogue.
Work on-going in our laboratory is directed towards silencing the expression of 
various enzymes responsible for the metabolism of butyrate and the proteins 
responsible for the transport of butyrate-CoA into the mitochondria. Silencing 
the machinery responsible for the metabolism of butyrate would identify those 
genes that were regulated by a butyrate metabolite at that point on wards.
On-going work is also focused on identifying the putative butyrate sensor 
through silencing the G-protein coupled receptors GPR41 and GPR43. Once 
identified, the downstream pathway activated by the butyrate sensor can be 
investigated, allowing the molecular mechanisms by which butyrate modulates 
gene expression to be further clarified. Further investigation is required to 
clarify the positive-modulation of bcl-xL seen when AA/C1 and HT-29 cell lines 
are treated with PRG-ba. As discussed in chapter 4, PEG-ba significantly up- 
regulates bcl-xL; this being in stark contrast to the down-regulation of bcl-xL 
seen when AA/C1 and HT-29 cell lines are treated with butyrate. It is hoped 
that co-treatment of butyrate and PEG-ba to AA/C1 and HT-29 cell lines will 
help to resolve the issue.
Further work is required to identify the mechanism by which butyrate regulates 
gene expression. The work presented here is a small step towards our greater 
understanding of these butyrate responsive regulatory pathways and their 
deregulation during the development of colorectal cancer.
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